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01 | General introduction 
Targeted anticancer therapies are increasingly used in oncology care as single agents 
or in combination with other classes of oncology care. Like other treatment options, 
targeted therapies are associated with adverse events (AEs) which may cause 
treatment adjustments and deterioration of quality of life (QoL). Targeted therapies 
may induce AE burden, with or without significant clinical evidence of tissue damage, 
(1, 2) while having far reaching consequences for patient adherence with care and 
therefore cancer treatment outcomes. To be able to complete treatment as planned 
and to maintain QoL, AEs need to be addressed according to the patient’s needs. 
Therefore, the patient’s view is a critical component of an integral approach to AEs of 
targeted agents. In the future perspectives part of this dissertation a newly developed 
co-care model of approach to AEs is presented. 
Targeted therapy refers to treatment with drugs that have been developed to “target” 
differences in characteristics of malignant cells compared to  normal cells. Unlike 
cytotoxic chemotherapy, targeted therapy drugs have a primary effect on the cancer 
cell. Scientists had expected that targeted agents would cause less AEs than cytotoxic 
chemotherapy because cancer cells are more dependent on the targets than are 
normal cells. However, targeted agents can have substantial AEs.(3) 
Due to the inflammatory processes,(4) the AEs of targeted therapies are generally 
distinct from those associated with cytotoxic chemotherapy and radiation therapy, and 
often require different management.(3) AEs are an adverse effect of the drug that is 
not its intended effect.(5) Targeted cancer therapies can have substantial AEs 
including mucocutaneous AEs,(6) high blood pressure, and hepatitis.(3) 
Certain AEs of some targeted agents have been linked to better patient outcomes. 
For example, patients who develop a papulopustular rash while being treated with 
epidermal growth factor receptor inhibitors (EGFRIs) may have a better cancer 
outcome to these agents than patients who do not develop the rash.(7) Similarly, 
patients who develop high blood pressure while being treated with an angiogenesis 
inhibitor may have better cancer outcomes, i.e. longer survival.(8) 
This dissertation focuses on mucocutaneous AEs involving skin and mucosal changes. 
Skin and mucosal AEs are the primary AEs associated with many targeted agents and 
can occur in up to 90% of people undergoing treatment with  targeted agents.(6) 
Examples of skin AEs are a maculopapular or papulopustular eruption (or 'rash'), hand-
foot skin reaction (HFSR), xerosis (abnormally dry skin), pruritus (itchiness), edema 
(skin swelling), hair alterations, nailfold infection (paronychia), and eyelid reactions. A 
mucous membrane is a membrane that produces mucus that covers delicate parts of 
the body such as in the nasal cavity,(9) the oral cavity, eyes, esophagus, intestines, 
anus, and genitals. Mucocutaneous symptoms can be very burdensome for patients, 





even when the treatment is effective in combating the cancer. These AEs can lead to 
decreased QoL, delay in treatment, dose modification or early cessation of the 
antineoplastic therapy, which may affect cancer outcomes.(10) It is thought that most 
mucocutaneous AEs - when approached systematically and at an early stage - can be 
controlled, often with simple, inexpensive and over the counter products. This would 
reduce the cost of care, enhance adherence to anticancer regimes, and lead to a more 
favourable clinical outcome.(11) However, healthcare providers (HCPs) sometimes 
find it difficult to successfully manage mucocutaneous AEs. If the symptoms persist, 
the AEs should be thoroughly evaluated before treatment modification. Choosing the 
most appropriate treatment is made easier in collaboration with an adverse event 
expert and the patient.(12) 
Patients are now more active in their treatment as they have access to their electronic 
medical files and disease related information. Also they are more involved in 
assessment of AE and treatment.(13) Policy makers and clinicians increasingly aim to 
take the patient’s perspective into account in medical decision making.(14-17) Patients 
may respond better to treatment and comply better to guidelines when they are 
involved in decision making and satisfied with their care and treatment setting.(18-20) 
However, this approach is not patient-driven. Patient-driven means, the patient is truly 
in center while patient-centric implies clinicians are in charge, even if the patient is at 
the center.(13, 21-23) Characteristics of patient-driven approach to AEs of targeted 
agents include: 
1. The patient and his/her social support use accurate terminology of an AE. In 
this way the patient actively contributes to determining the correct diagnosis of 
the AE. 
2. Assessing both symptoms and signs of an AE by the patient and the impact of 
such an event on his/her health related quality of life (HRQoL). 
3. Collecting and reporting the characteristics of an AE by the patient for more in-
depth information about the AE. 
4. Grading the severity of an AE by the patient. 
5. Evaluation of the taken measures; reconfirmation of general measures and 
education about the AE treatment to be initiated. 
6. Institute most appropriate and effective AE treatment strategies according to 
best evidence and the patient needs. 
To decrease the chance that patients develop potentially severe AEs that might lead 
to treatment adjustments, the patient needs to be educated about prophylactic 
measures at the initiation of treatment.(24-27) Education may take place in the 
outpatient setting, because many targeted agents are available to outpatients. 
Education about AEs includes informing the patient about AEs during therapy decision, 
before starting the therapy, during treatment, when AEs occur, and at initiating of AE 
treatment.(28) Education should include discussing preventive measures, the nature, 
recognition, and severity of common and potentially severe AEs associated with the 




agents provided. If the patient is trained to report these AE details correctly, unintended 
treatment delays or interruptions may be avoided. It is also important to encourage 
patients themselves decide how to integrate the daily care of skin and mucosa into 
their daily routine. For example, if a patient takes long, hot showers every day, it is 
important to be aware that the skin may become stressed, allowing deciding to then 
opt for intensive skin care after the shower or for taking a shorter shower and/or 
adjusting the water temperature.(12) When, despite preventive measures, an AE 
develops, it is even more important that skin and mucosa are healthy, as interventions 
using, for example, application of topical corticosteroids or keratolytics, may be too 
stressful for the skin or mucosa. 
The first critical step in a patient-driven AE approach when AEs occur, is using accurate 
terminology of AEs. Terminology is about labelling or designating concepts in the right 
context.(29) Several AE names may be used interchangeably, even though they do 
not actually mean the same thing. For example, the terms “side effects and adverse 
events”, “reaction and toxicity”, “oral mucositis and stomatitis”, “diarrhea and loose 
stool”, and “hand-foot syndrome and hand-foot skin reaction” may be used 
interchangeably. Promoting consistency of the appropriate terminology of the AEs is 
important for documenting and comparing treatment. When terms such as targeted 
therapy-associated non-toxic reaction and chemo- and radiation therapy-associated 
toxic reaction (toxicities) are used consistently, it will be more likely to define the 
appropriate treatment option. For example: While the targeted therapy-associated 
hand-foot skin reaction (HFSR) and the chemotherapy-associated hand-foot syndrome 
(HFS) have similarities, HFSR and HFS also differ. They both have erythema, blisters, 
scaling of the skin, tenderness, pain in the hand palms and foot soles, and resolution 
of the AE upon discontinuation of the drug in common, but the patterns are different. 
While HFSR lesions commonly appear on the friction/pressure points, HFS often 
covers the entire palms and soles.(30) Because of this different mechanism of action, 
the treatment of a HFSR is quite straight forward, while the treatment of a HFS remains 
challenging.(12) 
The second critical step in the patient-driven AE approach, is the self-assessment of 
symptoms and signs of AEs by the patient and the influence of the AEs on HRQoL. In 
oncology healthcare it is common to register signs of AEs by observable 
measurements assessed by clinician rated outcomes (CROs). However, in order to 
gain a deeper understanding of the patient’s experiences of an AE, there is also a need 
for patient reported outcome (PRO) assessments. PROs are “any aspect of an 
individual’s health status that comes directly from the individual without amendment or 
interpretation of the patient’s response by a clinician or anyone else”.(31, 32) PROs 
give valuable subjective information in addition to observable HCP assessments. This 
reflection of patient experience and the ability to capture the patient’s voice through 
PROs should be a central component of all clinical trials and regular clinical care.(33) 
PROs can be assessed by e.g. interviews and diaries or by questionnaires.(34-37) 





Publications by Basch et al. (38, 39) demonstrated that systematic collection of patient-
reported symptoms and telephone-based symptom management resulted in both 
higher QoL and survival improvement that rivaled the positive effects of many novel 
oncologic agents entering the market in 2016. Their studies show that current care 
delivery systems fall short in identifying symptoms since AEs are mainly reported by 
HCP’s. This finding is consistent with previous research showing that, compared with 
patients, physicians often underreport AEs.(40) In addition, the burden of AEs for 
patients who are adherent but experience unaddressed symptoms cannot be 
underestimated.(33) To fully harness the potential of real-time patient data, PROs 
should be included within the medical record,(41, 42) where oncologists and nurses 
can view responses and take action to meet patient needs. Since existing evidence 
clearly shows that patients and clinicians differ in their assessments and grading of the 
severity of AEs, ideally, a system that captures both patient and clinician assessments 
is appropriate.(43) Patient-reported symptoms not only cause patients to enter the 
medical system, they also may affect subsequent use and the costs of medical care.(1) 
To overcome the issue of the rare patient voice, the next generation of patient-driven 
studies should provide deeper insights into how the risk and impact of AEs is perceived 
by both patients and physicians. Such insights might especially highlight the balance 
between AEs and efficacy that needs to be achieved for a cancer drug to be perceived 
as valuable by patients and physicians.(28) 
Patient-driven AE approach requires self-report of the symptoms and impact. Patient 
self-report facilitates follow up since AE characteristics help to identify, differentiate, 
and more precisely describe a feature of the AEs.(44) For example, when reporting 
papules the following should be recorded by the patient: onset, site, location, severity, 
and associated signs such as shape and color (brown, purple, pink or red) and if scales 
are present. It is precisely this detailed reporting which is necessary to support the 
clinical decisions in treatment and follow up. In addition, clinical photographs, biopsies, 
and swabs by the HCP support the integral reporting of characteristics of AEs. 
Therefore, reporting AEs by characteristics by the patient as well as by the HCP, 
supplemented by appropriate testing (when needed) supports a precise and detailed 
AE recording.(12)  
Another requirement in a patient-driven AE approach is severity grading. Targeted 
therapy-associated mucocutaneous AEs for instance include important subjective 
patient tolerability and discomfort. In general, patients are able to accurately grade AEs 
themselves.(45, 46) A prerequisite is that the grading instruments contain clear 
language since patients may find it difficult to define their AEs in terms of 'grade 0', 
'grade 1', etc. Using an equivalent of this categorization, such as 'none', 'mild', 
'moderate' or 'severe', makes it easier to grade the AE. 
A vital next step in a patient-driven AE approach is the evaluation of the applied AE 
measures. Even if patients are aware of the importance of applying the intervention as 




prescribed, the patient may nevertheless at times apply it incorrectly while believing 
otherwise. For example, when a patient with itchy and dry skin is advised to apply a 
greasy cream at least three times a day, but uses a lotion instead. What the patient 
may not know is that a watery lotion does not have the same effect as a greasy cream 
on a dry and itchy skin. When seen at follow-up the patient may report no improvement. 
The limited or lack of effect may be due to not following correct treatment. Therefore it 
is important to evaluate if the AE interventions have resulted in the desired outcomes 
and to ascertain the reasons it may not have been effective. This evaluation should 
already take place after 48 hours of initiation of AE treatment since when no response 
occurred within this timeframe, poor response can be expected after 48 hours and 
adjustment of AE treatment should be considered before targeted anticancer treatment 
adjustment.(47) 
A fundamental step in approaching AEs is the treatment recommended. The patient 
plays a key role in all treatment processes and possibly even more in the treatment of 
AEs. Many treatment interventions involve skin care in general use of creams, 
antiseptic soaks, oral rinses, or other topical applications in the oral cavity. These 
interventions are stand-alone or may be given in combination with systemic treatments, 
such as steroids and antibiotics. In order to encourage adherence to the treatment 
recommended it is important that patients have sufficient information about the 
intervention(s). The patient should understand the reasons for both treatment and 
treatment outcome expectations, and be aware of the consequences if 
recommendations are not followed. The patient must also know which product to apply 
where, which a simple drawing can help achieve.(12)  
Within the research line that the author has been active in, two clinical trials 
regarding treatment options for skin and oral complaints have been performed: the 
BeCet and the COMTT study.(48) The outcomes of these AE treatment trials lay 
beyond the scope of this dissertation, but the instruments generated specifically for 
these trials in order to be able to assess, report and grade skin and oral AEs contain 
questions that evaluate the outcomes of the AE treatment. These instruments are 
discussed throughout the dissertation. 
Chapter 2 provides an overview of the prevalence and appearance of oral AEs 
with tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor 
(mTORI) treatment and the current assessment instruments commonly used in clinical 
trials in oncology. 
Chapter 3 provides a review of the clinical presentation, terminology, 
pathogenesis, assessment, and management of mTORI-associated oral AEs. 
Chapter 4 presents updates from the chemo-, radiation-, and targeted therapy-
associated mucosal reactions guideline. 
Chapter 5 presents a sub-analysis of the BeCet study. The current study studies 
the impact of the skin AEs on patients HRQoL, while the main study analyses the 
appearance and severity of skin AEs. 





Chapter 6 provides the process of translation and linguistic validation of the FACT-
EGFRI-18 questionnaire from English into Dutch. 
Chapter 7 identifies how the FACT-EGFRI-18 reveals the difficulties regarding the 
assessment of the mucocutaneous AEs from the patients’ point of view. 
A general discussion, summary, and future perspectives are presented in chapter 8 
and a Summary in Dutch is given in chapter 9. 
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02 | Oral Adverse Events Associated With Tyrosine 
Kinase and Mammalian Target of Rapamycin 
Inhibitors in Renal Cell Carcinoma: A Structured 
Literature Review. 
Oncologist 2011;17(1):135-44. 
C.B. Boers-Doets, J.B. Epstein, J.E. Raber-Durlacher, J. Ouwerkerk, R.M. Logan, 
J.A.C. Brakenhoff, M.E. Lacouture, H. Gelderblom 
ABSTRACT 
Background. Oral adverse events (OAEs) associated with multitargeted tyrosine 
kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors (mTORIs) are 
underestimated but frequent and novel presentations of mucosal manifestations. 
Because optimal antitumor activity requires maintaining the optimal dose, it is essential 
to avoid unintended treatment delays or interruptions. 
Methods. We review the reported prevalence and appearance of OAEs with TKIs and 
mTORIs and the current oral assessment tools commonly used in clinical trials. We 
discuss the correlations between OAEs and hand–foot skin reaction (HFSR) and rash. 
Results. The reported prevalence of oral mucositis/stomatitis of any grade is 4% for 
pazopanib, 28% for sorafenib, 38% for sunitinib, 41% for temsirolimus, and 44% for 
everolimus. Oral lesions associated with these agents have been reported to more 
closely resemble aphthous stomatitis than OM caused by conventional agents. In 
addition, these agents may result in symptoms such as oral mucosal pain, dysgeusia, 
and dysphagia, in the absence of clinical lesions. Because of these factors, OAEs 
secondary to targeted agents may be underreported. In addition, a correlation between 
OAEs and HFSR was identified. 
Conclusions. OAEs caused by TKIs and mTORIs may represent dose-limiting 
toxicities, especially considering the fact that even low grades of OAEs may be 
troubling to the patient. We discuss how these novel AEs can be assessed because 
current mucositis assessment tools have limitations. Prospective studies investigating 
the pathogenesis, risk factors, and management of OAEs are needed in order to 
minimize the impact on patient’s health-related quality of life. 
  






As a result of the introduction of targeted anticancer therapy for advanced renal cell 
carcinoma (RCC) and metastatic RCC (mRCC), the overall survival time of patients 
with this disease has increased dramatically. Currently, six U.S. Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) approved targeted 
agents are available for treating RCC: sunitinib malate (Sutent®; Pfizer, New York), 
sorafenib tosylate (Nexavar/Nexxava®; Bayer HealthCare, Leverkusen, Germany), 
pazopanib (Votrient®; GlaxoSmithKline, Greenford, U.K.), temsirolimus (Torisel®; 
Wyeth Pharmaceuticals, Philadelphia), everolimus (Afinitor®; Novartis 
Pharmaceuticals, East Hanover, NJ), and bevacizumab (Avastin®; Genentech, Inc., 
South San Francisco, CA) plus interferon-®2a. These agents are indicated as first- and 
second-line therapies. Bevacizumab differs from the other agents reported here in that 
it blocks vascular endothelial growth factor, whereas the other agents block multiple 
receptors and intracellular pathways (Table 1). 
With longer survival times, it has become even more important to optimize health-
related quality of life (HRQoL) during treatment. These agents have a spectrum of 
mucocutaneous adverse events (AEs) with oral adverse events (OAEs), hand–foot 
skin reaction (HFSR) (for sunitinib, sorafenib, pazopanib, and everolimus), and rash 
as disabling and dose-limiting AEs. There are no evidence-based management options 
to prevent and treat these AEs. 
Treatment of mRCC with Targeted Anticancer Agents 
Targeted anticancer therapy is a general term that refers to drugs that target pathways 
in the growth and development of a tumor cell. Targeted therapies such as 
(multitargeted) tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin 
inhibitors (mTORIs) for RCC demonstrate a high level of efficacy with acceptable 
tolerability [1]. Targeted therapies may be continuously administered for their long-term 
ability to inhibit tumor growth, progression, cell proliferation, and angiogenesis. 
In a short span of 4 years, the oral (multitargeted) TKIs sunitinib, sorafenib, and 
pazopanib, the i.v. mTORI temsirolimus, and the oral mTORI everolimus were 
approved by the FDA and EMA. Sorafenib received FDA and EMA approval in 2005 
[2], sunitinib received approval in 2006 [3], temsirolimus received approval in 2007 [4], 
everolimus received approval in early 2009 [5], and pazopanib received approval in 
late 2009 [6]. Sunitinib also received FDA and EMA approval in 2006 for the treatment 
of gastrointestinal stromal tumor (GIST) [3], and sorafenib received approval in 2007 
for the treatment of unresectable hepatocellular carcinoma (HCC) [2]. 
Treatment Delay, Dose Modifications, and Early Cessation 
Optimal antitumor activity requires maintaining the optimal dose in individual patients. 
In order to improve HRQoL and adherence, AEs should be prevented if possible and 
treated if necessary. Current oral formulations of targeted agents consist of various 
schedules (e.g., continuous administration or 4 weeks on and 2 weeks off for sunitinib 
only) to optimize the risk– benefit profile. 




Impaired HRQoL may have a negative impact on patient treatment adherence. 
Treatment over- or underadherence can have a significant impact on efficacy and the 
severity of treatment-related AEs [7]. Poor adherence may affect the therapeutic 
alliance, create skepticism in both the therapist and patient, induce resistance, worsen 
the disease or the prognosis attributed to missed doses, and increase health care costs 
[8]. Adherence to anticancer treatment is particularly important when prescribing self-
administered oral therapies [9]. Because sorafenib, sunitinib, pazopanib, and 
everolimus are taken in the outpatient setting, patient education on the correct 
treatment dosing, usage, and the nature, recognition, and severity of AEs is essential 
to avoid unintended treatment delays or interruptions. 
CONVENTIONAL CYTOTOXIC CHEMOTHERAPY- AND 
RADIOTHERAPY-INDUCED OAES 
There are a number of cancer treatment–related, clinically important AEs that disrupt 
the function and integrity of the mouth. These AEs include OAEs characterized by 
redness, swelling, and ulceration; xerostomia (subjective dry mouth); and 
dysgeusia/ageusia (altered taste/taste loss). OAEs can result in significant clinical 
consequences, including oral sensitivity and pain, and can affect function, such as with 
difficulty in chewing and swallowing food, potentially leading to nutrient and caloric 
deficits, difficulty taking oral medications, and a higher risk for local and systemic 
infections [9, 10]. 
Stomatitis is a general term that includes inflammation and ulceration of the 
mucosal lining of the mouth resulting from any cause. Oral mucositis (OM) is the more 
specific term that is used to describe oral mucosal inflammation and ulceration induced 
by cancer therapies [11]. Conventional cytotoxic chemotherapy- or radiotherapy-
induced OM is inflammatory mediated damage of the mucosal membranes, most 
commonly involving nonkeratinized mucosa, that line the oral cavity; the ulcerative 
phase of development presents clinically with irregular and often confluent ulceration 
that is typically preceded by regional erythema. Whereas the first phases of mucositis 
involve the submucosal connective tissue, the epithelial cells of these mucosal tissues 
have a high turnover rate, which may make them susceptible to the effects of cancer 
chemotherapy and radiotherapy on the connective tissue and epithelium [12]. It is now 
recognized that it is not just the epithelium that is affected by cytotoxic treatment, but 
also the underlying connective tissue. OM develops almost exclusively on 
nonkeratinized mucosal surfaces (e.g., the buccal and labial mucosa, lateral tongue, 
floor of mouth, and soft palate). 
The management of OAEs includes assessment, diagnosis, teaching oral care, 
administering interventions aimed at prevention and palliation of symptoms, and 
supporting patients in coping with symptom distress [9]. 
  





Table 1. Targeted agents for advanced RCC and dermatological AEs 
Agent Brand name 
Mode of 
action 




Sunitinib Sutent® TKI Advanced RCC, imatinib-resistant 
GIST 
81a, NR 
Sorafenib Nexxava®/Nexavar® TKI Advanced RCC, unresectable HCC 74a, NR 
Pazopanib Votrient® TKI Advanced RCC NR 
Temsirolimus Torisel® mTORI Advanced RCC NR 
Everolimus Afinitor® mTORI Advanced RCC after failure of 
sunitinib or sorafenib 
NR 
All severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 3.0. 
aFrom Lee et al. (2009) [13]. 
Abbreviations: AE, adverse event; EMA, European Medicines Agency; FDA, Food and Drug Administration; 
HCC, hepatocellular carcinoma; GIST, gastrointestinal stromal tumor; mTORI, mammalian target of 
rapamycin inhibitor; NR, not reported; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor. 
TKI- AND MTORI-INDUCED MUCOCUTANEOUS AES 
Targeted therapy–related AEs, such as rash, xerosis, pruritus, mucosal, and hair 
abnormalities, occur in up to 81% of patients during treatment with TKIs or mTORIs 
[13]. Recognizing the fact that head-to-head comparisons are lacking and 
interpretation and scoring of AEs may not be univocal, Lee et al. [13] found that 
cutaneous reactions were more diverse in patients treated with sunitinib than in those 
treated with sorafenib. HFSR and OAEs were the most common mucocutaneous AEs 
(Tables 2 and 3). 
TKI- and mTORI-Induced OAEs 
To date, information on the pathobiology of the OAEs induced by targeted therapies is 
limited. In addition, there is no consensus on terminology, and in the literature on OAEs 
associated with targeted therapies, the terms mucositis and stomatitis are used 
interchangeably. This makes comparison of OAE data from different authors difficult. 
An analysis of the appearance, course, and toxicity associations of mTORI-
associated OAEs demonstrated that the condition is distinct from conventional 
mucositis and more closely resembles the presentation of aphthous stomatitis [14]. 
OAEs appeared within 5 days of deforolimus administration and were discrete, circular 
or ovoid, superficial, well demarcated, and surrounded by an erythematous halo 
primarily involving nonkeratinized mucosa. Their clinical appearance and distribution 
were similar to that of aphthous stomatitis but inconsistent with conventional mucositis. 
The lack of other gastrointestinal involvement but the presence of a higher prevalence 
of concomitant cutaneous AEs provided additional evidence to suggest a distinction 
between mTORI-associated OAEs and conventional cytotoxic therapy–induced OM 
[14]. 
In the study of Sonis et al. [14] of 78 solid tumor patients treated with deforolimus, 
OAEs, reported as mucositis, were dose-limiting toxicities for this new class of agents. 
OAEs were reported in 66% of the 78 study participants. 




In a study of 30 mRCC patients treated with sunitinib, no correlation was found 
between the intensity of oral symptoms and clinical evidence of mucosal damage [15]. 
Patients were examined according to three standard assessments—the World Health 
Organization (WHO) Oral Toxicity Scale [16], National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) [17], and Oral Mucositis Assessment Scale (OMAS) [16]— 
and according to an experimental assessment (EA) [15]. The EA consisted of an 
assessment of a number of symptoms using a visual analog scale (VAS) (range, 0–
10) of dysgeusia, (subjective) dysphagia, odynophagia, and oral mucosal pain, which 
are subjective parameters, and objective mucosal erythema and ulceration. Whereas 
at the end of treatment the WHO Oral Toxicity Scale, NCI-CTC, and OMAS 
assessment were grade 0 in 62% of patients and grade 1 in 38% of patients, in the EA 
they observed no mucosal ulceration but 63% of patients experienced intense 
dysgeusia (VAS score, 7–10). Ten percent had intense (VAS score, 7–10) and 13% 
had moderate (VAS score, 4–6) odynophagia. Thirteen percent of the patients had 
acute pain (VAS score, 7–10) and 40% had intermediate pain (VAS score, 4–6). Three 
percent had moderate and 3% had severe dysphagia. Moderate erythema was 
observed in 40% of patients. 
TKI- and mTORI-Induced HFSR 
HFSR usually manifests as bilateral palmoplantar lesions, especially in areas of trauma 
or friction, such as over the interphalangeal joints, distal phalanges, or heels [18], and 
significantly affects patients’ QoL [13]. Although most commonly associated with 
sorafenib and sunitinib, it is also reported with pazopanib and everolimus [19, 20]. 
HFSR is associated with symptoms that are seen with OAEs too. Patients can 
develop localized, tender lesions that appear as blisters or hyperkeratosis, which in 
some cases can be surrounded by an erythematous halo (Fig. 1). Pain, dysesthesia, 
erythema, and edema [21, 22] are common symptoms on mechanically strained 
regions and can even appear without obvious skin alterations [23]. 
In a meta-analysis by Chu et al. [24] on the incidence of and potential relationship 
between tumor type and sorafenib-associated HFSR, in total, 4,883 patients with 
metastatic tumors from 11 trials were included for analysis. They found that, among 
3,252 patients with RCC, the prevalence of all-grade HFSR was 42.0% (95% 
confidence interval [CI], 24.9%–61.3%) and that of high-grade HFSR was 8.9% (95% 
CI, 6.3%–12.3%), whereas for 545 patients with malignancies other than RCC, the 
prevalence of all-grade HFSR was 27.6% (95% CI, 20.2%–36.4%) and the incidence 
of high grade HFSR was 9.1% (95% CI, 7.2%–11.3%). There was a significant 
difference detected between patients with RCC and those with cancers other than RCC 
in terms of the prevalence of sorafenib-associated all-grade HFSR (relative risk [RR], 
1.52; 95% CI, 1.32–1.75; p<.001). However, there was no significant difference 
between patients with RCC and those with cancers other than RCC in terms of the 
prevalence of high-grade HFSR (RR, 0.98; 95% CI, 0.76 –1.26; p<.86) [24]. 
 
 





Table 2. Prevalence and severity of OAEs 










OM/S 38b 29c 28a 25a 4e 41f 44g 
OM/S grade 3/4 0b NR NR NR 0e 3f 5g 
oral pain 53b 6c NR NR NR NR NR 
(Aphthous like) ulcers 33a 43a NR NR <1e NR NR 
Dysphagia (difficulty 
swallowing) 
7b NR NR NR NR NR 4g 
Difficulty oral intake NR NR NR NR NR NR NR 
Dry mouth 12i 6d NR NR NR NR 8g 
Dysgeusia 63b 21c NR NR 16e 20f 10g 









NR NR Mucosal 
inflam-
mation 19g 
Onset 1st -15th weeka; Before 
4th week in 81% of 
ptsa 
1st-8th weeka; Before 4th 
week in 90% of ptsa 
NR NR NR 
Dose interruption caused 
by oral AEs 
9a 7a NR NR NR 
Dose reduction caused 
by oral AEs 
26a 18h NR NR NR 
Treatment 
discontinuation caused 
by oral AEs 
0a NRa NR NR NR 
All severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 3.0. 
aLee et al. (2009) [13]. 
bFerrari et al. (2009) [15]. 
cAdams and Leggas (2007) [43]. 
dTheou-Anton et al. (2009) [44]. 
eEuropean Medicines Agency (2010) [45]. 
fKwitkowski et al. (2010) [46]. 
gNovartis (2010) [48]. 
hLlovet et al. (2008) [29]. 
iMotzer et al. (2009) [26]. 
Abbreviations: AE, adverse event; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; NR, 
not reported; OAE, oral adverse event; OM/S, oral mucositis/stomatitis; RCC, renal cell carcinoma. 
 
In a meta-analysis of HFSR with pazopanib [25], the overall incidences of all-grade 
and high-grade HFSR were 4.5% (95% CI, 2.5%–7.9%) and 1.5% (95% CI, 0.7%–
3.1%), respectively. The RRs for all-grade and high-grade HFSR with pazopanib 
monotherapy in comparison with controls were greater, reaching statistical significance 
for all-grade (RR, 6.05; 95% CI, 1.11–33.12; p=.038) but not for high-grade (RR, 2.51; 
95% CI, 0.12–51.9; p=.55) HFSR. We did not identify reports of HFSR caused by 
temsirolimus.  




Because of the high prevalence of HFSR associated with TKI use (Table 3), early 
detection and timely treatment are vital in managing patients during their drug courses 
to allow continued treatment [13]. 
 
















Any grade (%) 33a 43a 594 49a 7f NR 5g 
Grade 3/4 (%) 9b 4c 114 8e 1f NR NR 
Onset, days 5-82 (median 32.4)a 3-56 (median 18.4)a NR NR NR 
Transient dose interruption 30a 29a NR NR NR 
Temporary dose reduction 44a 40a NR NR NR 
Treatment discontinuation 
caused by severe HFSR 
19a 17a NR NR NR 
All severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 3.0. 
aLee et al. (2009) [13]. 
bMotzer et al. (2009) [26]. 
cAdams and Leggas (2007) [43]. 
dSzczylik et al. (2007) [47]. 
eLlovet et al. (2008) [29]. 
fEuropean Medicines Agency (2010) [45]. 
gNovartis (2010) [48]. 
Abbreviations: GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; HFSR, hand–foot skin 
reaction; NR, not reported; RCC, renal cell carcinoma. 
OBJECTIVE 
The aim of this study is to provide an overview of the prevalence and appearance of 
OAEs with TKI and mTORI treatment and the current oral assessment tools commonly 
used in clinical trials. We also wanted to find out if there is a correlation among OAEs, 
HFSR, and rash. 
METHODS 
Search Strategy 
We designed a search strategy to identify relevant literature that described OAEs 
resulting from targeted anticancer therapy among RCC patients in each database as 
outlined below. We performed our search in the electronic databases PubMed, 
Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
for literature published from 1980 through January 7, 2011, linking the subject search 
headings with text word, MESH terms, and substance name. We linked the key words 
“mucositis,” “stomatitis,” “ulcer,” “aphthous,” “oral pain,” “deglutition disorders,” 





“swallowing,” “dry mouth,” and “altered taste” to the generic agents and classes of drug. 
We didn’t make language restrictions. OAEs in patients with cancer types other than 
RCC, GIST, or HCC were not appropriate. Because of the paucity of OAE studies on 
TKIs and mTORIs at the time of the 
search, all publication types were 
considered.  
Selection Criteria 
We were primarily interested in the 
clinical presentation of OAEs 
caused by TKIs and mTORIs. To be 
included, a paper had to be focused 
on OAEs, including assessment as 
(one of) the primary or secondary 
outcomes, and focusing on TKIs or 
mTORIs. Papers that only 
described the appearance of OAEs 
as a safety issue were excluded. 
RESULTS 
Initial searching found a total of 630 citations; 239 hits in PubMed, 376 in Embase, and 
15 in CINAHL. After removing duplicates, 501 citations remained; 472 were discarded 
based on title or abstract because they did not meet the inclusion criteria and 29 
citations were included for review. 
TKI- and mTORI-Induced AE Profiles 
Although some targeted agents share a common mode of action, it should not be 
assumed that their AE profiles are comparable. Indeed, evidence indicates clinically 
relevant differences among the toxicity profiles of targeted therapies, including 
between agents with the same mode of action. For example, sorafenib and sunitinib 
are both multitargeted TKIs, but in patients with RCC, HFSR appears to occur more 
frequently with sorafenib (30%) than with sunitinib (19%) [13], whereas leukopenia, 
neutropenia, and anemia are common with sunitinib (78%, 77%, and 79%) but not with 
sorafenib. Febrile neutropenia or grade 4 thrombocytopenia did not occur with 
sorafenib. Grade 3 or 4 anemia occurred in 3% of patients and grade 3 or 4 
lymphopenia occurred in 13% of patients [26–28]. It should also be noted that the AE 
profile for a targeted agent may differ among tumor types. For example, HFSR may 
occur less frequently with sorafenib in patients with HCC than in patients with RCC 
(Table 3) [27, 29]. In a meta-analysis performed by Chu et al. [30], it was found that 
patients with RCC had a significantly greater risk for all-grade HFSR than patients with 
a malignancy other than RCC, 42% (95% CI, 24.9%–63.3%) and 27.6% (95% CI, 
20.2%–36.4%), respectively. 
Figure 1. Mammalian target of rapamycin inhibitor 
(mTORI)- induced hand–foot skin reaction (HFSR). 
HFSR caused by temsirolimus, an mTORI. HFSR is 
associated with symptoms that are seen with oral 
adverse events too. As shown in this picture, patients 
can develop localized, tender lesions that appear as 
blisters or hyperkeratosis, which in some cases can be 
surrounded by an erythematous halo. 




TKI- and mTORI-Induced OAEs 
OAEs are associated with many targeted agents. The oral burden can be very difficult 
for patients, even when the treatment is effective in combating the cancer. These 
circumstances can lead to lower HRQoL, delay in treatment, dose modification, or early 
cessation of critical antineoplastic therapy [13]. 
Clinical Presentation of TKI and mTORI OAEs 
A variety of oral signs and symptoms have been described in association with the use 
of TKIs and mTORIs. For example, sunitinib treatment has been associated with oral 
mucosal hypersensitivity, oral ulcers, cheilitis, and taste alterations [23, 31]. Oral 
lesions associated with mTORIs have been described as discrete, oval, superficial 
ulcers with an erythematous halo (Fig. 2), an appearance similar to that of aphthous 
stomatitis and unlike that of OM secondary to conventional chemotherapeutic agents 
[14]. Interestingly, and also unlike oral mucosal toxicity associated with conventional 
chemotherapy, patients on such targeted agents may sometimes present with oral 
complaints such as mouth pain, dysgeusia, and dysphagia in the absence of any 
clinically apparent lesion [14, 21, 32]. Such symptoms have been reported to rapidly 
improve during treatment- free intervals [23] and may occur again with additional 
dosing of the targeted agent. 
Prevalence of TKI- and mTORI-Induced OAEs 
Current data on the frequency of the OAEs associated with each of the different 
targeted agents are highlighted in Table 2. OAEs are early symptoms, generally 
observed in sunitinib and sorafenib patients 1–15 weeks after initiation of treatment. 
As outlined in Table 2, many OAEs are not separately reported. The highest score of 
any-grade OM or stomatitis is reported with everolimus (44%) and the lowest score is 
reported with pazopanib (4%). OAEs generally appear 1–15 weeks after initiation of 
treatment; symptoms began before the fourth week of treatment in 81% and 90%, 
respectively, of sunitinib- and sorafenib-treated patients. The presence of OAEs 
required dose reduction in 26% of the 
sunitinib-treated patients and in 18% 
of the sorafenib treated patients. No 
patient permanently discontinued 
treatment as a result of severe OAEs. 
With mTORIs, oral lesions have a 
rapid onset (usually within 5 days) and 
are usually of mild to moderate 
severity (NCI-CTCAE grade 1–2). 
Lesions are usually found on the 
mucosa of the lips, lateral tongue, 
buccal mucosa, and soft palate. 
Unlike viral-induced ulcers, they are 
not commonly seen on the hard palate 
Figure 2. Mammalian target of rapamycin 
inhibitor (mTORI)-induced oral adverse events. 
Aphthous stomatitis caused by temsirolimus, an 
mTORI. As shown in this picture, patients can 
develop localized, tender lesions that appear as 
aphthous stomatitis and that can be surrounded 
by an erythematous halo. 





or outer aspects of the lip. They often present as individual ulcers, similar to aphthous 
ulcers (canker sores): distinct round-oval lesions with grayish-white necrotic centers 
surrounded by a ring of erythema. Unlike radiation- and chemotherapy-associated 
mucositis, there is no pseudomembrane formation (Fig. 2). Occasionally they are 
severe (grade 3), but generally they are reversible by withholding treatment. In many 
cases mucositis improves or resolves spontaneously despite treatment continuation 
[33]. 
Assessment of TKI- and mTORI-Induced OAEs 
Numerous OM grading scales have been developed over the years to grade 
conventional mucositis [34]. The complexity and detail of these scales vary significantly 
and selection of a mucositis scale is influenced by the reason for assessing mucositis 
for either clinical care or OM research [35]. 
Targeted therapy may induce subjective symptoms of oral burden without 
significant clinical evidence [15]. No validated targeted therapy–specific grading scales 
are currently available. The frequently used OM scales like the WHO Oral Toxicity 
Scale, NCI-CTCAE, and OMAS are not designed to evaluate OAEs caused by TKIs 
and mTORIs and may result in underreporting and poor grading of OAEs in patients 
treated with these agents (Table 4). For example, the OMAS focuses on objective 
ulceration and redness, whereas the WHO Oral Toxicity Scale is mainly driven by the 
patient’s ability to eat and drink. The EA suggested by Ferrari et al. [15] may be more 
adequate for scoring TKI- and mTORI-induced OAEs. The Vanderbilt Head and Neck 
Symptom Survey (VHNSS), version 2.0, is a tool developed for head and neck cancer 
patients treated with chemoradiation. It assesses patient-reported symptom burden in 
the head and neck area and function loss within symptom subscales, including 
nutrition, taste, pain, voice, swallow, and mucous/dry mouth [36]. The Multinational 
Association of Supportive Care in Cancer (MASCC) Skin Toxicity Study Group 
proposed a grading system for the most common epidermal growth factor receptor 
inhibitor (EGFRI)-induced mucocutaneous AEs [37]. That scale is consistent with the 
grading principles and language of the CTCAE, version 4.0, and may be formally 
integrated into future CTCAE versions. 
Management of OAEs 
For the prevention of conventional OM, most recommendations begin with the use 
of oral care plans coupled with patient education [38]. A range of products is currently 
in development for the prevention and management of OAEs that fall into four main 
categories— cell resistance modifiers, mechanism specific inhibitors, damage control 
agents, and healing accelerators. However, to date, proven approaches for the 
prevention and treatment of OAEs are limited [38, 39]. No trials have assessed the 
management of TKI- and mTORI-induced OAEs. Sonis et al. [14] suggested that 
mTORI-induced OAEs were distinct entities from conventional OM.  
  




Table 4. Selected tools and their potential to assess OAEs caused by TKIs and TORIs 
Scale NCI-CTCv3.0a[51] WHO Oral Toxicity 
Scale [16] 
OMAS [16] VHNSS2.0 [36]  
Developed for Toxicities associated with 
conventional CT, RT, HSCT 
OM following 
conventional CT, RT, 
and HSCT 
OM due to HSCT H&N toxicities of 
(C)RT for HNSCC 
Scale description Clinician rated, objective, 
subjective, and functional 




functional parameters;  









scale for each 
item 
Main driver of scale Severity of AE; impact on 
ADL 
Ulceration and ability 














Depends on toxicity; (non-
keratinized) anatomical 













the head and 
neck area 


















alized oral sites 













Potential for use for 
TKI/mTORI oAEs 
+ 
Can be modified for this 
purpose 









Can be modified for this 
purpose 
- - - 
 
aCTCAEv3.0, because within CTCAEv4.0 oral ulcerations are not addressed. 
Abbreviations: ADL, activities of daily living; AE, adverse event; CT, chemotherapy; HNSCC, head and neck 
squamous cell carcinoma; HSCT, hematopoietic stem cell transplantation; mTORI, mammalian target of 
rapamycin inhibitor; NCICTCAEv3.0, National Cancer Institute-Common Terminology Criteria for Adverse 
Events, version 3.0; OAE, oral adverse event; OM, oral mucositis; OMAS, Oral Mucositis Assessment Scale; 
PRO, patient-reported outcome measure; QoL, quality of life; RT, radiation therapy; TKI, tyrosine kinase 
inhibitor; VHNSS2.0, Vanderbilt Head and Neck Symptom Survey, version 2.0; WHO, World Health 
Organization. 
 
The exact etiology of aphthous stomatitis has not been fully determined, but it is 
considered to involve immune mechanisms such as antibody-dependent cell-mediated 





cytotoxicity and immune complex formation; this is different from what is considered to 
occur with conventional OM [40]. Interventions for persistent TKI- or mTORI-related 
OAEs, therefore, may include the use of various agents such as topical corticosteroids 
and anti-inflammatory agents as well as supportive treatments such as local 
anesthetics and antimicrobials [40]. It is important, however, to avoid unfavorable drug 
interactions with TKI and mTORI drugs. 
 









for HCC pazopanib temsirolimus everolimus 
Any grade (%) 24a 14b 41c 19d 9e 47f 29g 
Grade 3 or 4 (%) 2a 1b 6c 1d <1e 5f 1g 
All severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 3.0. 
aMotzer et al. (2009) [26]. 
bAdams and Leggas (2007) [43]. 
cSzczylik et al. (2007) [47]. 
dBayer HealthCare (2009) [49]. 
eEuropean Medicines Agency (2010) [45]. 
fPfizer [50]. 
gNovartis (2010) [48]. 
Abbreviations: GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma. 
 
Correlation of OAEs with Dermatological AEs 
Correlation Between OAEs and HFSR 
Lee at al. [13] found a strong correlation between OAEs and HFSR in the patients they 
studied, who were treated with sunitinib and sorafenib. A significant correlation was 
found between the occurrence of stomatitis and severity of HFSR (p<.01, 2 test for 
trend). OAEs were observed in 72% of patients with grade 3 HFSR and in 47% of 
patients with grade 2 HFSR. OAEs were more likely to occur in patients with severe 
HFSR than in those with mild HFSR. There was a significant relationship between the 
occurrence of stomatitis and severity of HFSR (p=.004, 2 test for trend), although no 
significant correlation was found between HFSR severity and response to treatment 
[13]. 
Correlation Between OAEs and Rash 
Rash caused by TKIs or mTORIs can affect 9%–47% of patients (Table 5). Because 
there was a significant relationship found between the occurrence of OAEs and 
severity of HFSR in sunitinib- and sorafenib-treated patients, it is interesting to assess 
the potential for OAEs occurring with rash. As far as we know, there is no literature 
addressing this possible correlation. 





TKI- and mTORI-related OAEs are underrecognized although they may represent a 
dose-limiting toxicity for this new class of agents, especially considering the fact that 
even low grades of OAEs with chronic daily dosing may result in morbidity that may 
lead to dose reductions [14]. With the longer survival times for RCC patients, it has 
become even more important to optimize HRQoL during treatment. 
The prevalence of OAEs of any grade in renal cancer patients is 38% for sunitinib, 
28% for sorafenib, 4% for pazopanib, 41% for temsirolimus, and 44% for everolimus. 
Interestingly, targeted therapy may induce subjective symptoms of oral burden without 
objective clinical evidence (e.g., mucosal sensitivity and pain, odynophagia, 
xerostomia, and taste alterations). Because of these symptoms and aphthouslike 
ulcerations being distinct from conventional ulcerative OM, current tools are of limited 
value for OAE assessment. The EA from Ferrari et al. [15] and a modified version of 
the VHNSS, version 2.0, are potentially useful to grade OAEs. There is a gap in the 
current literature related to assessing OAEs, HFSR, and rash resulting from therapy 
with TKIs and mTORIs. Therefore, development of a comprehensive grading system 
for TKI- and mTORI-associated mucocutaneous AEs similar to the MASCC EGFRI 
mucocutaneous AE–specific scale seems appropriate. 
It is feasible that TKIs and mTORIs are associated with other less frequent or not 
yet investigated oral complications. For example, a case of jaw osteonecrosis 
associated with sunitinib has been reported [41], salivary gland function may be 
affected, resulting in hyposalivation and qualitative salivary alterations, and patients 
taking mTORIs may be at risk for periodontitis because these drugs induce 
immunosuppression and affect collagen synthesis. 
A strong correlation was found between severe OAEs and HFSR. The results of 
the current review suggest that OAEs induced by TKIs and mTORIs are distinct from 
conventional chemotherapy- and radiotherapy-induced OM. More studies are 
necessary into the pathobiology of OAEs induced by TKIs and mTORIs. In addition, 
studies of individual patient characteristics predisposing for toxicities are promising, 
because these may lead to optimal treatment strategies. For example, a recent study 
indicated that polymorphisms in genes encoding metabolizing enzymes, efflux 
transporters, and drug targets are associated with sunitinib-related toxicities [42]. 
Targeted agents have mucocutaneous AEs in common, with OAEs, HFSR, and 
rash as the most disabling AEs. Evidence-based management guidelines to prevent 
and treat these complications are required; presently they are lacking. 
Additional studies of management strategies may therefore be important for dose 
adherence to TKI and mTORI therapy and for the overall acceptance of this therapy 
for patients.  
Educating patients on the importance of reporting all AEs and on compliance with 
the prescribed dose may increase early recognition and ensure adherence to 
treatment, allowing the most effective treatment strategy for the patient. There is 
currently only limited evidence for the prevention and management of OAEs caused 





by targeted agents, which indicates the need for more evidence derived from well-
designed prospective clinical studies in order to improve management. 
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ABSTRACT 
With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in 
oncology, distinct cutaneous and oral adverse events have been identified. In fact, 
stomatitis and rash are documented as the most frequent and potentially dose-limiting 
side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely 
resembles aphthous stomatitis than oral mucositis due to conventional anticancer 
therapies. While most cases of mIAS are mild to moderate and self-limiting, more 
severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may 
cause significant pain and mucosal sensitivity may occur in the absence of clinical 
changes. Use of clinical assessment tools that are primarily driven by ulceration size 
may underestimate mIAS, and assessment should include patient-reported outcomes. 
This article provides an up-to-date review of the clinical presentation, terminology, 
pathogenesis, assessment and management of mIAS and other mTOR inhibitor-
associated oral adverse events. In addition, areas of future research are considered. 
 
  





Mammalian target of rapamycin (mTOR) is a serine/tyrosine protein kinase that acts 
as a master switch for protein synthesis, cell proliferation, cell cycle progression and 
cell survival, integrating signals from growth stimuli to cell cycle progression [1]. 
Dysregulation of the PI3K/AKT/mTOR signaling pathway has been identified in several 
human malignancies, and investigation of this signaling network has led to the 
development of targeted cancer therapies [2]. One of the primary pharmacologic 
targets has been mTOR, which occurs in two multiprotein complexes, mTORC1 and 
mTORC2. mTOR inhibitors that are currently in clinical use inhibit mTORC1 through 
allosteric binding and demonstrate efficacy with acceptable tolerability [2]. These 
agents are associated with sustained, durable clinical responses in several cancer 
types, including, for example, advanced renal cell carcinoma and neuroendocrine 
pancreatic cancers [3].  
The first mTOR inhibitor developed was sirolimus (Rapamune®; Wyeth-Ayerst, NJ, 
USA), which is used as an antirejection medication in solid and stem cell 
transplantation. For the treatment of cancer, two mTOR inhibitors are currently 
available: temsirolimus (Torisel®; Pfizer, NY, USA) and everolimus (Afinitor®; Novartis 
Pharmaceuticals, NJ, USA). Temsirolimus is  intravenously administered and is 
approved for the treatment of advanced renal cell carcinoma [101]. Everolimus is an 
oral mTOR inhibitor that is US FDA approved for the second-line treatment of 
advanced renal cell carcinoma [102], neuroendocrine pancreatic cancers, and 
aromatase inhibitor-resistant hormone receptor-positive, HER2-/neu-negative 
advanced breast cancers and for tuberous sclerosis complex related renal 
angiomyolipomas. In addition, everolimus was recently approved for nonresectable 
subependymal giant cell astrocytoma [103]. A third mTOR inhibitor, ridaforolimus 
(deforolimus, Jenzyl® [EU], Taltorvic® [US]; Merck & Co. Inc, NJ, USA) continues to 
be under clinical investigation for a range of cancers [104]. 
This new class of oncology drugs has a spectrum of adverse events (AEs) that are 
unique as compared with conventional anticancer chemotherapy. AEs include 
hyperglycemia, hyperlipidemia, hypophosphatemia, hematologic toxicities and 
mucocutaneous eruptions. In particular, stomatitis and skin rash are documented as 
the most frequent and potentially dose-limiting side effects [4,5]. When mTOR 
inhibitors are used for immunosuppression, they are often given in combination with 
other immunosuppressant agents, including corticosteroids that may actually diminish 
and/or prevent mouth and skin AEs. Moreover, the prevalence of mouth and skin 
toxicity could also be decreased owing to a significant lower dose applied in 
transplantation medicine. 
In the majority of cancer patients treated with mTOR inhibitors, stomatitis is 
reported as mild to moderate. However, even small lesions can be painful and 
invalidating since patients are treated continuously, rather than in cycles of determined 
length as in conventional chemotherapy [105,106]. As a consequence, even mild-to-
moderate oral AEs may have a negative impact on health related quality of life, leading 
to unplanned treatment delays or interruptions, dose reductions or ultimately to 
cessation of therapy [6,7]. Therefore, minimizing and managing oral AEs is important. 




This article reviews the clinical presentation, terminology, pathogenesis, 
assessment and management of mTOR inhibitor-associated stomatitis (mIAS). In 
addition, other reported oral AEs that have been associated with mTOR inhibitors will 
be described. 
Terminology 
The terminology and classification of oral AEs associated with mTOR inhibitors has 
been inconsistent throughout different clinical trials. For example, in a review article by 
Bellmunt et al. on the AEs of temsirolimus for the treatment of renal cell carcinoma, the 
frequencies of mucositis, stomatitis, aphthous stomatitis and mouth ulceration were 
reported as distinct categories [8]. Moreover, mucosal inflammation and tongue 
ulceration were reported as distinct oral AEs [107,Merck, Pers. Comm.]. The terms oral 
mucositis and stomatitis are often used interchangeably, but they do not reflect 
identical processes. Oral mucositis is a Medical Subject Headings term that describes 
inflammation of oral mucosa resulting from chemotherapeutic agents or ionizing 
radiation. It typically manifests as erythema or ulcerations and may be exacerbated by 
local factors, such as secondary infections and trauma. Stomatitis is a less specific 
term that refers more generally to any inflammatory condition of oral tissues [9,108]. 
In a seminal paper describing the unique clinical features of oral ulcerations 
associated with mTOR inhibitors, Sonis et al. proposed the term mIAS in order to 
provide clarity and delineation from oral mucositis due to conventional cytotoxic 
chemotherapy and radiation [7]. Other authors also emphasized the importance of  
using consistent terminology [4,5,10,11]. Among oral medicine specialists managing 
patients with oral mucosal lesions associated with mTOR inhibitors, there is consensus 
that the term mIAS is preferable to the term oral mucositis. 
Clinical presentation & prevalence of mIAS & other oral 
complications 
The clinical presentation of mIAS typically involves solitary or multiple ulcerations 
resembling aphthous stomatitis, characterized as distinct, ovoid ulcers with a central 
gray area surrounded by a ring of erythema (Figure 1). Typically, ulcerations are small 
(<0.5 cm), whereas oral ulcerations caused by traditional cytotoxic chemotherapy 
agents (e.g., 5-fluorouracil) are typically larger, more irregular in shape, with or without 
surrounding erythema and without elevated borders [5,7]. 
Similar to conventional mucositis and aphthous stomatitis, mIAS almost exclusively 
affects the nonkeratinized, movable oral surfaces, including the buccal and labial 
mucosa, lateral tongue, soft palate and floor of mouth. Ulcerations affecting the 
keratinized oral mucosa (gingiva, tongue dorsum and hard palate) are more likely to 
have an infectious, particularly viral etiology [12]. Although mTOR inhibitors are 
immunosuppressive, it is not clear whether this puts patients at risk for oral infections. 





mIAS lesions typically present with a rapid onset (usually within 5 days), most 
frequently in the first cycle of mTOR inhibitor therapy. Most often mIAS is graded as 
mild to moderate in severity grades 1–2, according to the oral mucositis scale of the 
National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-
CTCAE) [13]. Most cases improve or resolve spontaneously despite continuing mTOR 
inhibitor treatment [11]. However, even small ulcerations can be very painful and can 
interfere with a patient’s ability to chew and swallow and as a result may compromise 
nutritional status. In some patients mIAS may persist over an extended period. A study 
characterizing toxicity in patients enrolled in the Phase III RECORD-1 trial, which 
evaluated everolimus for the treatment of metastatic renal cell carcinoma, indicated 
that 42% of the patients developed stomatitis, of which 39% experienced mild-to-
moderate stomatitis that resolved within 3 days [14]. However, nearly 10% required a 
dosage modification or treatment interruption, while nearly half required supportive 
therapies for symptom control. In a recent systematic review evaluating 44 studies of 
mTOR inhibitors, mIAS was identified as the most frequent AE overall (73.4%), the 
third most frequent severe AE (20.7%), accounting for 27.3% of dose reductions, and 
13.1% of discontinuations, and was the most frequent dose-limiting toxicity (52.5%) 
[15]. In patients enrolled in ridaforolimus trials, there was a notably higher frequency 
of severe mIAS and related dose modifications and discontinuations compared with 
the other mTOR inhibitors, most likely related to the intensity of therapy [16–18,Merck, 
Pers. Comm.].  
Mucositis induced by chemotherapy and radiotherapy to the head and neck area 
often leads to difficulties with swallowing (dysphagia) and need for a liquid diet. 
Pharyngitis and dysphagia have also been reported with ridaforolimus, but seem to 
occur less frequently than in conventional cancer treatments [11,14]. Throat pain has 
been reported in association with oral ulcerations [7,107,Merck, Pers. Comm.]. In 
addition, other clinically important AEs that disrupt oral function have been described 
relating to the use of mTOR inhibitors. These include altered taste/taste loss 
(dysgeusia/ageusia), oral sensitivity and pain without the presence of clinical oral 
lesions, and xerostomia [19,107,Merck, Pers. Comm.]. Compared with mIAS, less 
attention has been paid to these AEs and they have not been well described.  
Pathobiology 
While significant progress has been made in obtaining insight into the pathobiologic 
mechanisms of mucositis due to cytotoxic drugs and/or ionizing radiation, mIAS is a 
recently recognized phenomenon and its pathogenesis is not well understood [7]. 
Although it is not clear what mechanisms are involved in the development of mIAS, it 
is probable that these differ from what occurs in conventional oral mucositis based on 
differences in clinical presentation. The association with concomitant cutaneous AEs 
provides additional evidence to suggest a distinction between mIAS and oral mucositis 
induced by conventional cancer therapies [7,10]. The clinical resemblance of mIAS to 




aphthous stomatitis may indicate common pathobiological pathways, but also the 
pathobiology of aphthous stomatitis is not well understood. The etiology of recurrent 
aphthous stomatitis is believed to be multifactorial, including genetic, environmental, 
hormonal and emotional factors, in addition to trauma and irritating food and drink. 
Immune dysregulation is thought to play a role and several potential mechanisms have 
been described, including antibody-dependent cell-mediated cytotoxicity [20]. 
Moreover, loss of peripheral 
tolerance resulting in 
autoimmune reactions may 
occur and cross-reactions 
between a microbial antigen 
and a peptide within the oral 
epithelium may play a role 
[21]. Recently, it has been 
suggested that CD4+CD25+ 
Tregs are decreased and 
function improperly in 
patients suffering from 
recurrent aphthous 
stomatitis. Tregs are vital for 
the maintenance of 
peripheral tolerance 
throughout life and when the 
generation and expansion of 
these cells are decreased, 
this may result in loss of 
control over autoreactive T cells and consequently lead to loss of peripheral tolerance 
of the oral mucosa [22]. 
By contrast, several in vitro studies suggest that mTOR inhibitors increase 
stimulation of Tregs leading to increased peripheral tolerance, but mechanisms of 
action of rapamycin and its analogs are multifaceted and can exert both 
immunosuppressive and immunostimulatory effects [23]. Of interest is the hypothesis 
that in patients with mTOR inhibitor-induced interstitial pneumonitis, mTOR inhibitors 
may bind directly to tissue proteins evoking an autoimmune-like inflammatory 
response, mediated by conventional CD4 cells in the absence of infection [24]. 
Consistent with this observation, proinflammatory properties of mTOR inhibitors have 
also been described in various experimental models [25] and similar mechanisms may 
be involved in the development of mIAS.  
Moreover, impaired wound healing has been suggested to play a pathobiological 
role in aphthous ulceration and may also be involved in the pathogenesis of mIAS. It 
is known that angiogenesis and vascular cell proliferation are important for wound 
repair, and both processes may be impeded by mTOR inhibitors [26]. Furthermore, 
mTOR inhibitors may induce glucose levels to increase in patients with pre-existing 
Figure 1. Typical mammalian target of rapamycin inhibitor-
associated stomatitis with ulceration and an erythematous 
halo clinically resembling aphthous stomatitis in a patient 
treated with temsirolimus. 





diabetes mellitus and in nondiabetic patients, which may also have a negative impact 
on wound healing. 
With respect to the non-mIAS oral AEs as a response to mTOR inhibiting therapy, 
the potential mechanisms are even less clear. Greater characterization of these AEs 
and their relationship with the presence or absence of mIAS is necessary before 
mechanisms can be elucidated. 
Assessment scales 
Numerous oral mucositis grading scales have been developed over the years to grade 
conventional mucositis [27]. The complexity and detail of these scales varies 
significantly and the selection of a mucositis scale is often influenced by the reason for 
assessing mucositis (clinical care or research) [28]. Frequently used scales for 
conventional oral mucositis assessment, such as the WHO Oral Toxicity Scale and the 
Oral Mucositis Assessment Scale [29], were not developed to evaluate mIAS 
ulcerations and mIAS-associated complaints. In clinical trials of mTOR inhibitors, AEs, 
including mIAS, have been described primarily according to NCI-CTCAE versions 2.0 
and 3.0 [19,109]. The mucositis scales of these prior versions of the NCI-CTCAE 
include grading of objective signs as well as subjective symptoms. However, such 
scales, which depend on ulceration size and extent, may underestimate the morbidity 
of mIAS, since even small localized ulcerations can be extremely painful and affect 
compliance. In this manner, the WHO scale may be a reasonable instrument for 
assessing mIAS. The mucositis component of the NCI-CTCAE version 4.0 is purely 
symptom and function driven [110]. However, this scale as well as the WHO scale 
emphasizes the impact of oral lesions on the subject’s diet (e.g., WHO grade 3 is given 
when only a liquid diet can be tolerated). Since mIAS typically does not impact patients’ 
diet to the same extent as conventional mucositis, such scales may not be sensitive 
enough to measure the impact of mIAS. In summary, scales developed for oral 
mucositis secondary to conventional chemotherapy and radiation therapy have several 
limitations when applied to mIAS. 
The primary variables determining the morbidity of mIAS are the pain experienced 
by the subject and the duration of the lesions. It is important that these factors be 
carefully assessed in scoring mIAS. An accurate assessment of the morbidity of the 
toxicity will allow for informed decisions on dose modification and interruption, which 
have far reaching consequences. Therefore, a new scale has been developed for 
mIAS. This scale has a subjective component measuring pain and an objective 
component measuring duration of lesions. The subjective grading criteria range from 
0 for no pain to 3 for a pain score of 6 or higher on a 0–10 scale. The objective grading 
criteria range from 0 for no visible lesion to 3 for lesion(s) persisting for more than 7 
days. It is suggested that dose modification be considered 
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Table 1. Selected tools and their potential to assess mammalian target of rapamycin inhibitor-associated stomatitis. 
Scale Developed for Scale description Main driver of scale Evaluation includes Suitable for use in 
mIAS 
Suitable for use 












OM induced by 
conventional CT, 
RT, HSCT 
Clinician- rated, combined, 
objective, subjective, and 
functional parameters; 0-4 
point scale 
Ulceration and ability 
to eat and drink 
Anatomical oral sites 
typical at risk for 
conventional OM and 
mIAS 
+/- 




- - [29] 
OMAS  OM due to HSCT Clinician-rated, objective 
tissue scale; yes/no score 
Cumulative surface of 
ulcerations, and 
severity of redness 
Anatomical oral sites 
typical at risk for 
conventional OM and 
mIAS 
+/- 












CT, RT, HSCT 
Clinician-rated, objective, 
subjective, and functional 
parameters; 0–5 point 
scale 
Severity of AE; need 
for interventions, 
impact on ADL 
Anatomical sites 
typically at risk for 
conventional OM and 
mIAS 






CT, RT, HSCT 
Clinician rated, objective, 
subjective, and functional 
parameters; 0–5 point 
scale 
Severity of AE; need 
for interventions, 
impact on ADL 
Oral and 
oropharyngeal 
symptoms and dietary 
limitation associated 
with conventional OM 
+/- 
High risk for 
underscoring of 
morbidity of mIAS 
+/- +/- [110] 
VHNSS2.0  Head and neck 
AEs of CRT/RT for 
HNSCC 
PRO; subjective and 
functional parameters; 
includes Likert scale for 
each item 
Severity of AEs 
associated with 




complications in the 
head and neck area, 
no objective 












mIAS scale mIAS Clinician-rated objective 
component and patient-
rated subjective 




to mIAS and severity 
of associated pain 




developed for mIAS 
- - [30] 
++: Highly suitable to assess mIAS; +: Suitable to assess mIAS; +/-: Somewhat suitable to assess mIAS; -: Not suitable to assess mIAS; ADL: Activities of daily living; 
AE: Adverse event; CRT: Chemoradiotherapy; CT: Chemotherapy; HNSCC: Head and neck squamous cell carcinoma; HSCT: Hematopoietic stem cell 
transplantation; mIAS: mTOR inhibitor-associated stomatitis; mTOR: Mammalian target of rapamycin; NCI-CTCAEv3.0: National Cancer Institute-Common 
Terminology Criteria for Adverse Events version 3.0; NCI-CTCAEv4.0: National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0; OM: 
Oral mucositis; OMAS: Oral Mucositis Assessment Scale; PRO: Patient-reported outcome measure; RT: Radiation therapy; VHNSS2.0: Vanderbilt Head and Neck 
Symptom Survey version 2.0. 





only when both subjective and objective grades are 3, representing persistent lesions 
with significant pain, despite analgesic use [30]. These parameters (duration and pain 
of the lesions) have an effect upon oral and pharyngeal function. 
In addition, detailed assessment of other oral and oropharyngeal AEs that may be 
associated with mTOR inhibitors use (e.g., swallowing problems, sensitive mucosa, 
dysgeusia and xerostomia) is warranted to obtain an insight of the prevalence and 
severity of these complaints and to assess whether these complaints are associated 
with mIAS or may also develop independently of clinically assessable oral ulceration. 
The Vanderbilt Head and Neck Symptom Survey version 2.0 measures patient-reported 
treatment-related symptom burden and oral health outcomes in the head and neck area 
and function loss within symptom subscales, including nutrition, taste, pain, voice, 
swallowing and mucus/dry mouth [31]. This scale may be adapted to assess such other 
mTOR inhibitor-associated oral complaints and their impact on patients’ health-related 
quality of life (Table 1). 
Prevention & treatment implications 
Prevention and treatment of mTOR inhibitor-associated oral complications can be 
critical in order to maintain regimen adherence and reduce the need for dose 
interruptions or reductions. To date, interventions aimed at managing mTOR inhibitor-
associated oral complaints are mainly based on expert opinion and show similarities 
with basic oral care measures aimed at the prevention and treatment of conventional 
oral mucositis as well as management strategies for aphthous stomatitis (Table 2). 
Management begins with assessment and patient education on oral hygiene measures, 
diet modifications and pain management [4,8,20,32]. In most cases pain can be 
controlled with mouthwashes or locally applied products containing lidocaine or doxepin 
and mucosal coating agents [33–35]. Additionally, over the counter non-narcotic 
analgesics may play a role, whereas prescription of opioids is seldom necessary 
[10,20,36]. Most often mIAS is self-limiting, but in persistent cases treatment with local 
or systemic corticosteroids may be considered. This is on the premise that mIAS 
resembles aphthous stomatitis, in which management protocols include the use of 
corticosteroids. Topical high-potency corticosteroid gels were reported to be effective in 
mIAS in a series of reports from both the solid organ transplantation and oncology 
literature [14,20,36]. In addition, intralesional administration of corticosteroids has been 
reported to be an effective treatment option [5]. In more severe and refractory cases, or 
when painful esophageal ulcers are present, pulsed high-dose systemic corticosteroid 
therapy may be indicated [10,20,36]. In severe and persistent cases, dose reductions 
may be considered [5], and specific strategies for dosage reduction have been 
described [14,37]. Dose modifications or permanent discontinuation of mTOR inhibitors 
should only be considered when palliative management options have failed or if the 
patient refuses to continue therapy. 




The role of oral infections that may develop in isolation or concomitant with mIAS is 
not clear. Potentially, oral bacteria, viruses and fungi may contribute to the severity of 
oral ulceration [38,39]. Secondary candidiasis is a common side effect of topical steroid 
therapy. If this occurs, topical antifungal therapy should be initiated. However, it should 
be taken into consideration that systemically absorbed azole antifungal agents may 
increase the serum concentration of the mTOR inhibitor and may increase toxic effects 
through cytochrome P450-mediated interaction. In such cases a topical nonazole 
antifungal agent is preferred. 
 





Prevention Educate patients on mTOR-associated oral complications and the importance of 
maintaining good oral care; pay special attention to mouthwash with saline at least 
four times a day 
Advise regular dental check-ups and dental prophylaxis 
Eliminate sources of trauma (e.g., sharp edges and ill-fitting prostheses) 
Advise to avoid hard, hot, sharp or spicy food 
Assess the oral cavity regularly and advise to inform caregiver at first signs and 




Increase the frequency of the mouthwash with saline, for example, every 1–2 h; if 
mouthwash is painful, recommend to use pain medication beforehand 
Assess the oral cavity regularly 
Diagnose and treat oral mucosal infections when present 
Assess severity of oral sensitivity/pain 
Provide pain management (e.g., viscous lidocaine 2%, coating agents, calcium 
phosphate solution and, when needed, systemic approaches following the WHO 
pain management ladder) 
Consider a topical NSAID (e.g., amlexanox 5% oral paste) 
Consider high potency corticosteroids (dexamethasone [0.1% mg/ml]; clobetasol gel 
or ointment [0.05%]) 
Severe mIAS Provide adequate pain management 
Consider intralesional triamcinolone (weekly; total dose 28 mg) and topical 
clobetasol gel or ointment (0.05%) 
In recurrent mIAS or esophageal lesions: consider systemic corticosteroids (high-
dose pulse 30–60 mg oral prednisone or prednisolone [1 mg/kg for 1 week followed 
by dose tapering over the second week]) 
Consider dose reduction of mTOR inhibitor 
Complaints of 
dry mouth  
Advice adequate fluid intake 
Consider sugarless chewing gum or candy, salivary substitutes, or sialogogues in 
patients with oral dryness 
This table is based, in part, on expert opinion-based recommendations provided by Pilotte et al. [10], 
de Oliveira et al. [11] and Scully [21]. 
mIAS: mTOR inhibitor-associated stomatitis; mTOR: Mammalian target of rapamycin. 
 
Dry mouth can be managed with increased hydration and use of taste and 
mechanical stimulation of the salivary glands with sugar-free chewing gum or candies. 





Palliation with mouth-wetting agents may provide temporary relief. In addition, the 
prescription of sialagogues can be considered in patients with hyposalivation [40]. In 
order to help patients coping with taste alterations, the addition of tastants to food, such 
as increased spices, sauces and umami flavoring, and elimination of tastes experienced 
as bitter or sour in the diet should be considered. 
Conclusion & future perspective 
mIAS and skin AEs are among the most frequent side effects of mTOR inhibitors used 
in anticancer treatment. However, oral complaints are probably under-reported in the 
literature since studies were not primarily directed to investigate oral complications and 
most available data originate from spontaneous patient reports in safety and efficacy 
studies of mTOR inhibitor agents. In addition, measurement scales and terminology 
differ among studies, which further complicates insight into the prevalence of these oral 
AEs. 
Prospectively designed observational studies using well-defined terminology and 
appropriate assessment and grading tools are necessary to better characterize the 
prevalence and severity of mIAS and other associated oral complications. In addition, 
the prevalence of oral complications associated with mTOR inhibitors may differ 
between agents and different routes and schedules of administration. 
An animal model of mIAS would allow better characterization of early events and 
mechanisms driving its pathology. Moreover, investigations into the relationship 
between oral and nonoral AEs, including those of the skin, may be helpful in obtaining 
a better understanding of potentially shared pathobiologic mechanisms and potentially 
lead to improved management strategies. In addition, new insights into mIAS 
pathogenesis and advances made in mIAS management may improve the management 
of aphthous stomatitis. 
An exploratory study identified polymorphisms in genes encoding for metabolizing 
enzymes, efflux transporters and drug targets that are associated with sunitinib-related 
AEs [41]. Similarly a future study aimed at identifying genetic markers of the 
pharmacokinetic and pharmacodynamic pathways of mTOR inhibitors that may 
predispose for the development of AEs might predict the risk of developing mIAS. This 
in combination with a better understanding of nongenetic determinants of mTOR toxicity 
should help to optimize drug treatment in individual patients.  
New mTOR inhibitor compounds are currently under development as anticancer 
agents. These agents have the ability to block both mTORC1 and mTORC2. These dual 
inhibitors are likely to be more efficacious than presently available mTOR inhibitors that 
only inhibit mTORC1, and induce the activation of other signaling pathways mediated 
by mTORC2, resulting in proliferative and survival signals that impede their anticancer 
efficacy. In addition, combinations of mTOR inhibitors, conventional cytostatic therapy 
and agents targeting growth factor receptors, such as EGFR, may result in enhanced 
anticancer efficacy [42]. However, these combined treatment approaches, particularly 




those involving EGFR inhibitors, may increase the incidence and severity of mucosal 
and skin AEs [4]. 
A growing number of cancer patients will be treated with mTOR inhibitors, most 
frequently as outpatients and over a long time span. This indicates a need for awareness 
and early recognition of oral complications not only among oncologists and oncology 
nurses, but also among community healthcare specialists, such as primary care doctors 
and dental professionals. Healthcare professionals should educate patients on the 
importance of early reporting of oral complaints. A combination of basic oral care 
measures, pain management and topical corticosteroid therapy appears to be an 
effective approach to management, but well-designed prospective studies are required. 
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Executive summary 
Mammalian target of rapamycin inhibitors 
▪ Three mammalian target of rapamycin (mTOR) inhibitors are currently used in 
oncology: temsirolimus, everolimus and ridaforolimus. 
Terminology 
▪ mTOR inhibitor-associated stomatitis (mIAS) is preferred to distinguish this entity 
from conventional chemotherapy-associated mucositis. 
Clinical presentation & prevalence of mIAS & other oral complications 
▪ Lesions are usually found on the nonkeratinized mucosa of the lips, floor of mouth, 
lateral tongue, buccal mucosa and soft palate. mIAS usually develops early after 
the administration of mTOR inhibitors and is self-limiting in most cases. 
Pathobiology 
▪ The pathobiology of mIAS is poorly understood, but may have similarities with 
mechanisms involved in aphthous stomatitis. These include immune mechanisms 
such as antibody-dependent, cell-mediated cytotoxicity and immune complex 
formation; this is different from what is considered to occur in conventional oral 
mucositis. 
Other mTOR inhibitor-associated oral complaints 





▪ These include oral pain and mucosal sensitivity, xerostomia, dysphagia, altered or 
loss of taste and decreased oral intake. 
Assessment scales 
▪ The development of separate assessment and grading tools for mIAS seems 
justified. Scales that are driven by ulceration size may under-report mIAS, since 
even small ulcers can be very painful. Modified versions of existing scales may be 
of value and should be validated for mTOR inhibitor-associated oral adverse 
events. An mIAS-specific assessment tool has been generated. 
Prevention & treatment implications 
▪ To date, evidence-based interventions for managing mIAS are not available. 
Principles of basic oral care including patient education on oral hygiene measures 
and avoiding hot, hard, spicy or acid foods are advised. In addition, other 
management strategies for aphthous stomatitis including pain management and 
the use of corticosteroids seem effective. 
Conclusion & future perspective 
▪ Prospective studies investigating the prevalence and clinical presentation of mIAS 
and other oral complications should be performed. In order to obtain meaningful 
outcomes, the use of well-defined terminology together with development of 
appropriate assessment and grading scales is mandatory. Experimental and 
clinical studies are required to characterize the pathogenesis of mIAS and clinical 
trials should be developed to evaluate interventions. Oncologists, oncology nurses, 
oral healthcare professionals, dermatologists, pharmacologists and basic scientists 
should be involved in these efforts. 
Concluding remarks 
▪ mIAS is a frequent but typically mild-to-moderate complication that is often self-
limiting. When necessary, management is generally effective. The relationship with 
other oral adverse events is less clear but these can also typically be managed 
conservatively. In some cases, patients may require dose reduction. 
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terminology 
Oral and gastrointestinal mucositis caused by high-dose chemotherapy and/or 
radiation continues to be an important clinical problem. Fortunately, there have been 
strategic advances over the past decade relative to understanding the molecular basis 
of the injury, which in turn continues to provide opportunity for development of drugs 
and devices to manage the toxicity. The guidelines delineated below represent updates 
from the version published in the 2011 Annals of Oncology [1] which were primarily 
based on the previous version of the guidelines produced by the Mucositis Study Group 
of the Multinational Association of Supportive Care in Cancer/International Society for 
Oral Oncology (MASCC/ISOO) [2].  
Three key advances have occurred in the three years following publication of the 
most recent ESMO mucositis guidelines. Both of these advances, as listed below have 
been completed at the international, interprofessional level: 
• A comprehensive update of oral and gastrointestinal tract mucositis guidelines 
previously produced by the Mucositis Study Group of MASCC in 2007 [2]. The most 
recent updated evidence-based guidelines, published in 2014 [3],represent the 
state-of-the-science for mucositis management in patients receiving conventional 
chemotherapy and/or head & neck radiation. 
• Expert opinion on management of oral mucosal lesions caused by targeted cancer 
therapies such as mammalian target of rapamycin (mTOR) inhibitors and multi-
targeted tyrosine kinase inhibitors (mTKI’s) [4]. 
• Novel approaches to enteral nutrition in patients receiving head and neck radiation 
[5-9]. In France and French-speaking countries, the Société Francophone de 
Nutrition et Métabolisme (SFNEP) and the Association Francophone pour les Soins 
Oncologiques de Support (AFSOS) published comprehensive recommendations 
for cancer patients [10-12]. 
Mucositis is defined as inflammatory and/or ulcerative lesions of the oral and/or 
gastrointestinal tract. Infectious disease, immune deficiency and medications can be 
causative. High dose cancer chemotherapy and radiotherapy in head and neck cancer 
are two of the major causes of mucositis. 
The terms oral mucositis and stomatitis are often used interchangeably, but they 
do not reflect identical processes [4, 13].  





‘Mucositis’ is a Medical Subject Heading term that describes inflammation of 
mucosa resulting from chemotherapeutic agents or ionising radiation. It typically 
manifests as erythema or ulcerations and may be exacerbated by local factors, such 
as secondary infections and trauma. Examples of chemotherapeutic agents which may 
cause oral mucositis are cyclophosphamide, doxorubicin, vincristine, etoposide, 
ifosfamide, methotrexate, docetaxel, paclitaxel, cisplatin, carboplatin, oxaliplatin, 
irinotecan, 5-fluorouracil (5-FU), leucovorin, and vinorelbine. 
‘Stomatitis’ refers more generally to any inflammatory condition of oral tissues [13]. 
This term should be used for oral complaints not related to chemotherapeutic agents 
or ionising radiation, such as targeted therapies. Clinically important adverse events 
(AEs) that disrupt the normal oral function have been described related to use of 
targeted therapies. These include altered taste and taste loss, oral sensitivity and pain 
without the presence of clinical oral lesions, and xerostomia [4]. Compared with mTOR 
inhibitor-associated stomatitis, less attention has been paid to these AEs and they 
have not been accurately described. Examples of targeted agents which may cause 
stomatitis are bevacizumab, erlotinib, sorafenib, sunitinib, gefitinib, and lapatinib. 
Regarding stomatitis induced by mTOR inhibitors, Sonis et al. proposed the term 
‘mTOR inhibitor-associated stomatitis’ (mIAS) in order to provide clarity and delineation 
from oral mucositis due to conventional cytotoxic chemotherapy and radiation [14]. 
There is consensus among oral medicine specialists managing patients with oral 
mucosal lesions associated with mTOR inhibitors that the term mIAS is preferable to 
the term oral mucositis [4, 15–18]. Examples of mTOR inhibitors are temsirolimus and 
everolimus. 
‘Alimentary tract mucositis’ refers to the expression of mucosal injury across the 
continuum of oral and gastrointestinal mucosa, from the mouth to the anus. 
oral mucositis in patients receiving head and neck radiation 
Incidence of World Health Organization (WHO) grade 3 or 4 oral mucositis in patients 
receiving head and neck radiation (e.g., 60-70 Gy) to the oral cavity approaches 85%, 
but all treated patients have some degree of oral mucositis. Mucositis is one of the 
prime limiting factors of chemoradiation for advanced head and neck carcinoma. The 
oral pain associated with the lesions frequently leads to the need for enteral nutritional 
support with or without use of a feeding tube or gastrostomy, as well as use of opioids, 
with the objective of maintaining dose intensity throughout the entire radiation regimen. 
oral and gastrointestinal mucositis in patients undergoing 
hematopoietic stem-cell transplantation 
Incidence of WHO grade 3 or 4 oral mucositis can be as high as 75% in patients 
undergoing hematopoietic stem-cell transplantation (HSCT), depending on the 
intensity of the conditioning regimen used and the use of methotrexate prophylactically 
to prevent graft-versus-host disease. Management of oral and gastrointestinal 




mucositis is one of the main challenges during the period of aplasia, with risk of sepsis 
related to degree of mucosal barrier breakdown and depth of marrow suppression. 
alimentary tract mucositis associated with standard multi-
cycle chemotherapy (with or without radiotherapy)  
A wide range of standard or high-dose chemotherapeutic regimens continues to be 
causative of clinically significant oral and gastrointestinal mucositis [1]. 
Chemotherapy with 5-FU, capecitabine, irinotecan, or tegafur can lead to a 
clinically significant incidence of alimentary tract mucositis (e.g. ∼25% of advanced 
colorectal cancer patients experiencing grade 3–4 diarrhoea secondary to irinotecan 
and oxaliplatin [2]). Eighteen percent of patients receiving carboplatin and paclitaxel 
plus radiotherapy develop severe oesophagitis. Phase I modelling of drug dose and 
sequence may be of benefit to future patients relative to these treatment paradigms. 
stomatitis in patients undergoing targeted therapy 
In recent years, unique oral mucosal lesions have been reported in association with 
administration of targeted cancer therapeutics (e.g. TKIs and mTOR inhibitors). 
Elting et al. determined via meta-analysis that mucosal toxicities associated with 
selected targeted agents were most frequent among patients treated with 
bevacizumab, erlotinib, sorafenib, or sunitinib, although this difference was confined to 
low-grade stomatitis [19]. The clinical significance of these findings is unclear given its 
low incidence and mild severity. This analysis by Elting et al. shows that stomatitis, 
gastritis, oesophagitis, and xerostomia are occasional complications of therapy with 
the targeted agents that they studied, but these problems are not significantly more 
common or more serious than those observed with standard of care regimens.  
In a systematic review evaluating 44 studies of mTOR inhibitors, mIAS has been 
identified as the most frequent AE overall (73.4%) [20]. The lesion was the third most 
frequent severe AE (20.7%), accounting for 27.3% of dose reductions, and 13.1% of 
discontinuations, and was the most frequent dose-limiting toxicity (52.5%). The 
majority of mIAS occurs soon after initiation of the agent [21]. 
gastrointestinal mucositis in patients undergoing targeted 
therapy 
The study by Elting et al. further showed most of the targeted agents studied were 
associated with significantly higher risks (2- to 8-fold) of developing either all-grade or 
high-grade diarrhea than the conventional regimens [19]. Their analysis showed that 
patients treated with erlotinib, gefitinib, lapatinib, sorafenib, and sunitinib have a 
significantly higher risk of having both allgrade and high-grade diarrhoea than those 
receiving conventional regimens. The risk can be as high as 8-fold for patients treated 
with lapatinib. These results are consistent with prior reviews and case series on this 
topic. Keefe et al. indicated that diarrhoea is a common side-effect of targeted therapy 





and, when used in combination with chemotherapy, these targeted drugs can  cause 
severe diarrhoea [22]. Harandi et al. also reported that diarrhoea is strongly associated 
with the use of anti-EGFR TKIs [23]. Other studies cited diarrhoea as a common side-
effect as well [24, 25]. 
Mechanisms underlying diarrhoea caused by targeted therapies have been less 
extensively studied than diarrhoea occurring secondary to chemotherapy. Additional 
research is thus needed relative to pathobiology of targeted therapy-associated 
diarrhoea, as well as optimal strategies for its prevention and treatment. 
diagnosis and pathology/molecular biology 
Diagnosis of oral and gastrointestinal mucositis caused by high dose cancer therapy 
is typically based upon history and clinical examination. The temporal relationship 
between timing of administration of chemotherapy or radiation in relation to the 
symptoms and signs is often sufficient to clinically document the condition. 
Diagnosis of oral mucosal lesions caused by targeted cancer therapies can 
typically be clinically confirmed by history and clinical examination. However, unlike 
oral mucositis caused by conventional cancer therapy, oral mucosal lesions may first 
occur several weeks or months after the initial dose exposure [14]. 
staging and risk assessment 
staging 
A variety of assessment scales exist for staging of oral and/or gastrointestinal injury. 
The WHO scale is frequently utilised in the context of grading mucosal injury as a 
primary outcome. The National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI-CTCAE) [26] instrument is also commonly utilised in oncological 
clinical trials. Scales developed for oral mucositis secondary to conventional 
chemotherapy and radiation therapy have several limitations when applied to targeted 
agents. Two assessment tools, the Vanderbilt Head and Neck Symptom Survey 
version 2.0 (VHNSS2.0) [27] and the mIAS scale [28] can be of use within this 
population. The VHNSS was designed to screen both for tumour and for treatment-
specific symptoms in patients with head and neck cancer undergoing concurrent 
chemoradiation and following cancer therapy. The list of possible symptoms is quite 
detailed. Since the oral complaints associated with targeted therapies are not fully 
explored, the VHNSS2.0 can be used to assess signs and symptoms of oral 
complaints, also not developed for this population [27]. In addition, the Bristol stool 
chart is available for the assessment of the consistency of the stool [29]. 
oral mucositis grading 
Two of the most commonly utilised scales for oral mucositis are the WHO and NCI-
CTCAE scales [26]: 




WHO scale for oral mucositis 
Grade 0 = no oral mucositis 
Grade 1 = erythema and soreness 
Grade 2 = ulcers, able to eat solids 
Grade 3 = ulcers, requires liquid diet (due to mucositis) 
Grade 4 = ulcers, alimentation not possible (due to mucositis) 
National Cancer Institute Common Terminology Criteria for Adverse Events version 
4.03 [26] 
The definition used for this grading is “A disorder characterized by inflammation of 
the oral mucosal [sic: “mucosa”]”. 
Grade 1 = asymptomatic or mild symptoms; intervention not indicated 
Grade 2 = moderate pain; not interfering with oral intake; modified diet indicated 
Grade 3 = severe pain; interfering with oral intake 
Grade 4 = life-threatening consequences; urgent intervention indicated 
Grade 5 = death 
Most of the scales that are utilized for clinical care incorporate the collective 
measurement of oral symptoms, signs and functional disturbances. By comparison, 
some scales are primarily centered in clinician-based observation of mucosal tissue 
injury (e.g., erythema, ulceration). These latter scales have particular value in clinical 
trial-based assessment of oral mucositis. 
gastrointestinal mucositis grading 
In contrast, there is a limited number of instruments available for assessment of 
gastrointestinal mucositis. These scales typically measure indirect outcomes of 
mucosal injury, including diarrhoea. However, interpretation of such data can be 
confounded by other clinical conditions and interventions that also contribute to the 
event being measured. New technologies may lead to enhanced assessment 
strategies for gastrointestinal mucositis. Tracheal mucositis, pharyngeal mucositis, 
laryngeal mucositis, small intestinal mucositis, rectal mucositis, and anal mucositis are 
terms that can be scored separately in the CTCAEv4.03 within the system organ class 
‘Gastrointestinal disorders–Other, specify’. Diarrhoea is a term that is scored frequently 
within gastrointestinal mucositis also, which should not be confused with loose stool. 
The Bristol stool chart [29] is a useful tool to help identify variation in consistency of 
stool. The stools are classified into seven types, with types 5 and 6 tending towards 
diarrhoea but still loose stool and type 7 actually as diarrhoea, since that is watery 
stool. Since according to the NCI-CTCAE definition only watery stool is diarrhoea, this 
delineation between the two types is important. Furthermore, it is important to delineate 
this range of stool consistency in order to optimise clinical decision making for these 
patients. For example, one can consider low-dose loperamide, with no chemotherapy 
dose modification, for the patient with a loose or mushy stool. Conversely, either high-
dose loperamide with risk for resultant constipation, and/or chemotherapy dose 





delay/dose interruption, may be warranted in the patient with systematically graded 
severe diarrhoea. 
diarrhea 
Definition: A disorder characterized by frequent and watery bowel movements 
NCI-CTCAE version 4.03 [26]. 
Grade 1 = increase of <4 stools per day over baseline; mild increase in ostomy 
output compared with baseline 
Grade 2 = increase of 4–6 stools per day over baseline; moderate increase in 
ostomy output compared with baseline 
Grade 3 = increase of ≥7 stools per day over baseline; incontinence; hospitalization 
indicated; severe increase in ostomy output compared with baseline; limiting self-
care ADL 
Grade 4 = life-threatening consequences; urgent intervention indicated 
Grade 5 = death 
targeted therapy-associated stomatitis grading. There is no separate definition for 
targeted therapy-associated stomatitis defined in the NCI-CTCAE version 4.03 [26]. 
Undefined AE’s can be graded within the system organ class “Gastrointestinal 
disorders - Other, specify” with the addition of stomatitis. 
Grade 1 = asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated 
Grade 2 = moderate; minimal, local or non-invasive intervention indicated; limiting 
age appropriate instrumental ADL 
Grade 3 = severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of existing hospitalization indicated; disabling; 
limiting self-care ADL 
Grade 4 = life-threatening consequences; urgent intervention indicated 
Grade 5 = death 
Use of clinical assessment tools that are primarily driven by ulceration size may 
underestimate mIAS and that assessment should include patient-reported outcomes. 
Boers-Doets and Lalla have thus proposed a new scale with a subjective component 
measuring pain and an objective component measuring duration of lesions [28]. It is 
suggested that dose-modification be considered only when both subjective and 
objective grades are 3, representing persistent lesions with significant pain, despite the 
use of analgesics or other palliative care. Measurement of mIAS using this scale is 
designed to facilitate optimal management of the underlying malignancy, resulting in 
improved outcomes. 
Subjective 
Grade 0 = no oropharyngeal pain attributed to mIAS 
Grade 1 = oropharyngeal pain attributed to mIAS, with average oropharyngeal pain 
score (over the last 24 hours) reported as 2 or less on a 0-10 scale 
Grade 2 = oropharyngeal pain attributed to mIAS, with average oropharyngeal pain 
score (over the last 24 hours) reported as 5 or less on a 0-10 scale 




Grade 3 = oropharyngeal pain attributed to mIAS, with average oropharyngeal pain 
score (over the last 24 hours) reported as 6 or more on a 0-10 scale 
Objective 
Grade 0 = no visible mIAS (i.e. no erythema and no ulceration, attributed to mIAS, 
in the oropharyngeal area) 
Grade 1 = oral and/or pharyngeal erythema, attributed to mIAS, but no ulceration 
Grade 2 = visible oral and/or pharyngeal ulceration(s), attributed to mIAS, of 
duration < 7 days 
Grade 3 = visible oral and/or pharyngeal ulceration(s), attributed to mIAS, with at 
least one ulceration persisting for ≥ 7 days 
risk assessment 
Risk of developing mucositis has classically been directly associated with modality, 
intensity, and route of delivery of the cancer therapy. Combination therapy (e.g. head 
and neck radiation with concurrent chemotherapy) may increase the severity of oral 
mucositis. Unlike success in reducing long-term salivary hypofunction and xerostomia 
when parotid glands are spared [30], incidence and severity of acute mucosal toxicity 
have not generally been significantly reduced by utilisation of state-of-the- science 
radiation technologies (e.g. volumetric modulated arc therapy). 
While this modelling continues to be valid, there appear to be additional risk factors 
(e.g. genetic polymorphisms) in some cohorts that account for a degree of clinical 
expression. Further study of these more recently defined factors will likely strategically 
advance the pathobiological model in relation to clinical expression of toxicity. 
Among patient-related risk factors, comorbidities (e.g. malnutrition) can contribute 
important risk. All patients should be screened for nutritional risk and early enteral 
nutrition initiated in the event swallowing difficulties develop. In addition, patients who 
develop clinically significant salivary hypofunction/xerostomia due to anti-emetic or 
other anti-cholinergic drugs administered during acute cancer treatment may 
experience increased discomfort from oral mucositis. 
preventive measures 
Preventive measures are important in reducing the severity of stomatitis. Sources of 
trauma (e.g. sharp edges and ill-fitting prostheses) should be eliminated and painful 
stimuli such as hot foods and drinks and hard, sharp, or spicy foods should be avoided. 
Effective oral hygiene is crucial; it is important that patients be appropriately educated 
about oral complications before treatment. The patient should also be advised to have 
regular dental examinations in order to have the oral cavity assessed and that they 
should inform the health care professional at first signs and symptoms of oral 
complications [4]. 





basic oral care and good clinical practice 
mucositis caused by chemotherapy and/or head & neck radiation. Basic oral care is 
key in preventing and reducing oral injury; educating the patient regarding oral hygiene 
is thus very important. A comprehensive Basic Oral Care protocol is outlined in Table 
1. McGuire et al. concluded that, due to inadequate and/or conflicting evidence, no 
guidelines for the prevention or treatment of oral mucositis were possible for the 
interventions of dental care, normal saline, sodium bicarbonate, mixed medication 
mouthwash, chlorhexidine in patients receiving chemotherapy or haematopoietic stem 
cell transplant, or calcium phosphate [31]. Based on this conclusion, no 
recommendation in favour of normal saline mouthwashes is possible. Rather, plain 
water can be used; this approach is typically well tolerated by patients and may 
promote patient adherence to basic mouth care practices. 
mIAS. Comparable measures can be followed for basic oral care in patients on 
targeted therapy, with one exception. With targeted agents, saline-containing 
mouthwashes should be used instead of plain water because of the microbial burden 
that is considered to intensify formation of oral injury in this population. There is 
currently no systemically derived evidence for this approach, but since targeted 
therapies are associated with inflammation and localised and systemic infections, this 
mucosal hygiene approach may be considered until a more comprehensive, evidence-
based approach has been developed. 
Evidence related to this modelling provides guidance as to types of microbial 
colonisation and clinical infection. For example, in a retrospective study of 221 patients 
treated with EGFR inhibitors, 38% demonstrated evidence of infection at sites of 
dermatological toxic effect [32]. Furthermore, 22.6% had cultures positive for 
Staphylococcus aureus (S. aureus), and 5.4% of the 221 patients cultured positive for 
methicillin-resistant S. aureus. Less frequent infections included herpes simplex 
(3.2%), herpes zoster (1.8%), and dermatophytes (10.4%), with Candida 
onychomycosis being the most common yeast infection (5.9%). The seborrhoeic 
region is the most frequently documented site of infection. In addition, patients with 
leucopenia have higher risk for infection than those patients who do not experience 
leucopenia (P = 0.005). Others have reported dermatological infection and 
inflammation associated with EGFR inhibitors [33, 34] as well as with VEGFR inhibitors 
[35, 36]. 
  




Table 1. Example of a Basic Oral Care Protocol (expert opinion) 
Two key strategies for mitigation of oral mucosal injury before and during treatment are: 
• Maintenance of optimal nutritional support throughout the entire period of cancer therapy. 
• Developing a daily oral hygiene routine, including four times daily brushing teeth with a soft brush 
and using mouth rinses. This approach can contribute to reduction and ideally prevention of oral 
tissue injury and associated pain, nutritional compromise and related adverse outcomes.  
The following information is presented as a portfolio of patient-based instructions: 
General measures: • Inspect daily your oral mucosa. 
• Have your dental team eliminate sources of trauma (e.g., ill-fitting 
prostheses; fractured teeth). 
• Lubricate lips with (sterile) Vaseline/white paraffin, lip balm or lip cream.  
• Drink ample amount of fluids to keep the mouth moist. 
Brushing teeth: • Use a soft toothbrush or swab (as tolerated) after meals and before sleep. 
Brushing with a soft toothbrush reduces risk of bleeding. Each month you 
should utilise a new soft toothbrush. 
• Clean the dentition and gingiva with a mild fluoride-containing, non-foaming 
toothpaste. 
• Brush teeth twice a day (after meals and at bedtime) according to the Bass 
or modified Bass method. If using an electric toothbrush, utilise the 
techniques cited in the product description instead. 
• Rinse the brush thoroughly after use with water and store the toothbrush in 
a cup with the brush head facing upward. 
• If you are used to do so, clean the area between the teeth once a day. 
Consult a dental hygienist/dentist about the most appropriate interdental 
cleaner (floss, toothpick, brushes). In case you are not used to use 
interdental cleaners on a regular base, do not start with it while on cancer 
therapy, since it can break the epithelial barrier, visible through gingival 
bleeding. 
Rinse mouth: • Rinse mouth with an alcohol-free, mouthwash upon awakening and at least 
four times a day after brushing, for approximately 1 minute with 15 ml 
mouthwash; gargle and then spit out. During the first half hour after rinsing 
avoid eating and drinking. 
Denture care: • Remove the dentures before performing oral care. Brush the dentures with 
toothpaste and rinse with water; clean the gums. 
• Defer wearing dental prostheses as much as possible until the lining tissues 
of your mouth are healed. If in the hospital soak the denture for 10 minutes 
in chlorhexidine 0.2% (e.g. Hibident®) before inserting in your mouth. 
Avoid painful stimuli: • Smoking 
• Alcohol 
• Certain foods such as tomatoes, citrus fruits, hot drinks and, spicy, hot, raw, 
or crusty foods. 
 
mTOR inhibitors such as everolimus and temsirolimus have immunosuppressive 
properties and may predispose patients to bacterial, fungal, viral, or protozoal 
infections, including infections with opportunistic pathogens. Localised and systemic 
infections, including pneumonia, mycobacterial infections, other bacterial infections, 
invasive fungal infections (such as aspergillosis or candidiasis), and viral infections 
(including reactivation of hepatitis B virus) have occurred in patients taking everolimus. 





Some of these infections can be severe, leading to sepsis, respiratory and/or hepatic 
failure, and fatality [37, 38]. 
It thus seems clinically prudent to optimise oral mucosal hygiene by utilising saline-
based oral rinses. As is the case with other types of oral mucosal injury caused by 
cancer therapy, patient education relative to types and management of oral mucosal 
injury caused by mTOR inhibitors is of prime importance to reducing severe oral 
ulcerations, maximising patient compliance, and clinical outcomes. 
management 
Several health professional organizations have reported strategies for management of 
oral and/or gastrointestinal mucositis caused by high-dose cancer therapies. These 
organizations include: 
• Multinational Association of Supportive Care in Cancer/ International Society of 
Oral Oncology (MASCC/ISOO) 
• Oncology Nursing Society (ONS) 
• American Society of Clinical Oncology (ASCO) 
• National Comprehensive Cancer Network (NCCN). 
The strategy for development of this management information ranges from systematic 
reviews (e.g., MASCC/ISOO) to a combination of systematic reviews and expert 
opinion (e.g., NCCN). 
The 2015 ESMO mucosal injury guidelines are comprised of three domains: 
i. MASCC/ISOO guidelines for management of mucositis caused by 
chemotherapy and/or head and head radiation [3] 
ii. Recently emergent data relative to systematic enteral nutrition [5–9] 
iii. Expert opinion on management of mucosal injury caused by targeted cancer 
therapies [4, 17, 18, 39], in part based on previously reported management 
of recurrent aphthous ulceration [40]. 
a) MASCC/ISOO guidelines for management of mucositis caused by chemotherapy 
and/or head and head radiation. 
These guidelines produced by MASCC/ISOO [3] represent the current state-
of-the-science in this field at the systematic review level (Table 2). 
 
  




Table 2. MASCC/ISOO Clinical Practice Guidelines for Oral and Gastrointestinal Mucositis [3] [(level 
of Evidence for each guideline is in brackets following the guideline statement)] 
Oral mucositis 
RECOMMENDATIONS IN FAVOR OF AN INTERVENTION (i.e. strong evidence supports 
effectiveness in the treatment setting listed) 
1) The panel recommends that 30 minutes of oral cryotherapy be used to prevent oral mucositis in 
patients receiving bolus 5-fluorouracil chemotherapy (II). 
2) The panel recommends that recombinant human keratinocyte growth factor-1 (KGF-1/palifermin) 
be used to prevent oral mucositis (at a dose of 60 μg/kg per day for 3 days prior to conditioning 
treatment and for 3 days post-transplant) in patients receiving high-dose chemotherapy and total 
body irradiation, followed by autologous stem cell transplantation, for a hematological malignancy 
(II). 
3) The panel recommends that low-level laser therapy (wavelength 630-680 nm, power of 40 to 150 
mW, and each square centimeter treated with the required time to a tissue energy dose of 2 
J/cm2), be used to prevent oral mucositis in patients receiving HSCT conditioned with high-dose 
chemotherapy, with or without total body irradiation (II). 
4) The panel recommends that patient-controlled analgesia with morphine be used to treat pain due 
to oral mucositis in patients undergoing HSCT (II).  
5) The panel recommends that benzydamine mouthwash be used to prevent oral mucositis in 
patients with H&N cancer receiving moderate dose radiation therapy (up to 50 Gy), without 
concomitant chemotherapy (I). 
SUGGESTIONS IN FAVOR OF AN INTERVENTION (i.e. weaker evidence supports effectiveness in 
the treatment setting listed) 
1) The panel suggests that oral care protocols be used to prevent oral mucositis in all age groups 
and across all cancer treatment modalities (III). 
2) The panel suggests that oral cryotherapy be used to prevent oral mucositis in patients receiving 
high-dose melphalan, with or without total body irradiation, as conditioning for HSCT (III). 
3) The panel suggests that low-level laser therapy (wavelength 630-680 nm, power of 40 to 150 mW, 
and each square centimeter treated with the required time to a tissue energy dose of 2 J/cm2) be 
used to prevent oral mucositis in patients undergoing radiotherapy, without concomitant 
chemotherapy, for H&N cancer (III). 
4) The panel suggests that transdermal fentanyl may be effective to treat pain due to oral mucositis 
in patients receiving conventional and high-dose chemotherapy, with or without total body 
irradiation (III). 
5) The panel suggests that 2% morphine mouthwash may be effective to treat pain due to oral 
mucositis in patients receiving radiation therapy for H&N cancer (III). 
6) The panel suggests that 0.5% doxepin mouthwash may be effective to treat pain due to oral 
mucositis (IV). 
7) The panel suggests that systemic zinc supplements administered orally may be of benefit to 
prevent oral mucositis in oral cancer patients receiving radiation therapy or chemoradiation (Level 
of Evidence III). 
RECOMMENDATIONS AGAINST AN INTERVENTION (i.e. strong evidence indicates lack of 
effectiveness in the treatment setting listed) 
1) The panel recommends that PTA (polymyxin, tobramycin, amphotericin B) and BCoG (bacitracin, 
clotrimazole, gentamicin) antimicrobial lozenges and PTA paste not be used to prevent oral 
mucositis in patients receiving radiation therapy for head and cancer (II). 
2) The panel recommends that iseganan antimicrobial mouthwash not be used to prevent oral 
mucositis in patients receiving high dose chemotherapy, with or without total body irradiation, for 





HSCT (Level of Evidence II), or in patients receiving radiation therapy or concomitant 
chemoradiation for H&N cancer (II). 
3) The panel recommends that sucralfate mouthwash not be used to prevent oral mucositis in patients 
receiving chemotherapy for cancer (I), or in patients receiving radiation therapy (I) or concomitant 
chemoradiation (II) for H&N cancer. 
4) The panel recommends that sucralfate mouthwash not be used to treat oral mucositis in patients 
receiving chemotherapy for cancer (I), or in patients receiving radiation therapy (II) for H&N cancer. 
5) The panel recommends that intravenous glutamine not be used to prevent oral mucositis in patients 
receiving high dose chemotherapy, with or without total body irradiation, for HSCT (II). 
SUGGESTIONS AGAINST AN INTERVENTION (i.e. weaker evidence indicates lack of effectiveness 
in the treatment setting listed) 
1) The panel suggests that chlorhexidine mouthwash not be used to prevent oral mucositis in patients 
receiving radiation therapy for H&N cancer (III). 
2) The panel suggests that granulocyte macrophage colony-stimulating factor (GM-CSF) mouthwash 
not be used to prevent oral mucositis in patients receiving high-dose chemotherapy, for autologous 
or allogeneic stem cell transplantation (II). 
3) The panel suggests that misoprostol mouthwash not be used to prevent oral mucositis in patients 
receiving radiation therapy for H&N cancer (III). 
4) The panel suggests that systemic pentoxifylline, administered orally, not be used to prevent oral 
mucositis in patients undergoing bone marrow transplantation (III). 
5) The panel suggests that systemic pilocarpine, administered orally, not be used to prevent oral 
mucositis in patients receiving radiation therapy for H&N cancer (III), or in patients receiving high 
dose chemotherapy, with or without total body irradiation, for HSCT (II). 
Gastrointestinal Mucositis (not including the oral cavity) 
RECOMMENDATIONS IN FAVOR OF AN INTERVENTION (i.e. strong evidence supports 
effectiveness in the treatment setting listed) 
1) The panel recommends that intravenous amifostine be used, at a dose of ≥340 mg/m2, to prevent 
radiation proctitis in patients receiving radiation therapy (II). 
2) The panel recommends that octreotide, at a dose of ≥100 μg subcutaneously twice daily, be used 
to treat diarrhea induced by standard- or high-dose chemotherapy associated with HSCT, if 
loperamide is ineffective (II). 
SUGGESTIONS IN FAVOR OF AN INTERVENTION (i.e. weaker evidence supports effectiveness in 
the treatment setting listed) 
1) The panel suggests that intravenous amifostine be used to prevent esophagitis induced by 
concomitant chemotherapy and radiation therapy in patients with non-small cell lung carcinoma 
(III). 
2) The panel suggests that sucralfate enemas be used to treat chronic radiation-induced proctitis in 
patients with rectal bleeding (III). 
3) The panel suggests that systemic sulfasalazine, at a dose of 500 mg administered orally twice a 
day, be used to prevent radiation-induced enteropathy in patients receiving radiation therapy to 
the pelvis (II). 
4) The panel suggests that probiotics containing Lactobacillus species be used to prevent diarrhea 
in patients receiving chemotherapy and/or radiation therapy for a pelvic malignancy (III). 
5) The panel suggests that hyperbaric oxygen be used to treat radiation-induced proctitis in patients 
receiving radiation therapy for a solid tumor (IV). 
RECOMMENDATIONS AGAINST AN INTERVENTION (i.e. strong evidence indicates lack of 
effectiveness in the treatment setting listed) 
1) The panel recommends that systemic sucralfate, administered orally, not be used to treat 
gastrointestinal mucositis in patients receiving radiation therapy for a solid tumor (I). 




2) The panel recommends that 5-acetyl salicylic acid (ASA), and the related compounds mesalazine 
and olsalazine, administered orally, not be used to prevent acute radiation-induced diarrhea in 
patients receiving radiation therapy for a pelvic malignancy (I). 
3) The panel recommends that misoprostol suppositories not be used to prevent acute radiation-
induced proctitis in patients receiving radiation therapy for prostate cancer (I). 
SUGGESTIONS AGAINST AN INTERVENTION (i.e. weaker evidence indicates lack of effectiveness 
in the treatment setting listed) 
None. 
Reprinted from [3]. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of 
American Cancer Society. This is an open access article under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non-commercial and no modifications or 
adaptations are made. 
Gy, grays; HSCT, hematopoietic stem cell transplantation; MASCC/ISOO, Multinational Association of 
Supportive Care in Cancer and International Society of Oral Oncology. 
 
  





Table 3: Oral Cavity Mucositis Guideline 
Modified from: MASCC/ISOO Clinical Practice Guidelines for Oral Mucositis [3] (Level of Evidence for 
each guideline is in brackets following the guideline statement) 
Diagnosis Therapy Prevention/ 
treatment 
Intervention 
Cancer of any 
kind 
All cancer treatment 
modalities 
Prevention Oral care protocols: The panel suggests that oral 
care protocols be used to prevent oral mucositis 
in all age groups and across all cancer 
treatment modalities (III). 
Treatment Doxepin mouthwash: The panel suggests that 
0.5% doxepin mouthwash may be effective to 
treat pain due to oral mucositis (IV). 
Bolus 5-fluorouracil 
chemotherapy 
Prevention Oral cryotherapy: The panel recommends that 30 
minutes of oral cryotherapy be used to prevent 
oral mucositis in patients receiving bolus 5-
Fluorouracil chemotherapy (II). 
Bone marrow 
transplant 
Prevention Pentoxifylline: The panel suggests against that 
systemic pentoxifylline, administered orally, be 
used to prevent oral mucositis in patients 




or without total body 
irradiation 
Treatment Transdermal fentanyl: The panel suggests that 
transdermal fentanyl may be effective to treat 
pain due to oral mucositis in patients receiving 
conventional and high-dose chemotherapy, 
with or without total body irradiation (III). 
Stem cell transplant Prevention Low-level laser therapy: The panel recommends 
that low-level laser therapy (wavelength 630-80 
nm, power of 40 to 150 mW, and each square 
centimeter treated with the required time to a 
tissue energy dose of 2 J/cm2), be used to 
prevent oral mucositis in patients receiving 
HSCT conditioned with high-dose 
chemotherapy, with or without total body 
irradiation (II). 
GM-CSF: The panel suggests against that 
granulocyte macrophage colony-stimulating 
factor (GM-CSF) mouthwash be used to 
prevent oral mucositis in patients receiving 
high-dose chemotherapy, for autologous or 
allogeneic stem cell transplantation (II). 
Pilocarpine: The panel suggests against that 
systemic pilocarpine, administered orally, be 
used to prevent oral mucositis in patients 
receiving high dose chemotherapy, with or 
without total body irradiation, for HSCT (II). 
Glutamine: The panel recommends against that 
intravenous glutamine be used to prevent oral 
mucositis in patients receiving high dose 
chemotherapy, with or without total body 
irradiation, for HSCT (II). 




Iseganan antimicrobial mouthwash: The panel 
recommends against that iseganan 
antimicrobial mouthwash be used to prevent 
oral mucositis in patients receiving high dose 
chemotherapy, with or without total body 
irradiation, for HSCT (II). 
Treatment Morphine: The panel recommends that patient-
controlled analgesia with morphine be used to 
treat pain due to oral mucositis in patients 
undergoing HSCT (II).  
Chemotherapy Prevention Sucralfate mouthwash: The panel recommends 
against that sucralfate mouthwash be used to 
prevent oral mucositis in patients receiving 
chemotherapy for cancer (I) 
Radiation therapy Treatment Sucralfate mouthwash: The panel recommends 
against that sucralfate mouthwash be used to 
treat oral mucositis in patients receiving 
radiation therapy (II). 






Prevention Benzydamine mouthwash: The panel 
recommends that benzydamine mouthwash be 
used to prevent oral mucositis in patients with 
H&N cancer receiving moderate dose radiation 
therapy (up to 50 Gy), without concomitant 
chemotherapy (I). 
Radiation therapy Prevention Chlorhexidine mouthwash: The panel suggests 
against that chlorhexidine mouthwash be used 
to prevent oral mucositis in patients receiving 
radiation therapy for H&N cancer (III). 
Misoprostol mouthwash: The panel suggests 
against that misoprostol mouthwash be used to 
prevent oral mucositis in patients receiving 
radiation therapy for H&N cancer (III). 
Pilocarpine: The panel suggests against that 
systemic pilocarpine, administered orally, be 
used to prevent oral mucositis in patients 
receiving radiation therapy for H&N cancer (III).  
PTA and BCoG: The panel recommends against 
that PTA (polymyxin, tobramycin, amphotericin 
B) and BCoG (bacitracin, clotrimazole, 
gentamicin) antimicrobial lozenges and PTA 
paste be used to prevent oral mucositis in 
patients receiving radiation therapy for H&N 
cancer(II). 
Treatment Morphine mouthwash: The panel suggests that 
2% morphine mouthwash may be effective to 
treat pain due to oral mucositis in patients 
receiving radiation therapy for H&N cancer (III). 
Sucralfate mouthwash: The panel recommends 
against that sucralfate mouthwash be used to 
treat oral mucositis in patients receiving 
radiation therapy (II) for H&N cancer. 









Prevention Iseganan antimicrobial mouthwash: The panel 
recommends against that iseganan 
antimicrobial mouthwash be used to prevent 
oral mucositis in patients receiving radiation 
therapy or concomitant chemoradiation for H&N 
cancer (II). 
Sucralfate mouthwash: The panel recommends 
against that sucralfate mouthwash be used to 
prevent oral mucositis in patients receiving 
radiation therapy (I) or concomitant 




Prevention Low-level laser therapy: The panel suggests that 
low-level laser therapy (wavelength 630-80 nm, 
power of 40 to 150 mW, and each square 
centimeter treated with the required time to a 
tissue energy dose of 2 J/cm2) be used to 
prevent oral mucositis in patients undergoing 
radiotherapy, without concomitant 
chemotherapy, for H&N cancer (III). 
Hematological 
malignancy 
Stem cell transplant 
revised from 2013 
MASCC/ISOO 
Guidelines 
based on current 
labeling indication 
Prevention KGF-1/palifermin: The panel recommends that 
recombinant human keratinocyte growth factor-
1 (KGF-1/palifermin) be used to prevent oral 
mucositis (at a dose of 60 μg/kg per day for 3 
days prior to conditioning treatment and for 3 
days post-transplant) in patients… 
• (Original MASCC/ISOO guideline): receiving 
high-dose chemotherapy and total body 
irradiation, followed by autologous stem cell 
transplantation, for a hematological malignancy 
(II). 
• (Updated ESMO guideline): …with hematologic 
malignancy treated with chemotherapy and/or 
targeted agents, and/or HSCT with or without 
TBI (local-regional radiotherapy alone not 
included), and who are anticipated to develop 
Grade 3 or Grade 4 oral mucositis.[41] 
Oral cryotherapy: The panel suggests that oral 
cryotherapy be used to prevent oral mucositis 
in patients receiving high-dose melphalan, with 
or without total body irradiation, as conditioning 
for HSCT (III). 
Oral cancer Radiation therapy or 
chemoradiation 
Prevention Zinc supplements: The panel suggests that 
systemic zinc supplements administered orally 
may be of benefit to prevent oral mucositis in 
oral cancer patients receiving radiation therapy 
or chemoradiation (III). 
     RECOMMENDATIONS IN FAVOR OF AN INTERVENTION: i.e. strong evidence supports 
effectiveness in the treatment setting listed. 
     SUGGESTIONS IN FAVOR OF AN INTERVENTION: i.e. weaker evidence supports effectiveness 
in the treatment setting listed. 




     SUGGESTIONS AGAINST AN INTERVENTION: i.e. weaker evidence indicates lack of effectiveness 
in the treatment setting listed. 
     RECOMMENDATIONS AGAINST AN INTERVENTION: i.e. strong evidence indicates lack of 
effectiveness in the treatment setting listed. 
MASCC/ISOO, Multinational Association of Supportive Care in Cancer and International Society of Oral 
Oncology; HSCT, hematopoietic stem cell transplantation; Gy, grays; BCoG, bacitracin, clotrimazole, 
gentamicin. 
 
The authors of this version of ESMO guidelines have reformatted the content 
in the MASCC/ISOO guideline in order to further facilitate clinician use (Tables 3 
and 4). 
In addition to this reformatting the following revision has been included in Table 
3, directed to the use of palifermin to prevent oral mucositis in patients undergoing 
haematopoietic cell transplantation: 
…with haematological malignancy treated with chemotherapy and/or targeted 
agents, and/or HSCT with or without total body irradiation (TBI) (local-regional 
radiotherapy alone not included), and who are anticipated to develop Grade 3 
or Grade 4 oral mucositis.  
This revision emerged as a result of changes in the labelling as approved by the 
United States Food and Drug Administration in recent years [41]. 
b) Recently emergent data relative to systematic enteral nutrition. 
Recent data have emerged regarding the impact of systematic enteral nutrition as 
a prophylactic measure. 
In this modelling, systemic enteral nutrition is administered before initiation of 
chemoradiation, to prevent oral mucositis-associated nutritional compromise and 
to optimise therapeutic dose intensity, during chemoradiation for head and neck 
and oesophageal carcinomas [5–9]. 
In French-speaking countries, SFNEP and AFSOS published comprehensive 
recommendations for cancer patients [10–12]. Due to mucositis incidence, and for 
the optimisation of cancer treatment of this type of patient, a prophylactic approach 
with systematic gastrostomy or feeding tube was explored in several trials in at-risk 
patients receiving chemoradiation for head and neck cancer. Unfortunately, only 
retrospective analyses or randomised trials with significant limitations are available 
[7–9]. No strong recommendation is possible in favour of this prophylactic 
approach. 
Hence, identification of at-risk patients who would need systematic enteral 
nutrition before chemoradiation remains unclear and is at the discretion of the 
clinicians in charge of the patient’s oncological treatment.  
c) Expert opinion on management of mucosal injury caused by targeted cancer 
therapies 
In the absence of confirmatory data from clinical trials, expert opinion-based 
recommendations in the review by Boers-Doets et al. [4] and others [17, 18] can be 
considered as delineated in Table 5. These statements reflect the state-of-the-science 
as it presently exists. 






In recent years, research has increasingly demonstrated that patient-specific genetic 
characteristics are an important variable in determining risk and incidence of cancer 
therapy-related toxicity, including, but not limited to, oral mucosal injury [42–44]. It is 
now clear that genetic variation across individuals, including single nucleotide 
polymorphisms, is a key contributor to the toxicity trajectory for mucosal injury as well 
as for other toxicities caused by cancer therapies. Additional research in this domain 
will likely allow the clinician to individualise the therapeutic approach for each patient 
before initiation of cancer treatment, to maximise tumour response while minimising 
toxicity. 
 
Table 4. Gastrointestinal Mucositis Guideline 
Modified from: MASCC/ISOO Clinical Practice Guidelines for Gastrointestinal Mucositis [3] (Level of 
Evidence for each guideline is in brackets following the guideline statement) 







Prevention Amifostine: The panel recommends that intravenous amifostine be 
used, at a dose of ≥340 mg/m2, to prevent radiation proctitis in 
patients receiving radiation therapy (II). 
Treatment Sucralfate enemas: The panel suggests that sucralfate enemas be 
used to treat chronic radiation-induced proctitis in patients with 





Prevention Sulfasalazine: The panel suggests that systemic sulfasalazine, at a 
dose of 500 mg administered orally twice a day, be used to prevent 
radiation-induced enteropathy in patients receiving radiation 




Treatment Octreotide: The panel recommends that octreotide, at a dose of ≥100 
μg subcutaneously twice daily, be used to treat diarrhea induced 
by standard- or high-dose chemotherapy associated with HSCT, if 













Prevention Amifostine: The panel suggests that intravenous amifostine be used 
to prevent esophagitis induced by concomitant chemotherapy and 










Prevention Probiotics: The panel suggests that probiotics containing 
Lactobacillus species be used to prevent diarrhea in patients 




ASA: The panel recommends against that 5-acetyl salicylic acid 
(ASA), and the related compounds mesalazine and olsalazine, 
administered orally, be used to prevent acute radiation-induced 
diarrhea in patients receiving radiation therapy for a pelvic 
malignancy (I). 








Prevention Misoprostol suppositories: The panel recommends against that 
misoprostol suppositories be used to prevent acute radiation-






Treatment Hyperbaric oxygen: The panel suggests that hyperbaric oxygen be 
used to treat radiation-induced proctitis in patients receiving 
radiation therapy for a solid tumor (IV). 
Sucralfate: The panel recommends against that systemic sucralfate, 
administered orally, be used to treat gastrointestinal mucositis in 
patients receiving radiation therapy for a solid tumor (I). 
     RECOMMENDATIONS IN FAVOR OF AN INTERVENTION: i.e. strong evidence supports effectiveness 
in the treatment setting listed. 
     SUGGESTIONS IN FAVOR OF AN INTERVENTION: i.e. weaker evidence supports effectiveness in the 
treatment setting listed. 
     RECOMMENDATIONS AGAINST AN INTERVENTION: i.e. strong evidence indicates lack of 
effectiveness in the treatment setting listed. 
MASCC/ISOO, Multinational Association of Supportive Care in Cancer and International Society of Oral 
Oncology; HSCT, hematopoietic stem cell transplantation; ASA, acetyl-salicylic acid. 
 
Table 5. Expert opinion recommendations for targeted therapy associated stomatitis (level of evidence is 
not applicable for these recommendations from the experts) 








Prevention Oral care protocols: Expert opinion suggests that oral care protocols 
be used to prevent stomatitis in all cancer groups and across all 
targeted therapy modalities 
Sodium bicarbonate containing mouthwash: Expert opinion 
suggests that patients should rinse their mouth with a bland non-
alcoholic, sodium bicarbonate containing mouthwash 4-6 times a 
day to prevent stomatitis 
Treatment Sodium bicarbonate containing mouthwash: Expert opinion 
suggests that the frequency of the bland non-alcoholic, sodium 
bicarbonate containing mouthwash be increased, if necessary up 
to each hour to treat stomatitis 
Analgesics: Expert opinion suggests that If patients find the 
mouthwash painful, they should be advised to use pain medication 
beforehand (e.g., viscous lidocaine 2%, coating agents, and, when 
needed, systemic approaches following the World Health 
Organization pain management ladder) to treat pain from 
stomatitis 
Chewing gum, candy, salivary substitutes or sialogogues: Expert 
opinion suggests that sugarless chewing gum or candy, salivary 
substitutes or sialogogues in patients with oral dryness should be 
considered to treat oral dryness 
Analgesics: Expert opinion suggests that adequate pain 
management e.g., anesthetic mouthwashes (viscous lidocaine 
2%), coating agents, or systemic analgesics following the WHO 
pain management ladder may be provided to treat pain from 
stomatitis 
Analgesics: Expert opinion suggests that with moderate pain a 
topical NSAID (e.g., amlexanox 5% oral paste) may be considered 





to treat moderate pain from stomatitis. When NSAIDs are not 
tolerated, consider acetaminophen (paracetamol) as maintenance 
therapy in combination with an immediate release oral opioid or 
fast acting fentanyl preparation (e.g. 50 microgram fentanyl nasal 
spray) to relief pain short-term, for instance before dinner. Fast 
acting fentanyl preparations are registered for patients who are 
already treated with opioids, they may also be considered in this 
population because of their short term pain relief. 
Analgesics: Expert opinion suggests that with persistent severe pain 
more aggressive pain management may be considered to treat 
severe pain from stomatitis. Since oral complaints can complicate 
administration of drugs by mouth, one should consider other kinds 
of administration routes, such as transdermal or intranasal routes. 
Other treatments: Expert opinion suggests that other treatments, 
such as coating agents, topical analgesic or anti-inflammatory 
agents, topical anesthetics, and alternative mouthwashes may be 
considered to treat stomatitis 
mTOR 
inhibitors 
Treatment Steroids; topical: Expert opinion suggests that with ulcers topical 
high potency corticosteroids should be considered first: 
dexamethasone mouth rinse (0.1 mg/ml); clobetasol gel or 
ointment (0.05%) to treat mIAS 
Steroid; intralesional injection: Expert opinion suggests that with no 
ulcer resolution, intralesional steroid injection (triamcinolone 
weekly; total dose 28 mg) in conjunction with oral expert AND 
topical clobetasol gel or ointment (0.05%) should be considered to 
treat mIAS 
Steroids; systemic: Expert opinion suggests that for highly 
symptomatic ulcers and for recurrent ulcers or esophageal lesions, 
systemic corticosteroids as initial therapy to bring symptom under 
control quickly (high-dose pulse 30–60 mg or 1 mg/kg) oral 
prednisone/prednisolone for 1 week followed by dose tapering 
over the second week should be considered to treat mIAS 
     SUGGESTIONS IN FAVOR OF AN INTERVENTION: based on expert opinion [17, 18]. 
WHO, World Health Organization; NSAID, nonsteroidal anti-inflammatory drug; mIAS, mTOR inhibitor-
associated stomatitis. 
follow-up and long-term implications 
Guidelines for prevention and treatment of mucositis caused by conventional cancer 
therapies as reported in this version of the ESMO Clinical Practice Guidelines are 
based on the recommendations of the recently updated guidelines from MASCC/ISOO. 
Those guidelines included a new recommendation directed to level II evidence 
regarding the use of low-level laser therapy to prevent oral mucositis caused by high-
dose chemotherapy conditioning regimens in the haematopoietic cell transplant setting 
(Table 2). 
In addition, new recommendations based on expert consensus opinion have been 
included, to address the state-of-the-science relative to oral mucosal lesions caused 
by targeted cancer therapies. 




There continues to be key progress relative to the molecular pathobiology, 
computational biology, and clinical impact of mucosal injury in cancer patients that may 
generate strategic research and clinical advances in the future. These advances will 
likely result in revisions of mucositis guidelines in the next 2–5 years. Examples of 
novel, important future opportunities based on the recent advances include [45]: 
Molecular modelling 
• mucosal homeostasis 
• naturally occurring mucosal disease 
• oral pain 
• oral mucosa and the oral microbiome 
• molecular basis for cancer patient-based variation in incidence and severity of 
oral mucosal injury 
• molecular imaging 
Development of molecularly targeted drugs, biologics, and devices 
• systems biological technologies to define key pathobiological pathways for 
targeting 
• incorporation of patient-based risk profiling into clinical trial designs 
Clinical practice - utilisation of state-of-the-science technologies for: 
• dissemination 
• measurement of clinical and health resource cost outcomes. 
There is also need and opportunity to conduct clinical trials with devices that have been 
initially reported as effective and safe in reducing the incidence and severity of oral 
mucositis in cancer patients. Such studies are essential to (i) validate current 
commercial claims, (ii) identify which patients may experience highest benefit, and (iii) 
assess the feasibility for use by these patients. 
It is important that basic, translational, and clinical research continue to investigate 
preventive and treatment modalities for oral mucositis, gastrointestinal mucositis, and 
stomatitis. This collective research could lead to the approval of new drugs and devices 
for which evidence-based, cancer patient-specific identification of risk and associated 
management of mucositis and stomatitis could become possible. 
 
Table 6. Level of evidence used in the MASCC/ISOO guidelines and reported in Tables 2–5 [3] 
I      Evidence obtained from meta-analysis of multiple, well-designed, controlled studies; randomised trials 
with low false-positive and false-negative errors (high power). 
II     Evidence obtained from at least one well-designed experimental study; randomised trials with high 
false-positive and/or false-negative errors (low power). 
III    Evidence obtained from well-designed, quasi-experimental studies such as non-randomised, controlled 
single-group, pretest–posttest comparison, cohort, time, or matched case–control series. 
IV    Evidence obtained from well-designed, non-experimental studies, such as comparative and correlational 
descriptive and case studies. 
V     Evidence obtained from case reports and clinical examples. 
Adapted from [46]. 
 






These clinical practice guidelines were developed in accordance with the ESMO 
standard operating procedures for clinical practice guidelines development. The 
relevant literature has been selected by the expert authors. Levels of evidence and 
grades of recommendation have been applied using the system described in the 
MASCC/ISOO guidelines (Table 2) and Tables 3 and 4 and are published in the 
MASCC/ISOO Clinical Practice Guidelines for Oral and Gastrointestinal Mucositis [3] 
and shown in Table 6. This manuscript has been subjected to an anonymous peer 
review process. 
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ABSTRACT 
Purpose The objective of this sub-analysis of the BeCet study (NCT01136005) was to 
examine health-related quality of life (HRQoL) of patients experiencing dermatological 
adverse events (AEs) during the first 6 weeks of epidermal growth factor receptor 
inhibitor (EGFRI) treatment. 
Methods Patients (n=85) treated with EGFRI completed five questionnaires during the 
first 6 weeks of treatment. 77 patients provided enough data for the sub-analysis. 
Experienced AEs were reported in the Dermatological Reactions Targeted Therapy–
Patients (DERETT-P), a symptom experience diary for patients treated with targeted 
therapy. The impact of EGFRI-associated dermatological adverse events on HRQoL 
was examined using four HRQoL questionnaires; the Functional Assessment of 
Cancer Therapy–EGFRI (FACTEGFRI-18), the Functional Assessment of Cancer 
Therapy–General (FACT-G), the 36-Item Short Form Health Survey (SF-36), and the 
Skindex-16. 
Results During the first 6 weeks of EGFRI treatment, physical discomfort was the most 
significantly affected domain. In the entire study population, xerosis (dry skin) (22.3 %) 
and pruritus (itchy skin) (16.9 %) were reported as the most impactful AEs. For patients 
experiencing a papulopustular eruption (acneiform rash) pruritus (24.2 %), xerosis 
(18.9 %), and papulopustular eruption (6.3 %) were reported as the most impactful 
AEs. Papulopustular eruption, xerosis, and pruritus all showed a significant negative 
effect on HRQoL, displayed in FACT-EGFRI-18 scores. 
Conclusions In addition to papulopustular eruption, xerosis and pruritus are major 
EGFRI-associated dermatological AEs with an impact on HRQoL, which warrant more 
attention in clinical practice and research. 
 
  







Epidermal growth factor receptor inhibitors (EGFRIs) are frequently used in treatment 
regimens of patients with solid tumors. Compared with cytotoxic chemotherapeutic 
agents, which may cause myelosuppression, nausea, vomiting, neuropathy, and 
alopecia, EGFRIs are associated with a lower incidence of systemic adverse events 
(AEs). However, patients treated with EGFRIs experience dermatological AEs (dAEs), 
such as papulopustular eruption (acneiform rash), xerosis (dry skin), pruritus (itchy 
skin), and paronychia (periungual inflammation), as well as mucosal and hair 
abnormalities [1, 2]. 
The most common AE of EGFRI treatment is a papulopustular eruption, occurring 
in 75 to 95 % of patients [1, 2]. The papulopustular eruption consists of acneiform 
follicular and perifollicular papules and sterile pustules, most pronounced on the face, 
scalp, upper back, and chest and is often accompanied by xerosis and pruritus. The 
papulopustular eruption is a relatively early-onset AE, usually occurring between 1 to 
3 weeks after initiation of treatment. The incidence is higher with monoclonal 
antibodies like cetuximab and panitumumab (more than 88 %) than with tyrosine 
kinase inhibitors like gefitinib, erlotinib, lapatinib, and afatinib (43–75 %). In about 80 
to 90 % of the skin reactions, the worst recorded severity is mild (grade 1) to moderate 
(grade 2), but in 10 % a more severe skin reaction (grade 3) is seen [1, 2]. In several 
studies, the presence and severity of the eruption has shown a correlation with a 
positive response to cancer treatment, as expressed in higher median survival rates 
[1–3]. However, patients reported that the papulopustular eruption interferes in their 
daily activities and in the appearance of their skin, because the EGFRI-associated 
dAEs, often in visible areas, make them worried, frustrated, and depressed and cause 
withdrawal from social activities [3, 4]. 
The physical discomfort caused by EGFRI treatment has been identified as having 
the most impact on health-related quality of life (HRQoL), especially the sensations of 
pain, burning, and skin sensitivity. The dAEs may lead to a decreased HRQoL and to 
dose reduction or discontinuation of anticancer treatment, even though the treatment 
might be effective in treating the cancer and reducing the dose may negatively affect 
cancer outcome [4]. At present, the consequence of the dAEs on HRQoL in patients 
with cancer receiving EGFRI treatment remains poorly understood. 
This sub-analysis of the ongoing BeCet study (NCT01136005) is aimed to provide 
a better understanding of HRQoL in patients with cancer receiving EGFRI treatment, 
using five different questionnaires. 




Patients and materials 
Patients 
The study population was derived from the ongoing BeCet study. This phase III 
randomized double-blinded trial compares Bepanthen against cetomacrogol cream on 
their preventive effect in decreasing the incidence of grade ≥2 EGFRI associated 
papulopustular eruption and assesses the Dutch version of Functional Assessment of 
Cancer Therapy- EGFRI (FACT-EGFRI-18) for reliability and validity [5, 6]. 
The study has been approved by the Medical Ethics Review Committees of each 
participating hospital. Twelve Dutch centers are currently recruiting patients starting 
with an EGFRI treatment for any type of cancer (i.e., panitumumab, cetuximab, 
lapatinib, gefitinib, erlotinib, or afatinib). Patients need to have an Eastern Co-operative 
Oncology Group performance status ≤2 and need to be able to complete 
questionnaires. 
The first 85 consecutive patients were included for this sub analysis between July 
2010 and May 2014. This analysis studies the impact of the dAEs on the HRQoL, while 
the main study analyses the appearance and severity of dAEs. There are no strict 
criteria for the sample size in HRQoL studies. Within a homogenous population there 
is lower variability in answers on HRQoL items, making a smaller sample size 
acceptable. 
Materials 
During the 6-week study period, patients completed five different questionnaires. They 
completed the symptom experience diary Dermatological Reactions Targeted 
Therapy–Patients (DERETT-P) and the FACT-EGFRI-18 weekly. Within the BeCet 
trial, these two questionnaires are measured weekly to provide detailed information 
about the incidence and severity curve of dAEs. For this sub-analysis, fewer data than 
in the main study collected are of relevance. These are the data of weeks 0, 2, and 4.  
In week 4, the Functional Assessment of Cancer Therapy–General (FACT-G), the 
36-Item Short Form Health Survey (SF-36), and the Skindex-16 questionnaires were 
completed for validation purposes of the FACT-EGFRI-18. Week 4 of treatment was 
chosen, because then most patients will have experienced a papulopustular eruption 
[7]. In this analysis, scores of these generic questionnaires were compared with 
previously published articles, to put the HRQoL of cancer patients treated with EGFRIs 
in perspective to similar samples. 
DERETT 
The Dermatological Reactions Targeted Therapy (DERETT) is available in two 
versions, for patients (DERETT-P) and HCP (DERETT-H), consisting of 61 and 50 
items, respectively. These tools gather information such as area involved, severity and 
duration of the symptoms, products used to treat symptoms, effectiveness of the 
supportive care interventions, treatment adherence, and symptom-related distress [8]. 
DERETT provides a more precise and clinically relevant information on the patient’s 





condition than Common Terminology Criteria for Adverse Events (CTCAE) grading 
alone. 
FACT-EGFRI-18 
The Functional Assessment of Cancer Therapy Questionnaire–EGFRI has been 
developed to assess HRQoL related to EGFRI-associated dAEs. The translation, 
linguistic validation, and qualitative assessment of the FACT-EGFRI-18 have been 
described [5, 6, 9]. The validations of the English and Support Care Cancer Dutch 
versions are ongoing. The FACT-EGFRI-18 consists of 18 items in three HRQoL 
domains: physical (7 items), social/ emotional (6 items), and functional (5 items). 
Scores are rated on a numerical analogue scale (0=not at all, 4=very much). A high 
domain score reflects a low HRQoL. On the other hand, a high total score indicates a 
high HRQoL [10]. 
FACT-G 
The FACT-G version 4 is a patient reposted outcome (PRO) measure with numerical 
analogue scales (0=not at all, 4=very much). The FACT-G version 4 consists of 27 
items in four HRQoL domains: physical (7 items), social/family (7 items), emotional (6 
items), and functional well-being (7 items). High total scores indicate a high HRQoL. 
The FACT-G has been validated for patients with cancer in general [11]. 
SF-36 
The 36-Item Short Form Health Survey (SF-36) is a generic HRQoL survey. The 
questionnaire consists of 36 items, covering eight scales: physical functioning, role 
limitations due to physical health and due to emotional problems, energy/fatigue, 
emotional well-being, social functioning, pain, and general health. A high total scale 
score represents a high HRQoL. The SF-36 can be used to measure HRQoL in general 
and specific populations, and has been validated for Dutch citizens, and patients with 
cancer [12]. 
Skindex-16 
The Skindex-16 is a 16-item PRO assessing dermatological symptoms on a numerical 
analogue scale (0=never bothered, 6=always bothered), where high scores represent 
a low HRQoL. It contains three domains: symptoms (4 items), emotions (7 items), and 
functioning (5 items). The Skindex-16 is reliable and valid for general skin diseases. It 
has been used more often to assess HRQoL in patients receiving EGFRI treatment, 
but does not address symptoms related to hair, nails, or mucous membranes, that are 
specific targets for EGFRIs [13]. 
Statistical analysis 
Descriptive statistics were used to describe the study population. In DERETT-P, the 
incidences of the AEs with the highest impact on HRQoL (Fig. 1) were determined per 
week and in total. The domain and total scores of FACT-EGFRI-18 during the first 6 
weeks of EGFRI treatment are displayed in a time plot (Fig. 2). With a one-way 
ANOVA, item and domain scores during treatment were compared to baseline, 




followed by a Bonferroni procedure to correct for multiple testing. Using the Mann–
Whitney test, FACT-EGFRI-18 scores during week 2 to 4 and Skindex-16 scores of 
week 4 were compared between different subgroups, i.e., gender, type of cancer,  
















Fig 1a Adverse events that patients reported as present in DERETT-P compared to b adverse events 
as having most impact on HRQoL as measured by DERETT-P. In (a), papulopustular eruption is 
reported as the most common adverse event, while (b) displays that xerosis and pruritus have a more 
profound impact on HRQoL. HRQoL health related quality of life. 
 
EGFRI agent, and age, as mainly in those weeks papulopustular eruption manifests 
[1]. To analyze HRQoL for patients experiencing a papulopustular eruption, their 
FACT-EGFRI-18 scores were compared with pre-treatment scores, also using the 
Mann–Whitney test. With manual two-sample t tests and one-sample Wilcoxon signed-
rank tests, mean and median scores of FACT-G, SF-36, and Skindex-16 were both 
compared to scores in previously published articles, in order to determine how HRQoL 
relates to these populations. DERETT-P and FACT-EGFRI-18 scores have not been 
described before and could, therefore, not be compared. All data analysis was 
performed with the Statistical Package for Social Sciences (SPSS) version 20. Overall, 
p<0.05 was accepted as a statistically significant result. 
Results 
Demographics 
Between July 2010 and May 2014, a total of 85 patients were included. Eight patients 
(9.4 %) with disease progression were excluded as they stopped EGFRI treatment 
before week 4 and, consequently, did not complete FACT-G, SF-36, and Skindex-16. 
In total, 77 patients were evaluable. Six (7.79 %) of them stopped EGFRI treatment 
after week 4 because of disease progression and/or death, but produced enough  





data to be considered evaluable 
for this study. The mean age of 
the included study population 
(n=77) was 65.0 years (SD 
9.91). Forty-six patients (59.7 
%) were male. The majority of 
the patients were of Caucasian 
origin (96.1 %) and three 
patients of other origin (Asian 
and Hindu) (Table 1). Patients 
were mainly diagnosed with 
non-small cell lung cancer 
(NSCLC) and colorectal cancer, 
41.6 and 39.0 %, respectively. 
Panitumumab (37.7 %) and 
erlotinib (32.5 %) were the most 
prescribed EGFRI drugs. Of the 
DERETT-P, FACT-EGFRI-18, 
FACT-G, SF-36, and Skindex-
16 questionnaires, 50, 47.4, 
25.9, 25.9, and 23.5 %, 
respectively, were not 
completed. The main reasons 
for the uncompleted 
questionnaires were that the healthcare provider did not hand out the questionnaire in 
the uneven weeks (weeks 1, 3, and 5) and early discontinuation due to disease 
progression. Some patients did not complete the questionnaires because they did not 
feel the need to do so since their AEs stayed almost the same as during the previous 
measures, most prominent in patients with many or nearly none experienced AEs. 
Patient burden and burn out may also play a role.  
Impact of various adverse events 
The DERETT-P questionnaire asks patients to report if they experienced certain AEs 
and in which severity. Secondly, the questionnaire asks from which AE they 
experienced the most hinder. Xerosis and pruritus were reported most often: mean 
22.3 and 16.9 %, respectively. The remaining dAEs were reported by means less than 
4.8 %. Fig. 1a displays the incidence of the four AEs which have the highest impact on 
HRQoL during the 6-week study period, while Fig. 1b displays the AEs with the highest 
impact on HRQoL over time. The peak of impact of xerosis on HRQoL was in week 5 
(33.3 %), and at week 6 for pruritus (25.0 %). Papulopustular  
Table 1 Patient demographics (n = 77) 








































SD standard deviation, NSCLC non-small cell lung 
cancer, HNC head and neck cancer 
*Expressed in mean (SD) [range] 




a            b 
 
c            d 
 
Fig. 2a Mean (standard error of the mean) FACT-EGFRI-18 total scores per week. b Mean (standard 
error of the mean) of all grade FACT-EGFRI-18 domain scores per week. c Mean (standard error of the 
mean) of grade 1/2 FACT-EGFRI-18 domain scores per week. d Mean (standard error of the mean) of 
grade 3/4 FACT-EGFRI-18 domain scores per week. FACTEGFRI-18 Functional Assessment of Cancer 
Therapy–EGFRI, EGFRI epidermal growth factor receptor inhibitor 
 
eruption was reported as having the most impact on HRQoL by 4.2 % of all patients, 
with a peak in week 4 (9.4 %).  
Since a papulopustular eruption may overlap xerosis and pruritus and, therefore, 
the outcome may be different in patients who did develop a papulopustular eruption 





compared to those who did not, we explored the patients that experienced a 
papulopustular eruption separately. Even in this subgroup, AEs having most impact on 
HRQoL remained pruritus (24.2 %), xerosis (18.9 %), a burning sensation of the skin 
(8.4 %), and lastly a papulopustular eruption (6.3 %). 
 
Table 2     Domain and total scores FACT-EGFRI-18 per week 








0 1.41 (1.80) 0.490 (2.20) 0.470 (1.69) 69.5 (5.23) 
1 2.90 (3.49) 1.29 (2.80) 0.760 (2.21) 67.0 (8.03) 
2 5.42 (4.13) 1.45 (2.01) 1.200 (1.86) 63.8 (7.00) 
3 5.32 (4.10) 1.08 (2.10) 0.970 (1.83) 64.6 (6.95) 
4 6.00 (5.14) 1.57 (2.60) 1.780 (3.27) 62.6 (9.75) 
5 5.41 (4.24) 1.86 (3.02) 1.410 (2.69) 63.2 (8.97) 
6 6.65 (5.01) 1.70 (3.28) 1.870 (3.13) 61.6 (10.1) 
Scores are presented in mean (standard deviation). Domain scores are calculated as the sum of all 
corresponding items, with taking into account that at least 50% of the items need to be answered 
for a reliable calculation. The total score is calculated by subtracting the domain scores from 72 (the 
maximum possible total score), and correct for the number of answered items. Resulting, a low 
HRQoL is reflected by a high domain score and a low total score. 
FACT-EGFRI-18 Functional Assessment of Cancer Therapy–EGFRI 
 
Quality of life during EGFRI treatment 
Table 2 and Fig. 2 show the development of total and domain scores of FACT-EGFRI-
18 over time. Scores on the physical domain were significantly higher during all 6 
weeks compared to baseline (p<0.001). The functional domain for all grades showed 
a significantly higher score in the sixth week compared to baseline (p=0.039). In 
patients with grade 1/2, the dispersion in these domains is relatively low (Fig. 2c). 
However, the social-emotional domain did show significant changes within the grade 
3/4 sample (Fig. 2d).What stands out is the large spread on the domains of “social-
emotional” and “functional” in patients with grade 3/4 at weeks 0 and 1. This was also 
the case prior to the start of the EGFRI treatment; in week 0, the standard error is 
negative and as the weeks pass this spread decreases. For all domains and items, a 
higher score represents lower HRQoL. The total FACT-EGFRI-18 score decreased 
during treatment, reflecting decrease in HRQoL.  
There were no significant differences between FACTEGFRI-18 scores for gender 
(total score men 63.40, women 63.92) or cancer type (total scores ranging from 63.7 
to 68.00). Patients younger than 50 years scored significantly (p=0.015) lower on the 
functional domain (score 0.91 <50 years versus 1.61 61–70 years (mean age)). 
Patients above 81 years experienced more impact on the physical domain (p=0.028) 
(2.94 versus 5.06 in the mean age group of 61–70) and total score (p=0.020) (68.56 




by >81; 63.84 by 61–70), compared to patients in the mean age range between 61 and 
70 years. 
The presence of papulopustular eruption during the study period significantly 
decreased HRQoL as measured by FACTEGFRI-18 (p<0.001). This was most 
prominent for the physical domain (Table 3). FACT-EGFRI-18 scores were also 
analyzed separately for xerosis and pruritus, showing a significant reduced HRQoL 
(p<0.014). 
 
Table 3      HRQoL with papulopustular eruption displayed in FACT-EGFRI-18 scores 
Week Papulopustular eruption Domain scores FACT-EGFRI-18 
Physical Social-emotional Functional 
0 n = 0 1.41 (1.80) 0.490 (2.20) 0.470 (1.69) 
1 n = 19 4.58 (4.03)* 2.21 (3.65)* 1.42 (3.06)* 
2 n = 31 6.97 (3.70)* 2.00 (2.21)* 1.61 (1.94)* 
3 n = 24 6.54 (3.98)* 1.50 (2.45)* 1.42 (2.15)* 
4 n= 30 7.27 (5.75)* 1.77 (2.85)* 2.43 (3.95)* 
5 n = 19 6.79 (4.13)* 2.37 (3.29)* 1.84 (3.08)* 
6 n = 24 7.13 (4.16)* 1.92 (2.80)* 1.92 (2.21)* 
Scores presented in mean (SD) 
FACT-EGFRI-18 Functional Assessment of Cancer Therapy–EGFRI, HRQoL Health-related 
quality of life 
*p < 0.05, a significantly lower HRQoL compared with week 0 (baseline) 
 
FACT-G scores were compared with the scores of Cella et al. [11], which included 
other types of cancer, i.e., leukemia, lymphoma, prostate cancer, and ovarian cancer 
without EGFRI treatment. Our study population scored significantly higher on the 
physical (p=0.014) and emotional domains (p=0.013),with higher scores indicating a 
higher HRQoL. Scores on the social family and functional domains did not differ 
significantly. 
Scores on SF-36 were first compared to scores of a sample of a Dutch healthy 
control population in order to examine the difference in HRQoL of EGFRI treated 
cancer patients with healthy individuals [14]. The current study population had a higher 
mean age and scored significantly lower on all domains (p<0.028), meaning lower 
HRQoL. Secondly, SF-36 scores were compared with a group of cancer patients about 
to start chemotherapy or radiotherapy. The current study population was older, 
consisted of fewer females, had more patients with NSCLC and colorectal cancer, and 
fewer with breast cancer. Scores were similar for most SF-36 domains. Only for 
physical functioning (p=0.042) and general health (p<0.001), the current study 
population scored significantly lower, meaning a lower HRQoL [14]. 
Skindex-16 separately identified a significant lower total score when papulopustular 
eruption was present (p<0.002), but not for the presence of xerosis or pruritus. The 
Skindex-16 scores did not differ significantly between patients experiencing 
papulopustular eruption, xerosis, or pruritus (Table 4).  





Table 4 Comparison of mean and median Skindex-16 scores for patients experiencing 


























 n = 30 n = 24 n = 21 n = 67 n = 163 n = 120 
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Joshi et al. [4] displayed mean scores while Rosen et al. [14] displayed median scores. Therefore in the 
current study both are displayed to make comparison possible 
AE adverse event  
aNo standard deviations were given in Joshi et al. [4] 
bA statistically significant result compared with patients from the current study experiencing 
(papulopustular) eruption 
cA statistically significant result compared with patients from the current study experiencing xerosis 
dA statistically significant result compared with patients from the current study experiencing pruritus 
 
The current Skindex-16 scores were compared with the data of Joshi et al. [4] and 
Rosen et al. [15], both a retrospective investigation of Skindex-16 scores of patients 
with dAEs due to cancer treatment in a specialty referral clinic. The study of Joshi et 
al. is the most comparable to the current study as they focused on patients treated with 
EGFRIs. Joshi et al. [4] analyzed more women, more patients younger than 50 years, 
and more patients treated with cetuximab and erlotinib. Rosen et al. [15] included 
patients with targeted as well as non-targeted therapy, who were generally younger, 
more often female, and less often of Caucasian ethnicity. Our study patients with 
papulopustular eruption and xerosis scored higher HRQoL on all Skindex-16 domains 
as patients in Joshi et al. [4] (p<0.001) and in Rosen et al. [15] (p<0.032). This was 
most marked on the emotional level. Our patients with pruritus had equal scores on 
the physical domain compared to both studies, and a comparable score on the 
functional domain with patients in Rosen et al. [15] receiving non-targeted therapy 
(Table 4). Even though not significant in the relatively small sample size, patients with 
pruritus showed a trend of higher scores on Skindex-16 and FACT-EGFRI-18 
(indicating a lower HRQoL) than patients with papulopustular eruption or xerosis. 





The current results show that xerosis and pruritus have a major negative impact on 
HRQoL during the first 6 weeks of EGFRI treatment. This also applies for the patients 
affected by papulopustular eruption, from which only 6.3 % report the presence of 
papulopustular eruption as having the highest impact on HRQoL. These findings were 
confirmed also in the STEPP trial [16, 17]. 
In Gandhi et al. [18], patients reported xerosis as having the most negative impact on 
HRQoL and pruritus as the third most impactful of all dAEs. In addition, xerosis was 
reported as having the second most negative impact on HRQoL of all unexpected AEs 
due to cancer treatment. Since xerosis and pruritus are less frequent reported EGFRI-
associated dAEs, not all patients are counseled about these possible dAEs before 
initiating treatment. Therefore, they cannot engage in anticipatory coping; a method to 
deal with anticipated AEs. In an interview study of Frith et al. [19], strategies were 
identified for patients to cope with anticipated cancer treatment AEs. First, patients try 
to foresee the amount of distress and accompanying emotions through “affective 
rehearsal,” followed by acceptance of possible AEs and gathering resources to 
manage them through “behavioral rehearsal,” a method to modify interpersonal skills 
and social interactions. The final strategy is finding ways to control the development of 
the AEs and the personal emotional reactions on them [19]. 
Since this is the first report of FACT-EGFRI-18 scores, we are not able to compare 
our data to data from other trials. Our analysis showed that during the first 6 weeks of 
EGFRI treatment, patients experience influence on their HRQoL primarily due to 
physical symptoms, especially irritation, xerosis, pruritus, and nail sensitivity. The 
reversed FACT-EGFRI-18 scores of papulopustular eruption, xerosis and pruritus 
decreased significantly on the total scores (p<0.014) indicating a high HRQoL. The 
non-reversed FACT-EGFRI-18 scores increased significantly on the domain scores 
(p<0.012) reflecting a low HRQoL. Only patients experiencing xerosis in week 1 and 
patients experiencing pruritus in week 5 did not have a significant higher score on the 
functional domain, meaning a non-significant different score compared to before 
treatment. 
Cella et al. [11] used the FACT-G questionnaire in a population with different 
cancer types and treatments, and EGFRI-treated patients were not included. EGFRI 
treatment is considered more tolerable compared to conventional cytotoxic treatments, 
because systemic AEs are less frequent [20]. This could explain the higher score on 
the physical and emotional domains in the current study population. Aaronson et al. 
[14] measured pre-treatment SF-36 scores, resulting in fewer AEs, which explain a 
higher physical functioning and general health. 
The study of Joshi et al. [4] analyzed Skindex-16 scores at any time of AE 
development instead of the current fixed measurement at week 4 of treatment. In 
addition, the referral to a specialty clinic might have increased patients’ worry about 
the severity of the AEs. Rosen et al. [15] measured patients at any moment during all 
types of cancer treatment, causing a broader range of dAEs, which influences Skindex-





16 scores. This could also explain a better HRQoL for patients with papulopustular 
eruption or xerosis. In addition, patients with pruritus had similar Skindex-16 scores on 
the physical domain as the patients in the specialty referral clinic in Joshi et al. [4] and 
Rosen et al. [15]. These findings suggest that the impact of pruritus on HRQoL might 
be larger than papulopustular eruption and xerosis. The similar score on the physical 
domain of Skindex-16 of patients with acne vulgaris suggests clinical similarities with 
EGFRI papulopustular eruptions. Patients with EGFRI-associated papulopustular 
eruption are generally more likely to accept the temporary eruption as part of their 
treatment for cancer, especially since they are usually informed about its association 
with effectiveness of treatment, which can clarify the different impact on emotions and 
functioning [17, 20, 21]. 
This study required a substantial effort for patients to complete consecutive 
questionnaires at the intended assessments. There might be a selection bias as 
missing data were from relatively sicker patients, which could result in overestimating 
the overall HRQoL and underestimating the impact of dAEs on HRQoL. Another cause 
may be the missing data from patients who did not experience noticeable AE changes 
and, therefore, did not complete the questionnaires in the weeks without AE changes. 
The incidence of dAEs might be reduced as all patients received close monitoring and 
preventive and reactive treatment. As all factors mentioned above are more likely to 
have improved HRQoL of patients, the expectation is that the current results are indeed 
realistic and may be even more profound when less confounding factors would be 
present. Because the study population consisted mainly of patients from Caucasian 
origin, with NSCLC or colorectal cancer, current results may not apply to all EGFRI-
treated cancer patients. 
Conclusion 
Clinical and research endeavors in patients with various cancers who receive medical 
management consisting of EGFRIs have focused mainly on papulopustular eruption 
as an EGFRI-associated AE, which resulted in an important decrease in HRQoL. 
However, the current study shows that xerosis and pruritus are also important AEs with 
a major impact on HRQoL. This justifies more focus on HRQoL related to these 
symptoms and on their prevention and treatment in future research. 
In clinical practice, xerosis and pruritus are infrequently discussed during patient 
counseling prior to treatment, as they are less visible than the more common 
papulopustular eruption. Providing patients adequate information about treatment and 
possible AEs has shown a positive result on patients’ emotional and physical well-
being. Counseling patients prior to EGFRI treatment about potential xerosis and 
pruritus is therefore important, as well as taking preventive measures against these 
AEs [18, 19, 22, 23]. 
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ABSTRACT 
Purpose: The Functional Assessment of Cancer Therapy-Epidermal Growth Factor 
Receptor Inhibitor 18 (FACT-EGFRI-18) is a patient-reported outcomes questionnaire 
developed to assess the effect of EGFRI on patients. The FACT-EGFR-18 was 
translated into Dutch and evaluated in order to document that the translation 
adequately captures the concepts of the original English-language version of the 
questionnaire and is readily understood by subjects in the target population. 
Method: Translation of the FACT-EGFRI-18 from English to Dutch was accomplished 
by employing the Functional Assessment of Chronic Illness Therapy (FACIT) 
multilingual translation methodology. Ten native-speaking residents of the target 
country who reported EGFRI associated dermatological adverse events (dAEs) were 
asked to review the translation of the harmonized FACT-EGFRI-18. 
Results: Participants generally found the Dutch FACT-EGFRI-18 easy to understand 
and complete. In addition, the translation retained the original meaning of the FACT-
EGFRI-18 items and instructions. Based on the results of the cognitive debriefing 
interviews, no changes to improve clarity and comprehension of translations were 
identified. 
Conclusions: The Dutch FACT-EGFRI-18 demonstrates content validity and linguistic 
validity, and was found conceptually equivalent to its English source, thus confirming 
linguistic validation. The results suggest that the Dutch FACT-EGFRI-18 can be 
applied to measure dAE related health related quality of life in Dutch-speaking patients 











Several types of anticancer agents lead to dermatological adverse events (dAEs); 
dAEs are the primary side effects associated with targeted anticancer agents, 
especially those targeting the epidermal growth factor receptor (EGFR) signal 
transduction pathway (Balagula et al., 2011). The most common dAEs are defined as 
those affecting the skin, hair, nail bed, mucosa or eyelids. DAEs can result in skin rash 
(papulopustular eruption), itching (pruritus), abnormally dry skin (xerosis cutis), painful 
mucosal surfaces, dry conjunctivae of the eye, periungual inflammation, and oedema 
in up to 90% of patients during treatment with EGFR Inhibitors (EGFRI) (Iacovelli, 
2007; Lacouture and Melosky, 2007; Perez-Soler and van Cutsem, 2007). They can 
have significant impact on quality of life because they can hinder daily activities and 
make it difficult to maintain patients’ privacy about their illness, even when the 
treatment is effective in combating the cancer. The aesthetic discomfort, which is 
frequently associated with a burning sensation, itching or painful skin or nails, can lead 
to a decreased health related quality of life (HRQoL), dose reduction and even to a 
refusal to continue with further treatment (Hu et al., 2007). Oral complications can 
cause pain and affect oral function such as oral intake of food and medications, may 
impact nutrition, affect speech, ability to maintain oral hygiene and patients may be 
forced to remove their oral prostheses. 
HRQoL 
The concept of HRQoL can be defined as the extent to which one’s usual or 
expected physical, emotional, and social well-being is affected by a medical condition 
or its treatment (Cella, 1994). One difficulty for clinicians trying to conceptualize a 
patient’s HRQoL is due to its multidimensional nature that encompasses multiple 
aspects of a person’s well-being (Ratanatharathorn et al., 2001). Empirical 
investigation of the aspects of dAEs that have the most detrimental impact on patients’ 
HRQoL can help guide interventions to manage these toxicities and maximize patients’ 
HRQoL (Wagner et al., 2007). Joshi et al. measured the effect of EGFRI-induced dAEs 
on HRQoL. They concluded that toxicities including rash, xerosis, paronychia, and 
pruritus adversely affect HRQoL, with rash associated with a greater decrease. 
Younger patients reported a lower overall HRQoL than older patients undergoing the 
same toxicities (Joshi et al., 2010). 
dAE related HRQoL assessment 
Having accurate baseline and post treatment data is essential to evaluating the 
HRQoL of patients and subsequently determining the effectiveness of management 
(Ikeda et al., 2003), which can range from counselling to pharmacologically based 
therapies. Prior to this study, Dutch patients with dAEs due to EGFRI treatment were 
not likely to have a formal assessment or reassessment of their dAEs related HRQoL 
because there was no Dutch EGFRI associated dAE specific HRQoL measurement 




tool available. If EGFRI treatment-related HRQoL is to be improved, data on the 
prevalence, severity, and impact of dAE on HRQoL must be obtained and the 
effectiveness of various interventions on the HRQoL documented.  
FACT-EGFRI-18 
To date there have been two HRQoL questionnaires developed for EGFRI treated 
patients: the Functional Assessment of Side- Effects to Therapy-EGFRI (FAST-
EGFRI) (Wagner et al., 2007) and the Functional Assessment of Cancer Therapy-
EGFRI-18 (FACTEGFRI- 18) (Wagner et al., 2010). The 38-item FAST-EGFRI was the 
first EGFRI specific HRQoL questionnaire. The FACT-EGFRI-18 is based on the 
FAST-EGFRI and is a symptom specific subscale of the Functional Assessment of 
Chronic Illness Therapy (FACIT) measurement system used for assessing dAEs 
(FACIT.org, 2010). The FACT-EGFRI-18 is an 18-item Likert-scaled questionnaire, 
arranged in three HRQoL dimensions: physical (7 items), social/emotional (6 items), 
and functional well-being (5 items) (Wagner et al., 2007). To provide a better fit for 
scale items, the item groups are reorganized in skin, nail and hair side effect domains. 
The response scores ranged from 0 to 4 and the response categories include ‘Not at 
all’, ‘A little bit’, ‘Somewhat’, ‘Quite a bit’, and ‘Very much’. Negatively worded items 
(e.g. “My skin bleeds easily” or “My skin condition affects my mood”) are reverse-
scored so that all participants who experience a higher severity of symptoms receive 
a lower score. The FACT-EGFRI-18 was developed according to the FACIT 
measurement system (FACIT.org, 2010; Webster et al., 2003). Table 1 shows the 18 
items by subscale. 
Instrument equivalence 
Dutch is the native language spoken in The Netherlands and in about sixty percent 
of the populations of Belgium and Suriname, the three member states of the Dutch 
Language Union. Most speakers live in the European Union, where it is a first language 
for about 23 million and a second language for another 5 million people (not including 
speakers of closely related Afrikaans) (Ardizzoni et al., 2002; European Commission, 
2006; Nederlandse Taalunie, 2012). It also holds official status in the Caribbean island 
nations of Aruba, Curacao, and Saint Maarten, as well as Australia, Canada, France 
(French Flanders), Germany, Indonesia, South Africa, and the United States. 
When adapting measures for use in non-English-speaking populations, the 
translation process is a key factor in ensuring the appropriateness of the instrument in 
the target language. Qualitatively translation issues inevitably arise, such as issues 
related to semantic nuance, differences in dialect, or use of colloquial or idiomatic 
expressions. Employing a comprehensive translation methodology seeks to resolve all 
conceptual or linguistic concerns.  
Ensuring conceptual equivalence among the adapted versions is critical, as 
translations that deviate from the intended meaning could affect how individuals 
perceive the connotation associated with specific test items: Patients may seem to 
understand the intent, but their perception and understanding of the intent may differ 





from that of the English source. In this manner, linguistic nuances can create 
conceptual inequalities that can go undetected. This happens when there are 
significant differences in cultural values between the source and target cultures or 
when there are differences in how individuals of different groups qualify their symptoms 
(Guyatt, 1993; Kleinman, 1987; Marquis et al., 2005). This limits comparison of results 
from different studies, and also negates the possibility of pooling data for larger studies 
(Chang et al., 1999; Sireci, 1997; Yu et al., 2004) and ultimately inhibits a clinician’s 
ability to interpret and apply assessment results because he or she may inadvertently 
over- or under-represent the severity of their patient’s health status.  
 
Table 1 
FACT-EGFRI-18 items by subscale. 
Physical well-being 
1. I am bothered by a change in my skin’s sensitivity to the sun 
2. My skin or scalp itches 
3. My skin bleeds easily 
4. My skin or scalp is dry or “flaky” 
5. My skin or scalp feels irritated 
6. My eyes are dry 
7. I am bothered by sensitivity around my fingernails or toenails 
Social/emotional well-being 
1. My skin condition affects my mood 
2. I feel unattractive because of how my skin looks 
3. I am embarrassed by my skin condition 
4. I avoid going out in public because of how my skin looks 
5. I am bothered by increased facial hair 
6. I am bothered by hair loss 
Functional well-being 
1. My skin condition interferes with my social life 
2. Sensitivity around my fingernails makes it difficult to perform household tasks 
3. My skin condition interferes with my ability to sleep 
4. Changes in my skin condition make daily life difficult 
5. The skin side effects from treatment have interfered with household tasks 
FACT-EGFRI-18 = Functional Assessment of Cancer Therapy-Epidermal Growth 
Factor Receptor Inhibitor. 
 
Translation & cultural adaptation of patient reported outcome 
measures  
European regulatory bodies have raised concerns over the validity of measures 
developed in one language and then used in other languages (Chassany et al., 2002). 
The European Regulatory Issues and Quality of Life Assessment (ERIQA) group 
recommends that a rigorous approach is taken in the translation of patient-reported 




outcome (PRO) measures for use in international settings to achieve conceptual and 
semantic equivalence across languages (Acquadro et al., 2008). Because of the 
increased need to translate and culturally adapt PRO measures, content integrity 
during translation has to be maintained (Wild et al., 2009; Wild et al., 2005; Wyrwich 
et al., 2013). In response to a growing demand for more global and universally 
applicable clinical assessment instruments, a number of outcome based assessment 
tools have been developed from a cross-culturally sensitive perspective. This is in an 
effort to aid clinicians and researchers to more accurately understand the multifaceted 
attributes of what constitutes HRQoL and associated well-being. The literature shows 
a myriad of HRQoL assessment measures being adapted and validated for use with 
non-English-speaking populations (Butt et al., 2005; Eremenco et al., 2005a; 
Eremenco et al., 2004; Peterman et al., 1997). 
FACIT translation system 
The Functional Assessment of Chronic Illness Therapy (FACIT) translation 
measurement system (Bonomi et al., 1996; Eremenco et al., 2005b) utilizes health-
care and translation experts from culturally appropriate geographic regions in order to 
develop linguistic and culturally equivalent translations that are appropriate for 
individuals with an average education level for the target culture. The methodology 
also calls for pilot testing of the translations to ascertain if patients from different 
backgrounds and with similar health symptoms understand the terminology in a 
consistent manner. Even with these safeguards, there is the possibility of psychometric 
inequivalence, which may be due to small sample size used in pilot studies or the 
sociodemographic profile of a particular sample (Arnold et al., 2009a,b). 
The present study sought to conduct a linguistic validation of the FACT-EGFRI-18 
questionnaire for the Dutch speaking population in The Netherlands. The purpose is 
to examine whether the Dutch translation adequately captures the concepts of the 
original English-language version of the questionnaire and is readily understood by 
participants in The Netherlands. 
Methods 
The FACT-EGFRI-18 was originally developed and validated in English (Wagner 
et al., 2010 2359/id). To create a Dutch version, we followed the standard multilingual 
translation and validation methodology developed by Bonomi et al. (1996) and adopted 
by the FACIT organization (FACIT.org, 2010). Due to the non-interventional design of 
this study, it was exempt from review by an ethics committee, per national and 
institutional standards and policies.  






Following the FACIT validation methodology (FACIT.org, 2010), the required ten 
participants were recruited by clinical investigators from three hospitals in The 
Netherlands. The hospitals were selected from the participating hospitals for the BeCet 
trial (NCT01136005), where the 
formal validation of the Dutch FACT-
EGFRI-18 is ongoing. Participants 
were eligible if they spoke Dutch as 
their native and primary language 
and had the ability to read standard 
Dutch; had been diagnosed with 
cancer; treated with an EGFRI; 
experiencing dAEs; if they had an 
Eastern Cooperative Oncology 
Group Performance Status (ECOG 
PS) ≤ 2; were at least 18 years of 
age and provided verbal informed 
consent to participate in the study. 
Demographic data collected 
included age, sex, diagnosis, date of 
diagnosis, primary language 
spoken, country of origin, current 
place of residence, and functional 
performance status. Table 2 
summarizes the major demographic 
variables that were collected. 
Procedure 
Translation of the English FACT-EGFRI-18 into Dutch was conducted according to 
the FACIT translation methodology (Cella and Webster, 1997; Eremenco et al., 2005a; 
FACIT.org, 2010; Webster et al., 2003). Two forward translations, one reconciliation of 
the two forward translations, a back translation into English, and a review by Dutch-
speaking health-care experts were required, along with field testing on a small patient 
population. A schematic overview of a typical linguistic validation process is illustrated 
in Table 3. 
During the translation from English to Dutch, priority was given to achieving 
appropriate translation of the meaning/intent of each question in a grammatically 
correct manner, as opposed to simple translation of every individual word. Additional 
reviews by the FACIT organization and a committee of bilingual Dutch EGFRI therapy 
experts confirmed that the Dutch version was a harmonized translation of the English 
questionnaire. The translations were then tested via cognitive debriefing interviews in 
participants with EGFRI associated dAEs residing in The Netherlands. Cognitive 
Table 2 
Demographic and clinical characteristics of 
the validation sample (N = 10). 
Characteristics  Mean (range) N 
Age  70 (63-81)  
Gender   
Male  6 
Female  4 
Diagnosis of cancer   
Colon cancer  6 
Lung cancer  3 
Breast cancer  1 
EGFRI treatment   
Panitumumab  6 
Erlotinib  2 
Gefitinib  1 
Lapatinib  1 
ECOG PS; rating (0-4)   
0  3 
1  4 
2  3 
ECOG PS = Eastern Cooperative Oncology 
Group Performance Status. 




debriefing is a standardized interview conducted by a trained interviewer following a 
subject’s review and completion of a PRO instrument. 
Participants were interviewed in their homes as it was assumed they would feel 
more comfortable and talk more candidly there. A field tester monitored the 
administrations and then participants were asked to complete the FACT-EGFRI-18. 
Afterwards the field tester conducted a cognitive debriefing interview with each 
participant to assess if they experienced any difficulty understanding items, to see if 
items were irrelevant or offensive to them, to assess the items’ personal and cultural 
relevance as well as the patients’ overall comprehension of them, and to determine if 
any translations were poorly phrased or overly colloquial. Interviewing was conducted 
using a script that was read to the participants: “As you know, we are testing a 
questionnaire for use in clinical trials and want to know if it can be easily understood. 
Would you please tell me which items were difficult to understand and why they were 
difficult? Also, could you suggest a better way to phrase these items?” The interviewer 
judged whether items were correctly paraphrased and recorded any comprehension 
problems or proposed changes to the wording. In keeping with regulatory guidelines 
and good clinical practice, cognitive debriefing information was captured on a data 
collection form. 
In the subsequent qualitative analysis, linguistic validation teams, consisting of the 
original translators, back translator, project manager, interviewer, and survey research 
expert, evaluated the debriefing results. The teams categorized problems that 
emerged during the debriefing as: conceptual e a function of the original English; 
linguistic e a function of the words used to translate the English concept; or stylistic e 
a function of the subject’s preference for a different wording. When warranted, the 
original translators of the questionnaire created a new harmonized translation of 
problem words or sentences and the back translator created a new back translation for 
review by a survey research expert. Once all issues were resolved, final forward and 
back translations were created. 
Results 
Participants 
After creating comprehensive translations which were approved by the translators, 
project manager, and survey research expert involved in its production, debriefing 
interviews were conducted with 10 participants with EGFRI associated dAEs from the 
Netherlands. Participants were a-select recruited. The study coordinator contacted the 
hospitals to find out if they had patients who met the inclusion criteria. All patients who 
were approached were included. No one refused. The participants ranged in age from 
63 to 81 years, mean age was 70 years. Among the 10 participants, 6 patients were 
male and colon cancer was the most common cancer diagnosis (Table 2). 






The translation process went smoothly except one phrase. In the item ‘I am 
bothered by a change in my skin’s sensitivity to the sun’, ‘I am bothered by’ was first 
back translated into ‘annoying’ (‘dat ik last heb’), which was not acceptable to the 
FACIT organization based on Dutch translations of the item in other linguistically 
validated FACIT questionnaires. The FACIT organization provided the phrase ‘Ik vind 
het vervelend’. However, that phrase was too long and vague in this context; 
participants would not understand what this item was about. Because it was strongly 
recommended that we used this phrase, we were limited in providing a fluent sentence. 
We agreed to be consistent with this item but be inconsistent with the word ‘sensitivity’ 
in order to be able to create a fluent Dutch sentence.  
The word ‘sensitivity’ was first back translated into ‘has become more sensitive’, 
which was not acceptable to the FACIT organization. The forward translation from 
 
Table 3 
FACIT translation methodology (FACIT.org, 2010). 
Step Process Personnel Requirements/ 
Purposes 
1 Using the English source, produce two 
forward translations of each item 
2 native speakers of 
target language (1 in the 
US and 1 in native 
country) 
Use simple language 
and capture meaning 
2 Reconcile the initial translation of the items 
based on the two forward translations 
1 native speaker, 
familiar with multiple 
dialects 
Resolve discrepancies 
3 The reconciled translation is back-translated 
by a native English speaker fluent in the target 
language 
1 native English 
speaker 
Use simple language 
4 Three independent professional bilingual 
translation experts review the reconciled 
translation 
3–4 bilingual experts 
and coordinating team 
Review steps 1–3 and 
finalize translations 
5 The translation team finalizes and 
subsequently harmonizes the translations 
across all countries and/or languages within 
the scope of the project 
Language coordinator 
and bilingual expert 
Proof-read 
6 Final translations are proofread  2 bilingual experts from 
the translation team 
Proof-read 
7 The translated questionnaire is field tested 
with cancer patients from the target 
population to determine if further revisions are 
necessary 
Native speaking 




8 The final instrument is considered 
conceptually equivalent to its English source 
and is ready to be used in clinical or research 
settings 
- - 
‘sensitivity’ was ‘gevoeliger is geworden’. The FACIT organization provided the word 
‘gevoeligheid’ because this was the word used in other Dutch FACIT questionnaires. I 




few would have used this word, the literal back translation then would be: ‘I am 
bothered that the sensitivity of my skin for the sun is changed’ which was not 
acceptable for the translators. So we agreed to be inconsistent with the translation of 
this word compared to previous translations of other FACIT questionnaires and use 
the Dutch word ‘gevoeliger’ (‘more sensitive’) instead of ‘gevoeligheid’ (‘sensitivity’). 
Cognitive debriefing 
During the linguistic validation process, special attention was paid to ensure that 
the translated items communicated the desired intent. Since the forward translators 
had some discussions during the translation process about the phrase ‘I am bothered 
by a change in my skin’s sensitivity to the sun’, additional questions about this item 
were added by the FACIT Translation Services to the ‘Patient Interview Form’. 
Questions were: “What does the phrase ‘I am bothered’ mean in this item?”, “What are 
some examples of ‘change in your skin’s sensitivity to the sun’?” and ”The idea of this 
item is to ask if you are distressed, both physically and emotionally. Is there a better 
way to express this idea? If so, please provide your suggestion.” The term ‘bothered’ 
was described by our participants as ‘not being allowed to do what you want to’; ‘limited 
in opportunities’, ‘troublesome because others have to take you into account’, ‘you 
have to adapt’, and ‘you must remember to take a cap and sunscreen with you’. 
Participants’ responses confirmed that the meaning of this item is correctly understood 
and the item ‘Ik vind het vervelend’ captured the original concept. Further, to confirm 
that participants were appropriately interpreting items, they were asked to give 
examples of undesirable events. For example, for the phrase ‘change in your skin’s 
sensitivity to the sun’, participants reported that they have to sit in the shade, others 
needed to be more considerate with the patients, and they needed to wear a hat, even 
in the car. Qualitative analysis of all translations derived from employing the FACIT 
translation methodology revealed no important issues to change. 
Overall, patients commented that the Dutch FACT-EFRI-18 was easy to complete 
and the items were relevant. Results from the post-questionnaire debriefing interviews 
suggested that the translations were accurately understood by the participants in a 
manner that was conceptually equivalent to the English source. 
Discussion 
As more and more patients will be treated with targeted therapies including EGFRI, 
it becomes increasingly important to understand the multidimensional experiences of 
these agents associated dAE related HRQoL. The FACT-EGFRI-18 is the first 
instrument measuring dAE related HRQoL in Dutch cancer patients undergoing EGFRI 
therapy. Further, use of validated and standardized tools will allow comparison of 
outcomes in different studies and in meta-analyses, to advance patient care and 
improve outcomes.  
In our study, use of the established FACIT translation methodology in conjunction 
with the qualitatively based debriefing interview indicated that the constructs being 





measured in the Dutch version of the FACT-EGFRI-18 were conceptually equivalent 
with the original English version prior to field testing with patients. All patients 
responded that the FACT-EGFRI-18 was easy to understand and items were relevant 
to measuring HRQoL. This methodology facilitated the translation of the instrument, 
and use in further translations of this and other survey tools is therefore recommended. 
Study limitations 
Study limitations included participants with different kinds of cancer, EGFRI 
treatment, and dAEs. At the same time, different cancers and treatment allows testing 
of the questionnaire across a range of patients. Another limitation was the relatively 
small participant sample, however, the number of 10 participants was prescribed by 
the FACIT organization. All participants were residents from the Netherlands as 
spoken Dutch tends to vary based on geography and differences in dialect could be 
present in different regions. Since demographic, economic, geographic, political, and 
sociological differences make each culture unique, linguistic and conceptual 
equivalence may not necessarily assume generalizability of results across cultures 
(Anderson and Gerbing, 1988). The Dutch questionnaire is only linguistically validated 
for the population from The Netherlands. To cover a Dutch version for all the native 
Dutch speakers around the world, validation should be done in those countries and in 
other languages. 
Clinical and research implications 
The results of the linguistic validation suggest that the Dutch version of the FACT-
EGFRI-18 can be applied to measure EGFRI associated dAE related HRQoL in Dutch 
speaking cancer patients in The Netherlands. Before the Dutch version can be used in 
other Dutch speaking countries like Belgium, the Caribbean island nations of Aruba, 
Curacao, and Saint Maarten, as well as Australia, Canada, France (French Flanders), 
Germany, Indonesia, South Africa, and United States the linguistic validation should 
be performed in at least in Belgium and Surinam before we called it a universal version. 
A single (universal) Dutch version of the questionnaire is warranted. 
This scale development will help clinicians in the Netherlands to collect more 
information about the impact of dAEs on the HRQoL due to EGFRI. The result of this 
scale development process can be applied to all patients treated with EGFRI. The 
instrument can help researchers and clinicians to assess mcAE related HRQoL, to be 
able to select interventions, and evaluate their effectiveness. Thus, the use of this tool 
will be able to improve patients’ dAEs treatment and HRQoL. 
Formal validation and reliability testing of the Dutch FACTEGFRI-18 is being 
conducted in the BeCet multicenter trial (NCT01136005) of 160 patients with all dAEs 
severity grades (National Cancer Institute Cancer Therapy Evaluation Program, 2010). 
In addition, the translation and linguistic validation of the FACT-EGFRI-18 into German 
is ongoing. The FACT-EGFRI-18 is available at www.facit.org. 





Translations of the FACT-EGFRI-18 questionnaire from English into Dutch 
adequately captured the concepts in the original English version of the questionnaire, 
thereby demonstrating the conceptual, semantic, and cultural equivalence of the 
translation. Participants experiencing EGFRI associated dAEs demonstrated an ability 
to understand the concepts in the questionnaire. Based on the results of the cognitive 
debriefing interviews, no changes to improve clarity and comprehension of translations 
were needed. Additionally, by utilizing the FACIT translation methodology and 
incorporating translation experts, the translation of the Dutch FACT-EGFRI-18 is 
considered a promising clinical tool for evaluating the HRQoL of Dutch speaking 
patients with EGFRI associated dAEs from The Netherlands. These methods and this 
current study have implications for HRQoL questionnaire development using different 
questionnaires and in different languages. 
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events. 
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ABSTRACT 
Purpose The functional assessment of cancer therapy epidermal growth factor 
receptor inhibitor 18 (FACT-EGFRI- 18) is a patient-reported outcomes questionnaire 
developed to assess the effect of EGFRI on health-related quality of life (HRQoL). 
Methods Ten native-speaking residents of The Netherlands who reported EGFRI-
associated mucocutaneous adverse events (mcAEs) were administered the 
questionnaire. Patients were subsequently asked a standardized series of questions 
about the items’ personal relevance.  
Results Responses reflected a major negative impact of mcAEs due to EGFRI on 
physical, social/emotional, and functional domains. In some cases, especially in the 
social/-emotional domain, the responses to the qualitative interview indicated a greater 
impact on HRQoL than the numerical ratings previously selected for the Dutch FACT-
EGFRI-18 questions.  
Conclusions Based on these interviews, we identified that the physical items 
associated with mcAEs interfere most with HRQoL. The results suggest that the FACT-
EGFRI-18 can be applied to measure mcAE-related HRQoL in cancer patients 
undergoing EGFRI therapy. In addition, patients feel the need to rate their symptom 










Epidermal growth factor receptor inhibitors  
The use of targeted therapies such as epidermal growth factor receptor (EGFR) 
inhibitors is increasing. It is well know that mucocutaneous adverse events (mcAEs) 
are the primary side effects associated with agents targeting the EGFR signal 
transduction pathway [1]. The most common mcAEs are defined as those affecting the 
skin, hair, nail bed, mucosa, or eyelids. mcAEs can result in skin rash (papulopustular 
eruption), itching (pruritus), abnormally dry skin (xerosis cutis), painful mucosal 
surfaces, dry conjunctivae of the eye, periungual inflammation, and edema in up to 90 
% of patients during treatment with EGFR inhibitors (EGFRI) [2–4]. They can have 
significant impact on health-related quality of life (HRQoL) because they can hinder 
daily activities and make it difficult to maintain the patients’ privacy about their illness, 
even when the treatment is effective in combating the cancer. The mcAEs result in 
discomfort, which is frequently associated with a burning sensation, itching, or painful 
skin or nails and can lead to a decreased HRQoL, that may lead to dose reduction and 
even to a refusal to continue with further treatment [5]. Oral complications can cause 
pain and affect oral function such as oral intake of food and medications; they may 
impact nutrition, affect speech, the ability to maintain oral hygiene, and patients may 
be forced to remove their oral prostheses. Other oral symptoms can include taste 
change or taste reduction and dry mouth.  
Many practitioners assume the cosmetic appearance of the rash to be the most 
bothersome for patients, but they may have a tainted perspective on patient’s mcAEs 
influence on HRQoL. However, patients’ concerns and emotions were most adversely 
impacted by associated symptoms of irritation, pain, stinging, and itching [6]. This 
discrepancy may exist because the mcAE grade seems inversely correlated with the 
impact on the HRQoL. This discrepancy between assessment of mcAEs and the effect 
on HRQoL may lead to inadequate management. 
Symptom burden and HRQoL 
Symptoms are subjectively experienced responses of a patient to a disease, injury, a 
physical disturbance, or produced by treatment side effects and can cause changes in 
HRQoL. Conversely from signs that can be observed by others, symptoms can only 
be known from reports provided by the patient [7–9]. The concept of symptom burden 
can be described as a summary of the severity and impact of symptoms, reported by 
patients with a specific disease, or due to a certain treatment. It is not only 
measurements of HRQoL that can be divided in physical and mental domains; 
symptoms also can be described to be either physical, psychological (more associated 
with well-being and mental health), or emotional (frustration, worry), where the 
classification relates to the origin of the symptoms [7, 9, 10]. Symptom burden can be 
pronounced and can thereby negatively influence different domains in life, leading to 
an impaired HRQoL [11]. 




The concept of HRQoL can be defined as the extent to which one’s usual or 
expected physical, emotional, and social well-being is affected by a medical condition 
or its treatment [12]. One difficulty for clinicians trying to conceptualize a patient’s 
HRQoL is due to its multidimensional nature that encompasses multiple aspects of a 
person’s wellbeing [13]. Empirical investigation of the aspects of mcAEs that have the 
most detrimental impact on patients’ HRQoL can help guide interventions to manage 
these toxicities and maximize patients’ HRQoL [14]. Joshi et al. measured the effect of 
EGFRI-induced mcAEs on HRQoL. They concluded that toxicities including rash, 
xerosis, paronychia, and pruritus adversely affect HRQoL, with rash associated with a 
greater decrease. Younger patients reported a lower overall HRQoL than older patients 
with the same toxicities [11]. 
Assessment of symptom burden and HRQoL in EGFRI patients with 
patient reported outcomes 
In the care of EGFRI-treated patients, it is essential to explore the patient’s experiences 
and effects of living with mcAEs. A patient-reported outcomes (PROs) instrument is 
defined as any measure of a patient's health status that is elicited directly from the 
patient and assesses how the patient “feels or functions with respect to his or her health 
condition” [15], giving valuable information and cannot be replaced by health-care 
provider assessments. PROs can be achieved by interview, diaries, or questionnaires 
[7, 16]. Assessment of symptom burden and HRQoL can be the primary outcome 
during a treatment or after an intervention [17, 18]. 
If EGFRI treatment-related HRQoL is to be improved, data on the prevalence, 
severity, and impact of mcAE on HRQoL must be obtained, and the effectiveness of 
various (medical) interventions on the HRQoL, documented. Efforts have been made 
to develop objective documentation of the effects of mcAEs on HRQoL due to these 
agents. Documentation by the health-care provider can be achieved by using the 
National Cancer Institute-Common Terminology Criteria for Adverse Events version 
4.0 (NCI-CTCAE v4.0) scoring [19], and the Functional Assessment of Cancer Therapy 
Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFRI-18) can be used by 
patients to assess HRQoL associated with dermatological side effects. 
FACT-EGFRI-18 questionnaire 
The FACT-EGFRI-18 [20] is a symptom-specific subscale of the Functional 
Assessment of Chronic Illness Therapy (FACIT) measurement system used for 
assessing dermatological adverse events [21]. The FACT-EGFRI-18 is an 18-item 
Likert-scaled questionnaire, arranged in three HRQoL dimensions: physical (seven 
items), social/emotional (six items), and functional well-being (five items) [14]. To 
provide a better fit for scale items, the item groups are reorganized in skin, nail and 
hair side effect domains. The response scores ranged from 0 to 4, and the response 
categories include “not at all,” “a little bit,” “somewhat,” “quite a bit,” and “very much.” 
Negatively worded items (e.g. “My skin bleeds easily” or “My skin condition affects my 
mood”) are reverse-scored, so that participants who experience a higher impact of 





symptom burden on HRQoL receive a lower score. The FACT-EGFRI-18 was 
developed according to the FACIT measurement system [21, 22]. 
The FACT-EGFRI-18 was originally developed and validated in English [20] and 
was recently translated and linguistic-validated into Dutch. To create a Dutch version, 
the standard multilingual translation and validation methodology developed by Bonomi 
et al. [23] and adopted by the FACIT organization [21, 22, 24, 25] was followed. 
As part of the linguistic validation, a part of a translation process, participants with 
EGFRI-associated mcAEs residing in The Netherlands were invited to review the 
recently translated FACT-EGFRI-18 questionnaire. While for the linguistic validation 
itself, it is relevant whether the translation is culturally correct, linguistically correct, 
clear about the information the instrument is trying to elicit from the patient, and if the 
questions are understood; the actual answers given are not part of the linguistic 
validation. Here, we report these data.  
The aim of this study was to identify how the18-item symptom specific, patient-
reported outcome (PRO) measurement (FACT-EGFRI-18) reveals the impact of the 
mcAEs on HRQoL. 
Patients and methods 
Participants 
Following the FACIT validation methodology [21], the required ten participants needed 
for the linguistic validation were recruited by clinical investigators from three hospitals 
in The Netherlands. The hospitals were selected from the participating hospitals for the 
BeCet trial (NCT01136005), where the formal validation of the Dutch FACT-EGFRI-18 
is ongoing. Participants were eligible if they spoke Dutch as their native and primary 
language and had the ability to read standard Dutch; had been diagnosed with cancer; 
treated with an EGFRI; experiencing mcAEs; if they had an Eastern Cooperative 
Oncology Group Performance Status ≤2; and were at least 18 years of age and 
provided verbal informed consent to participate in the study. Demographic data 
collected included age, sex, diagnosis, EGFRI agent, primary language spoken, 
country of origin, current place of residence, and functional performance status.  
Procedures 
The newly developed Dutch FACT-EGFRI-18 was used in ten patients undergoing 
EGFRI treatment and experiencing mcAEs. Participants were interviewed in their 
homes as it was assumed that they would feel more comfortable and talk more candidly 
there. A field tester proctored the administrations, and then participants were asked to 
complete the FACT-EGFRI-18. Afterwards, the field tester conducted an interview with 
each participant in a structured interview fashion to assess the items’ personal 
relevance as well as the patients’ overall comprehension of them. 
In keeping with regulatory guidelines and good clinical practice, interview 
information was captured on a data collection form. Any difficulties that the patients 
experienced with the questionnaire were recorded during the time they completed the 




questionnaire. The patients’ problems in completing the questionnaire were reviewed. 
Patients could rate the items of the three domains between 0 (not at all) and 4 (very 
much). In scoring the FACT-EGFRI-18, the possible range of scores is from 0 to 72. 
To obtain the 0–72 score, each item response was subtracted from 4 so that 0 indicates 
low HRQoL and 4 indicates high HRQoL [21]. 
Due to the noninterventional design of this study, it was exempt from review by the 
local ethics committee, per national and institutional standards and policies. 
Results 
All questionnaires were thoroughly checked when handed in, and if there were 
answers missing, the patients were approached and given the chance to complete. 
Participants 
Interviews were conducted with ten participants with EGFRI-associated mcAEs from 
The Netherlands. Participants were a select recruited. The study coordinator contacted 
the hospitals if they treated at that moment patients who met the inclusion criteria. All 
patients who were approached were included. No one refused. The participants ranged 
in age from 63 to 81 years; mean age was 70 years. Among the ten participants, six 
patients were male, and colon cancer was the most common cancer diagnosis. Three 
patients rated their Eastern Cooperative Oncology Group Performance Status a 0, four 
a 1, and two a 3. Table 1 summarizes the major demographic variables that were 
collected. 
Response to the Dutch FACT-EGFRI-18 questionnaire 
Most patients were able to complete the questionnaire by themselves, with little 
assistance from their partners/family. Based purely on the way the questions were 
worded, patients initially tended to rate the severity of the mcAEs without incorporating 
the impact of mcAEs on their HRQoL. Patients were instructed to circle or mark one 
number per line to indicate their response as it applied to the past 7 days. Table 2 
shows the 18 items by subscale. Several subjects asked the researcher about the 
general aim of the questions, whether we were interested in the experienced intensity 
of the mcAEs or whether we wanted to know if they were emotionally or functionally 
distressed by it. After an explanation that their responses should incorporate the impact 
of the mcAEs on their HRQoL, patients often chose another response level than they 
had originally planned. 
During the interviews, patients gave a wide range of information about their 
dermatological experiences with EGFRI therapy. Overall, patients commented that the 
FACT-EGFRI-18 items were relevant. They reported difficulties in questions 1, 2, 6, 
16, and 17 pertaining to the exact location and the relationship of the experienced  






Table 1 Demographic and clinical characteristics of the participants (N = 10) 
 Patient no. 
 1 2 3 4 5 6 7 8 9 10 
Gender Female Female Male Male Male Male Male Female Male Female 
Year of Birth 1947 1946 1929 1937 1947 1943 1946 1933 1936 1936 
Cancer Diagnosis Colon Colon Lung Lung Colon Colon Lung Colon Colon Breast 






Erlotinib Panitumumab Panitumumab Lapatinib 
Concurrent 
cytotoxics 
No No No No No No No No No Capecitabine 
Patient Rated PS 2 0 2 1 1 1 0 1 0 2 
EGFRI epidermal growth factor receptor inhibitor, PS performance status rating (0–4) (0 = fully active, able to carry on all pre-disease performance without 
restriction; 4 = completely disabled, cannot carry on any self-care, totally confined to bed or chair) 
 
mcAEs with EGFRI treatment; e.g. how a flaky scalp should be scored if a patient already experienced dandruff, and how to 
respond on the question about the interference with household tasks when the patient does not have to do any, but is bothered 
by sensitivity around the fingernails (Table 3).  
It was remarkable that with all the eight patients where a partner/child was present during the pilot testing, the partner/ child 
helped remind the patient that there was a greater impact of the symptom burden on the HRQoL than the patient wanted to rate 
in the first place. While patients stressed being grateful for receiving anticancer treatment, because of their strong will to live, their 
families were more focused on the HRQoL including the mcAEs. Patients did express an appreciation for the opportunity to discuss 
their difficulties coping with their mcAEs. 
As outlined in Table 2, responses reflected a major impact of mcAEs on physical, social/emotional, and functional domains. 
The physical domain items received the highest ratings (indicating a more negative impact), followed by the functional domain 
and the social/emotional domain. The mcAEs “change in the skin’s sensitivity to the sun,” “itching of skin or scalp,” and “easy skin 
bleeding” had the greatest impact on patients’ HRQoL.  
As per the FACIT.org protocol, patients rated first the influence of the mcAEs on their HRQoL and then provided comments 
about their ratings (why they gave that rating). We found that some comments matched the rating and some were discordant. 




Table 2    FACT-EGFRI 18 questionnaire, arranged by the original sub scores and by highest 
numerical ratings 
Instructions to the Patients: Below is a list of statements that other people with your illness have said are important. 
Please circle or mark one number per line to indicate your response as it applies to the past 7 days. 
   Patient no.  









Q5 I am bothered by a change in my skin’s 
sensitivity to the sun 
4 2 2 1 4 1 4 2 2 0 22 
Q3 My skin or scalp itches 3 2 3 3 2 1 0 3 1 3 21 
Q4 My skin bleeds easily 3 0 2 3 2 4 1 4 2 0 21 
Q2 My skin or scalp is dry or “flaky” 2 3 3 2 1 0 0 3 3 2 19 
Q1 My skin or scalp feels irritated 2 2 2 1 1 1 0 3 2 3 17 
Q14 My eyes are dry 1 3 3 1 3 1 0 3 0 2 17 
Q15 I am bothered by sensitivity around my 
fingernails or toenails 















Q7 My skin condition affects my mood 2 1 0 0 2 1 0 3 0 1 10 
Q11 I feel unattractive because of how my 
skin looks 
4 0 0 0 0 1 0 2 2 0 9 
Q9 I am embarrassed by my skin condition 0 0 0 0 3 1 0 1 0 0 5 
Q10 I avoid going out in public because of 
how my skin looks 
3 0 0 0 1 1 0 0 0 0 5 
Q18 I am bothered by increased facial hair 3 0 0 0 0 0 1 0 0 0 4 











Q8 My skin condition interferes with my 
social life 
3 0 0 0 4 1 0 2 1 0 11 
Q16 Sensitivity around my fingernails 
makes it difficult to perform household 
tasks 
2 0 0 1 1 2 0 4 0 0 10 
Q6 My skin condition interferes with my 
ability to sleep 
0 0 2 0 2 1 0 3 0 0 8 
Q12 Changes in my skin condition make 
daily life difficult 
2 0 0 0 3 1 0 0 1 1 8 
Q13 The skin side effects from treatment 
have interfered with household tasks 
3 0 0 0 2 1 0 1 0 0 7 
  Sum individual item score 38 13 18 15 34 20 6 38 14 13  
  FACT-EGFRI symptom index score 34 59 54 57 38 52 66 34 58 59  
FACT-EGFRI symptom index score, the possible range of scores is from 0 to 72. To obtain the 0–72 score, each 
item response was subtracted from 4 so that 0 indicates low QoL and 4 indicates high QoL. Numerical ratings: 0 
= not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much 
FACT-EGFRI-18 Functional Assessment of Cancer Therapy Epidermal Growth Factor Receptor Inhibitor 18; Q 
question number of FACT-EGFRI-18; SUM item subscore: responses of all ten patients per item together 
 
  





Table 3    Site of Adverse event and symptom burden 
Patient no. Question by the interviewer: 
Would you please tell me which items were 
difficult to understand and why they were 
difficult? 
Answers given 
4 Q16: Sensitivity around my fingernails 
makes it difficult to perform household 
tasks. 
Q17: I am bothered by hair loss. 
Q16: I do not have household tasks, but I 
experience hinder from the sensitivity around 
my fingernails. 
Q17: I have hair loss, but I’m not bothered by it 
5 Q1: My skin or scalp feels irritated. 
Q6: My skin condition interferes with my 
ability to sleep. 
Q17: I am bothered by hair loss. 
Q1: Depending on where it is. On the scalp 
since a little while (appeared first in the face, 
body). Now also on the head, neck & 
sideburns. 
Q6 & Q17: do you want to know if it developed 
or if I suffer from it? 
7 Q2: My skin or scalp is dry or “flaky”. 
Q17: I am bothered by hair loss. 
Q2: I had already dandruff, that’s why difficulty 
to tell. 
Q17: hair is flatter and curlier, so different. 
Patient no 1, 2, 3, 6, 8, 9, and 10 reported no difficulties 
 
Patient no. 5 experienced the highest impact of symptom burden on his HRQoL. 
He rated question no. 5, physical domain about skin’s sensitivity to the sun, with a 4 
(very much), while his comment was as follows:  
I wear shirts with long sleeves and long trousers; I wear a cap, even when 
swimming. It has been a torture. If I do not do this, I get second degree burns (I 
had these on hands). It hinders in the freedom and interaction with others. The 
situation is just worthless, restricting movement, ‘bothered’ is too mild; I have had 
a lot of trouble. It is now limited, because I always sit under the umbrella out of the 
sun now. 
Patient no. 8 rated with a 3 (quite a bit) on question no. 7, social/emotional domain: 
“My skin condition affects my mood,” while her comment was the following: 
Do you see how I look? I even no longer have a face; I look stupid; that makes me 
sad.  
Patient no. 5 rated with a 3 (quite a bit), on question no. 12, functional domain: 
“Changes in my skin condition make daily life difficult,” while his comment was as 
follows: 
I have very much difficulty with sitting and lay down because of my pimples 
between my buttocks, and all day care; I rub twice a day with various ointments. 
On the other hand, there were comments from the patient which did not match the 
previously given numerical ratings of the same question. For example, patient no. 6 
rated a 1 (a little bit) on question no. 5, physical domain: “I am bothered by a change 
in my skin’s sensitivity to the sun,” while his comment was the following: 




It burns while sitting in the car and the sun burns on the window; then I have to 
change my seat to the opposite side in the car. 
The greatest inconsistency between the numerical rating and the given comments 
was in the social/emotional domain. Patient no. 9 rated a 0 (not at all) on question no. 
7, social/emotional domain: “My skin condition affects my mood,” while his comment 
was as follows: 
I get grumpy, easily irritated; I don’t allow the grandchildren to kiss me, I find it 
unpalatable.  
Also, patient no. 9 rated a 1 (a little bit) on question no. 8, functional domain: “My 
skin condition interferes with my social life,” while his comment was the following: 
Greetings are cooler and I avoid touching others. 
Six patients gave feedback that not all the mcAEs they wanted to report were 
included in the questionnaire. For example, questions regarding sensitive eyes, a 
runny nose, bloody or crusty nasal cavity due to pimples, dry mouth, tickling and 
tingling sensations, and pain touching the hair were symptoms patients mentioned that, 
in their view, should be added to the questionnaire. 
Discussion 
Major findings 
In our study, a number of major findings are noted. Items that assess physical 
symptoms cause the highest HRQoL impact; an inverse correlation between the 
intensity of mcAEs and HRQoL is found. Patients wanted additional items added to the 
FACT-EGFRI-18 questionnaire. Overall, patients found it useful to discuss their 
experienced mcAE burden.  
Many health-care practitioners assume the cosmetic appearance of rash to be 
most troublesome to the patients; however, this was not supported by patient data. 
Based on the interview results, we identified that symptom burden associated with 
mcAEs are interfering most with HRQoL. The physical discomfort, “Increased 
sensitivity to sunlight (burning sensation),” “itching of the skin or scalp,” and “bleeding 
of the skin” were symptoms patients identified as having the most impact on their 
HRQoL. Results of our study were consistent with the results in the study of Wagner 
and Lacouture [6], who also identified physical discomfort as the most troublesome 
with sensations of pain, burning, and skin sensitivity having the most HRQoL impact. 
The patients’ natural inclination was to rate their symptom severity rather than the 
extent to which it interfered with HRQoL. Based on some inconsistencies between 
numerical rating and the associated comments, there is a possibility that our 
instructions were not clear enough. Our participants felt the need to rate the 
experienced mcAEs instead of the experienced influence of the mcAEs on their 
HRQoL. When patients can separately rate the mcAEs and the influence of the mcAEs 
on their HRQoL, they may be able to better capture the effects on HRQoL. Combining 





the mcAE-related HRQoL with the experienced mcAEs in a two-part scale could be 
interesting for future research. As more and more patients will be treated with EGFRI, 
it will become increasingly important to understand the multidimensional experiences 
of mcAE-associated HRQoL. This is an important challenge for health-care providers 
in their effort to assess PROs. 
During the qualitative interviews, patients gave a wide range of information about 
their experiences regarding the FACT-EGFRI-18. They gave additional information 
regarding the mcAEs they experienced and their struggle to cope with them. It was 
interesting that patients emphasized being grateful for receiving anticancer treatment, 
while their family was focused on the HRQoL including the experienced mcAEs. 
Six patients responded that they miss the possibility to rate some mcAEs in the 
FACT-EGFRI-18 (Table 4). This suggests that not all the mcAEs can be reported while 
patients feel the need to do so. Questions regarding sensitive eyes, a runny nose, 
bloody or crusty nasal cavity due to pimples, dry mouth, tickling and tingling sensations, 
and pain touching the hair and some space for additional comment were mentioned by 
the participants as items that should be added. Other oral issues like sensitive teeth, 
taste changes, oral sensitivity/pain at rest, eating, and oral burning sensation are 
additional mcAEs to consider for assessment. As it is important to cover relevant 
symptoms and domains to find valuable information without making a questionnaire 
too lengthy, we recommend adding these mcAEs in a next version, since not all mcAEs 
are assessed now. 
 
Table 4    Participant recommendations for additional mcAE items 
Patient no. Question by the interviewer: 
Is there anything else that should have been included related to your skin condition? Would 
you please tell me what should be added? 
1 ▪ Dry mouth, little saliva, also in the nose 
2 Nothing to add 
3 Nothing to add 
4 ▪ Dry mouth 
▪ Nasal crusts 
▪ I often have to blow my nose (runny nose), at night it is the opposite: very dry 
5 ▪ Nosebleed because of the pimples in the nose and thin skin on the whole body 
6 ▪ Hands and feet; cracks, very hard cuticles 
▪ Pain occurs in the skin, not beneath the skin 
▪ Sensitive eyes 
▪ Seeing double 
▪ Rub the eyes 
7 Nothing to add 
8 ▪ Space for notes on the answers chosen 
9 Nothing to add 
10 ▪ Tickling sensation on the skin like an insect walking 
▪ Tore scalp, painful/ stinging, (as though you throat is being cut) 
▪ Tingling on hair border, touching the hair hurts 
 





One of the study limitations was the relatively small patient sample; however, the data 
collected were qualitative, and no statistical analyses were completed. It has to be 
mentioned that the ten patients are required by the FACIT organization as mentioned 
in the “Background” section. Patients had different kinds of cancer, EGFRI treatment, 
and mcAEs, which may have caused unbalanced data. At the same time, different 
cancers and treatment allow testing of the questionnaire across a range of patients. 
To develop a questionnaire suitable for all mcAEs can be challenging. Different mcAEs 
can be present with a more or less pronounced symptom burden and the interference 
with the patients’ life situation depending of the experienced mcAEs. The questionnaire 
addresses mainly the cutaneous AEs (17 questions) and only one question addresses 
mucosal AEs (dry eyes). 
Clinical and research implications 
As more and more patients will be treated with targeted therapies including EGFRI, it 
becomes increasingly important to understand the multidimensional experiences of 
these agents associated mcAE-related HRQoL. Use of validated and standardized 
tools will allow comparison of outcomes in different studies and in meta-analyses, to 
advance patient care and improve outcomes. 
A mcAE PRO should consist of three separate parts where part I describes 
demographic data, part II, the mucocutaneous-specific symptom burden, and part III, 
the impact of the mucocutaneous-specific symptom burden on HRQoL. Further 
development with more mcAE items incorporated and combined with symptom 
assessment will provide more complete information. Since mcAEs are also elicited by 
other targeted anticancer therapies such as non-EGFRI tyrosine kinase inhibitors, 
mammalian target of rapamycin inhibitors, and BRAF inhibitors, it would be worthwhile 
to develop one questionnaire suitable for all these targeted agents instead of only for 
EGFRIs. 
Conclusion 
Results from the first experiences with the FACT-EGFRI-18 described how negatively 
affected patients who receive EGFRI can be with a pronounced symptom burden and 
impaired HRQoL. Based on the interview data, we identified that the physical items 
associated with mcAEs are interfering most with HRQoL. These results are consistent 
with the results in the study of Wagner and Lacouture, who also identified physical 
discomfort as the most troublesome and having the most HRQoL impact. 
Since participants wanted to rate the prevalence, intensity, and also the duration 
of the symptoms, while we were interested in the distress from the symptoms, a two-
step measurement tool assessing both symptom burden and HRQoL would be more 
appropriate in this population. The fact that the FACT-EGFRI-18 only evaluates 
HRQoL, not symptoms, that not all the experienced mcAEs can be assessed, and that 
is developed for one kind of targeted therapy, implicates further research needs. 
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08 | General discussion, summary & future 
perspectives 
General discussion and summary 
This thesis presents three notable findings: the voice of the patient is inconsequently 
incorporated in scientific research regarding AEs; available instruments may be of 
limited value for approaching targeted therapy-associated mucocutaneous AEs; and 
available knowledge about a patient-driven approach to AEs is not broadly 
incorporated in research and clinical care. 
The voice of the patient is inconsequently incorporated in scientific research and 
the HCP plays the central role in AE diagnosis and management. The incidence of the 
AEs is mainly measured by HCP’s with suboptimal scales. As a result there may be 
underreporting of AEs. In addition, the non-validated CTCAE scoring system for the 
grading of the AEs is most commonly used while more precise grading instruments are 
available. Currently, most AE grading is performed by HCP’s rather than by patients. 
The instruments evaluated in this thesis may be of limited value for the education, 
assessment, reporting, grading, and evaluation of targeted therapy-associated 
mucocutaneous AEs since: 
• there is no consensus on AE terminology, and therefore the same AEs may be 
diagnosed and named differently 
• the majority of the instruments currently used were not developed for the AEs 
associated with targeted therapies 
• some instruments were developed specifically for subgroups of the targeted 
agents; EGFRI, mTORI, and TKI 
• not all the known symptoms and signs of AEs are incorporated in current 
instruments 
• the majority of the instruments are not validated, and  
• the majority of the instruments are not available in multiple languages. 
In addition, the number proven approaches for the treatment of skin and mucosal 
AEs is limited. Studies to date mainly report secondary outcomes of larger studies with 
other primary outcomes. Furthermore, the AE studies are based on inconsistent 
terminology and the AEs are assessed and graded with suboptimal scales. There is a 
lack of prospective studies investigating the terminology, symptoms and signs of AEs, 
their impact on health related HRQoL, the reporting of AE characteristics, grading the 
AEs, and management of AEs with scales specifically developed for targeted agents. 
Instruments for PRO and CRO are available, but they are not used consequently. 
Current knowledge about a patient-driven approach including education, terming, 
assessing, reporting, grading, evaluating, and treating targeted therapy specific AEs is 
not imbedded broadly in research.(1) In the several manuscripts of this dissertation 





one or more of these crucial steps is addressed. The instruments evaluated in this 
dissertation are listed in box 1. 
Box 1. Evaluated instruments listed in alphabetical order 
• Bristol Stool Chart: The Bristol Stool Chart focuses on variation in consistency of 
stool.(2) The stools are classified into seven types, with types 5 and 6 tending 
towards diarrhea but still loose or mushy stool and type 7 actually diarrhea, watery 
stool. Since according to the NCI-CTCAE definition only type 7, the watery stool, is 
diarrhea, the differences between the two types is important. 
• DERETT: The Dermatological Reactions Targeted Therapy (DERETT) is a 
targeted therapy specific instrument with focus on the assessment of the 
mucocutaneous AEs and the influence of these AEs on HRQoL. DERETT is 
available in two versions, a symptom experience diary for patients (DERETT-P) 
and a symptoms & signs assessment instrument (DERETT-H) for HCPs. These 
instruments gather information such as area involved, severity and duration of the 
symptoms, products used to treat symptoms, effectiveness of the supportive care 
interventions, treatment adherence, and symptom-related distress.(3) 
• EA: The Experimental Assessment (EA) is an oral assessment instrument that 
assesses a number of symptoms using Visual Analogue Scale (VAS) (0–10) 
including dysgeusia, dysphagia, odynophagia, and oral mucosal pain which are 
subjective parameters. The scale adds an objective measure of mucosal erythema 
and ulceration.(4) The EA may have utility in assessing TKI- and mTORI-induced 
oral AEs. 
• FACT-EGFRI-18: The Functional Assessment of Cancer Therapy-Epidermal 
Growth Factor Receptor Inhibitor-18 (FACT-EGFRI-18) is an 18-item Likert-scaled 
PRO questionnaire. It is arranged in three HRQoL domains: physical (7 items), 
social/emotional (6 items), and functional well-being (5 items).(5-7) The validation 
of the Dutch Version of the FACT-EGFRI-18 is part of the BeCet trial. 
• FACT-G: The Functional Assessment of Cancer Therapy-General (FACT-G) is a 
cancer specific instrument with focus on PRO measures using numerical analogue 
scales (0=not at all, 4=very much). The FACT-G version 4 consists of 27 items in 
four HRQoL domains: physical (7 items), social/family (7 items), emotional (6 
items), and functional well-being (7 items).(8) 
• FAST-EGFRI: The Functional Assessment of Side-Effects to Therapy-EGFRI 
(FAST-EGFRI) is an EGFRI specific instrument with focus upon the assessment of 
HRQoL.(7) The 38-item FAST-EGFRI was the first EGFRI specific HRQoL 
questionnaire. 
• MESTT: The MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT) is a grading 
system for the most common EGFRI-associated mucocutaneous AEs.(9) The 
MESTT is an event-specific grading system that can be used to standardize 
assessment, optimize the use of EGFRIs, and enable researchers to conduct more 




informative, controlled studies in this patient population. The scale is consistent with 
grading principles and language of the CTCAEv4.0. 
• mIAS scale: The mammalian target of rapamycin inhibitor (mTORI)-associated 
stomatitis (mIAS) scale is a mTORI specific instrument with focus on mIAS.(10) 
This scale has a subjective component measuring pain and an objective 
component measuring duration of lesions. 
• MOATT: The MASCC Oral Agent Teaching Tool© (MOATT) was developed to 
meet an identified need for HCPs involved in the education of patients receiving 
oral anticancer agents. The MOATT provides a structured format to ensure that all 
key areas of patient assessment and teaching are addressed. It allows for 
individualized teaching and uses evidence-based tenets in patient education. The 
MOATT is well researched and easy to use.(11) 
• NCI-CTCAE: The National Cancer Institute’s Common Terminology Criteria for 
AEs (NCI-CTCAE) is a general instrument used by clinicians to report toxic effects 
of cancer treatment. Currently, decisions about dose modifications due to AEs are 
based on clinician assessment utilizing the CTCAE grading system. Despite its 
widespread use and its utility, the CTCAE has not been validated.(12) 
• NCI-PRO-CTCAE: The National Cancer Institute’s Patient-Reported Outcomes 
version of the CTCAE (PRO-CTCAE) system provides a web-based platform to 
collect patient reports of symptoms for the purpose of enhancing AE reporting and 
grading.(12, 13) 
• OMAS: the Oral Mucositis Assessment Scale (OMAS) focuses on objective 
measure of mucosal ulceration and erythema.(14)  
• Oral Care Protocol is a generic education instrument with focus on oral 
hygiene.(15) 
• SF-36: The 36-Item Short Form Health Survey (SF-36) focuses upon the 
measurement of functional status in general and specific populations, including 
oncology.(16) The questionnaire covers eight scales: physical functioning, role 
limitations due to physical health and due to emotional problems, energy/fatigue, 
emotional well-being, social functioning, pain, and general health. 
• SKINDEX-16: The Skindex-16 is a PRO assessing dermatological symptoms for 
general skin diseases using a numerical analogue scale. It contains three domains: 
symptoms (4 items), emotions (7 items), and functioning (5 items). It has been used 
to assess HRQoL in patients receiving EGFRI, but does not address symptoms 
related to hair, nails, or mucous membranes, that are specific targets for 
EGFRIs.(17) 
• VHNSS2.0: The Vanderbilt Head and Neck Symptom Survey (VHNSS) version 2.0 
was designed to screen both for tumor and treatment-related symptoms in patients 
with head and neck cancer undergoing concurrent chemoradiation. It assesses 
patient-reported symptom burden in the head and neck area and function loss 
within symptom subscales, including nutrition, taste, pain, voice, swallow, and 
mucous/dry mouth.(18, 19) The modified VHNSS2.0 is adapted from the original 





VHNSS2.0 to make it suitable for the targeted therapy population and is being 
tested in the COMTT trial.(3) 
• WHO OTS: The World Health Organization (WHO) Oral Toxicity Scale (OTS) 
classification of oral toxicity that combines descriptions of mucosal changes, pain, 
and functionality into a single composite score(20, 21) that is mainly driven by the 
patient’s ability to eat and drink. 
 
In chapter 2 the terminology of TKI and mTORI-associated oral AEs, assessment of 
symptoms and signs, grading and treatment of the AEs as one entity were addressed. 
The objective of this study was to provide an overview of the prevalence and 
characteristics of oral AEs with TKI and mTORI treatment and the current oral 
assessment instruments commonly used in clinical trials. It was discussed how these 
novel AEs can be assessed because current mucositis instruments have limitations for 
this patient population. Also explored were the correlations between oral AEs and 
HFSR and rash. 
No consensus on AE terminology was found. This finding is consistent with the 
findings in the literature. The terminology and classification of oral AEs associated with 
targeted therapies has been inconsistent throughout different clinical trials. This makes 
comparison of AE data difficult. In the literature, the terms mucositis and stomatitis are 
used interchangeably, however, they do not reflect the same clinical condition.(12, 22) 
‘Stomatitis’ refers more generally to any inflammatory condition of oral tissues,(12) but 
has been recommended for use in oncology in lesions with aphthous-like appearance 
such as oral lesions associated with targeted therapies. In a review article on the AEs 
of temsirolimus for the treatment of renal cell carcinoma, the frequencies of mucositis, 
stomatitis, aphthous stomatitis and mouth ulceration were reported as distinct 
categories, while the differences between these descriptors were not defined.(23) 
Moreover, mucosal inflammation and tongue ulceration were reported as distinct oral 
AEs.(24) There is consensus among oral medicine specialists managing patients with 
oral mucosal lesions associated with mTORIs that the specific term of mTOR inhibitor-
associated stomatitis (mIAS) is preferable to the general term oral mucositis which is 
associated with cytotoxic chemo- and radiotherapy.(22, 25-28)  
The newly developed PRO DERETT-P and CRO DERETT-H,(3) wherein common 
mucocutaneous AEs are listed by subtype, and the modified VHNSS2.0 may be of help 
in assessing the signs and symptoms of the related AEs in detail. 
Generic oral AE scales OMAS and WHO OTS are available, however these are 
not specific for targeted therapies. No controlled trials have assessed the management 
of TKI- and mTORI-induced oral AEs as the primary outcome measure. Interventions 
for persistent TKI- or mTORI-related oral AEs, currently may include corticosteroids 
and other anti-inflammatory agents as well as supportive treatments such as local 
anesthetics and antimicrobials.(29) 




Chapter 3 addressed the prevention, terming, assessment of AE symptoms and signs, 
reporting, grading, and treatment of the AE as one entity and by subtype of mTORI-
associated mucosal AEs. The objective of this chapter was to provide an up-to-date 
review of the clinical presentation, terminology, pathogenesis, assessment and 
management of mIAS and other mTORI-associated oral AEs. 
For the prevention of conventional oral mucositis and targeted therapy-associated 
stomatitis, most recommendations begin with oral care plans coupled with patient 
education.(15, 30) A range of products are currently in development for the prevention 
and management of oral AEs that fall into four main categories: cell resistance 
modifiers, mechanism specific inhibitors, damage control agents, and healing 
accelerators. However, to date, proven approaches for the prevention and treatment 
of oral AEs are limited.(30, 31) 
Generic and specific CRO instruments are available to assess the incidence of 
targeted therapy-associated oral AEs. In the majority of the papers the CTCAE grading 
instrument(12) is used to assess the incidence of AEs, while this instrument is not 
developed for this purpose. The CTCAE is a blunt instrument, developed to grade the 
severity of AEs. For assessing the incidence of targeted therapy-associated oral AEs 
the oral assessment instruments OMAS(14) and WHO OTS(20, 21) are available. 
Because of the symptoms of targeted agents-associated stomatitis, the modified 
version of the VHNSS, version 2.0,(3) the mIAS scale(10) and the EA(4) are potentially 
useful to assess oral AEs. The Bristol Stool Chart can be used to measure the 
gastrointestinal mucosal injury, namely the consistency of stool to be able to make a 
distinction between e.g. diarrhea and loose or mushy stool.(2) 
We found that a variety of grading scales for staging the severity of targeted 
therapy-associated mucocutaneous AEs are available, while these scales are rarely 
used in research and daily practice. There is a gap between the availability and the 
use of these scales as seen in the literature. Currently, the CTCAE is commonly utilized 
in oncology clinical trials by clinicians to report overall toxic effects of cancer 
treatment.(12) Consequently, decisions about dose modifications due to AEs are 
based on clinician assessment utilizing the CTCAE grading system. It is noted that, 
despite its widespread use and utility, drawing conclusions out of the CTCAE for the 
treatment of the AE is sub-optimal, since the CTCAE is not a validated instrument, and 
has weaknesses in differentiation levels of severity of AE and does not specifically 
assess the impact on HRQoL. 
In chapter 4 the prevention, terming, assessment of AE symptoms and signs, grading, 
and treatment of the AEs of chemotherapy, radiation therapy and targeted therapy-
associated mucosal injury in the ESMO guidelines was discussed. Accurate 
assessment of the morbidity of the mucosal AEs will allow for informed decisions on 
dose modification and interruption, which may have far reaching consequences. The 
development of specific instruments for targeted therapy-associated mucosal AEs 
seems justified. 





It was found that no controlled trials have assessed the management of targeted 
therapy-associated mucosal AEs as a primary outcome measure. While there is 
currently no systemically derived evidence for an approach to management, since 
targeted therapies are associated with inflammation and localized and systemic 
infection, mucosal hygiene, anti-inflammatories, and pain management may be 
considered until a more comprehensive, evidence-based approach has been defined. 
In the absence of confirmatory data from clinical trials, expert opinion-based 
recommendations can be considered. These statements reflect the state-of-the-
science as it presently exists.(22, 27, 28) 
In chapter 5 we report that xerosis and pruritus have a major negative impact on 
HRQoL during the first 6 weeks of EGFRI treatment. The objective of this sub-analysis 
of the BeCet study was to examine HRQoL of patients experiencing skin AEs during 
the first 6 weeks of EGFRI treatment, using five different questionnaires. AEs were 
reported in DERETT-P. The impact of EGFRI-associated dermatological AEs on 
HRQoL was examined using four HRQoL questionnaires; FACT EGFRI-18, FACT-G, 
SF-36, and the Skindex-16. The findings are congruent with the findings in the STEPP 
trial.(32, 33) In literature, xerosis and pruritus are less frequently addressed EGFRI-
associated skin AEs. As a result, not all patients are counseled about these possible 
skin AEs before initiating treatment. However, providing patients adequate information 
about possible AEs and their treatment has shown a positive result on patients’ 
emotional and physical well-being.(34-36) Counseling patients prior to EGFRI 
treatment about potential xerosis and pruritus is therefore important, as well as taking 
preventive measures against these AEs.(37-40) 
The targeted therapy specific instruments that have been evaluated in these 
studies, are the DERETT-P,(41, 42) FAST-EGFRI,(7) and FACT-EGFRI-18.(6) The 
DERETT-P is mainly a symptom and signs scale but includes questions like “which 
symptoms bothered you most?”, “why?”, and “How much did the symptoms influence 
your HRQoL?” The FAST-EGFRI is the preliminary version of the FACT-EGFRI-18 and 
in this thesis we report the use of an English and Dutch version of the FACT-EGFRI-
18. Because measures of HRQL describe the patient’s experience as the result of 
therapeutic care, they are valuable and vital additions to physiological or biological 
measures of health status.(43) The HRQoL assessment instruments we have used are 
the SF-36,(36) the FACT-G,(8, 35) and Skindex-16.(17) 
There is a discongruity in functional domains in the different scales that were 
evaluated throughout this thesis. The SF-36 covers eight scales: physical functioning, 
role limitations due to physical health and due to emotional problems, energy/fatigue, 
emotional well-being, social functioning, pain, and general health.(16) Within the 
FACT-G the following three HRQoL domains are addressed: physical, emotional, and 
social well-being /family.(44) Skindex-16 addresses symptoms, emotions, and 
function,(45) while the FAST-EGFRI and the FACT-EGFRI-18 are constituted by 
physical, social/emotional, and functional well-being domains.(6, 7) These different 




formats complicate the comparison of the outcomes of the different scales and 
differences between studies. 
It was found that there are no reporting instruments available which address solely 
the AE characteristics. The targeted therapy specific instruments DERETT-P and 
DERETT-H have items regarding reporting AE characteristics incorporated. The 
DERETT-P questionnaire also allows report of the severity of the AEs and which AE 
was most impactful. In the open fields in the diary, patients can elucidate their AEs. In 
a drawing they can record the site of the AEs; questions about the appearance of the 
symptoms and signs and the duration of the AEs are incorporated.(3, 41) In addition, 
the ‘objective’ reporting of AE characteristics may be supported by photographs, 
biopsies and swabs. 
Evaluation of the outcome of an intervention and education is critical in ongoing 
care. It was found that no evaluation instruments in the literature exist that specifically 
address the outcome of the applied measures for targeted therapy-associated AEs. 
The targeted therapy specific instruments DERETT-P and DERETT-H have evaluation 
items incorporated, however. Questions about the taken measures and the effect of 
the taken measures are incorporated in both versions of DERETT.(3, 41) 
Chapter 6 addressed the translation and linguistic validation of the FACT-EGFRI-18 
instrument from English into Dutch. The translation was  accomplished by employing 
the Functional Assessment of Chronic Illness Therapy (FACIT) multilingual translation 
methodology. The FACT-EGFRI-18 only evaluates HRQoL and not symptoms, not all 
skin and mucosal AEs can be assessed, and it is only available for one type of targeted 
therapy. The above points justify further development of this questionnaire for use in 
targeted therapy. 
Despite the fact that the Dutch version of the FACT-EGFRI-18 seems to be content-
wise and linguistically valid (chapter 6), we found in chapter 7 that from the patients’ 
point of view, the questionnaire can be improved on several points. FACT-EGFRI-18 
evaluations show: 
1. The FACT-EGFRI-18 provides 17 items addressing the skin and only one item 
addressing the mucosa. 
2. In addition to assessing the impact of the AEs on a patients’ HRQoL, patients 
also felt the need to rate their symptom burden. The patients’ natural inclination 
was to rate the prevalence, intensity, and duration of the symptoms rather than 
the extent to which it interfered with HRQoL, based on the interpretation of the 
questions. 
3. Some inconsistencies between numerical rating and the associated comments 
suggest that clear instructions regarding completion of the instrument needs to 
be provided. 
4. Six out of the ten patients gave feedback that not all the skin and mucosal AEs 
were included in the questionnaire. Questions regarding sensitive eyes, a runny 
nose, bloody or crusty nasal cavity due to pimples, dry mouth, tickling and 





tingling sensations, pain touching the hair, and some space for additional 
comment were mentioned by the participants as items that should be 
incorporated into the questionnaire. 
5. Patients reported difficulties in 5 of the 18 items pertaining to the location and 
the relationship of the skin and mucosal AEs with EGFRI treatment; e.g. how a 
flaky scalp should be scored if a patient already experienced dandruff, and how 
to respond on the question about the interference with household tasks when 
the patient does not do any, but is bothered by sensitivity around the fingernails. 
6. The partner/child of a patient noticed that there was a greater impact of the 
symptom burden on the HRQoL than the patient rated. While patients stressed 
being grateful for receiving anticancer treatment, their families appeared to be 
more focused on the HRQoL of the patient including skin and mucosal AEs. 
7. Patients expressed an appreciation for the opportunity to discuss their 
difficulties coping with their skin and mucosal AEs. 
The above points justify further development of this questionnaire for use in targeted 
therapy. Additional mucocutaneous AE items in combination with symptom 
assessment will provide more complete information. Since skin and mucosal AEs are 
also elicited by other targeted anticancer therapies such as non-EGFRI tyrosine kinase 
inhibitors, mTORI, immuno-oncology and BRAF inhibitors, it would be worthwhile to 
develop a questionnaire suitable for all these targeted agents instead of only for 
EGFRIs. 
In the various articles for this thesis, one or more of the six components of a systematic 
AE approach are addressed. In addition, the preventive measures including education, 
AE terminology, assessment of the AE symptoms and signs, reporting the AE 
characteristics, grading the severity of the AEs, evaluating and (re-) education about 
the taken AE measures, and AE treatment are discussed. Table 1 provides an 
overview of AE steps referred and studied in each manuscript. As outlined in Table 2, 
there are instruments developed to assess targeted therapy-associated AEs by PRO 
and CRO. In addition, instruments not specific developed for these agents can be 
considered for use as well. 
Future perspectives 
The approach to AEs and effective prevention and treatment of AEs are an important 
part of the optimal treatment for patients receiving targeted therapies. Figure 1 uses 
this base and illustrates a new model of a patient-driven AE co-care approach. 
Patients and HCPs start and end the AE approach together, while the assessments 
before and during therapy can be performed separately but in close collaboration with 
each other, yielding more comprehensive evaluation and leading to improved  




TABLE 1. Overview of the adverse event steps referred and studied in each manuscript 
Chapter Adverse Events Education Terming Assessment 




skin mucosal preventive 
measures 





by CRO by PRO taken 
measures 
AEs 
2. Oral AE’s 
associated with TKI 









no studied (7)* studied studied studied studied no referred referred referred no referred 







studied (3)* studied studied studied studied no no studied studied no studied 







referred studied referred studied studied studied referred studied referred referred 







no studied no studied studied no no no no no 







no studied no studied studied no no studied no no 
AE = adverse event, HRQoL = Health Related Quality of Life, CTCAE = Common Terminology Criteria for Adverse Events; CRO = Clinician Rated Outcome; 
PRO = Patient Reported Outcome; TKI = tyrosine kinase inhibitor; RCC = renal cell carcinoma; mTORI = Mammalian Target of Rapamycin Inhibitor; EGFRI 
= Epidermal Growth Factor Receptor Inhibitor; *= number of AEs addressed; AEs = adverse events; CRO = clinician rated outcome; PRO = patient reported 
outcome; HRQoL = Health Related Quality of Life; light grey = referred; dark grey = studied 
  





TABLE 2. Instruments that may be used to chart targeted therapy-associated adverse events 
Instruments  Adverse 
Events 
Education Terming Assessment AE Symptoms & Signs Reporting Grading AEs Evaluation Treatment 
addressed preventive 
measures 
















Generic           
Skin           
































Skin     Skindex-16      







  OMAS 
WHO OTS 
   
Muco-
cutaneous 
          
AEs = Adverse Events; CRO = Clinician Rated Outcome; PRO = Patient Reported Outcome; HRQoL = Health Related Quality of Life; MOATT = MASCC 
Oral Agent Teaching Tool(11); Oral Care Protocol(15); mIAS scale = mTOR Inhibitor Associates Stomatitis(10); Derett-H = Dermatological Reactions 
Targeted Therapy-Healthcare Professionals(42); OMAS = Oral Mucositis Assessment Scale(14); WHO OTS = World Health Organization (WHO) Oral 
Toxicity Scale (OTS)(20, 21); Modified VHNSS2.0 = modified Vanderbilt Head and Neck Symptom Survey version 2.0(3); EA = Experimental Assessment(4); 
Derett-P = Dermatological Reactions Targeted Therapy-Patients(41); FACT-Egfri-18 = Functional Assessment of Cancer Therapy-Epidermal Growth Factor 
Receptor Inhibitor-18(5); FAST-Egfri = Functional Assessment of Side Effects to Therapy-Epidermal Growth Factor Receptor Inhibitor(7); VHNSS2.0 = 
Vanderbilt Head and Neck Symptom Survey version 2.0(18); Bristol Stool Chart(2); SF-36 = Short Form Questionnaire(36); FACT-G = Functional 
Assessment of Cancer Therapy - General(8); Skindex-16 = Skin Index(17); MESTT = MASCC EGFRI Skin Toxicity Tool(46); CTCAE = Common 
Terminology Criteria for Adverse Events.(12); PRO-CTCAE = Patient-Reported Outcomes version of the CTCAE(13, 47) 




outcomes. Patients report AE characteristics and severity, the effect of AE measures 
and the AE treatment they desire. Patients also report the impact of the AEs on their 
HRQoL. The HCP is supportive to the patient. At initiation of a new treatment, the 
patient may need guidance from the HCP in approaching AEs, since the HCP may be 
expected to be experienced and provide guidance & support where necessary. When 
a treatment becomes more chronic, a patient will may become more experienced and 
therefore less dependent on the HCP’s support in measuring AEs. For obtaining some 
AE treatments, patients may be independent of the HCP, e.g.: obtaining hemorrhoid 
cream, foot salt, vinegar, insoles, and mouth rinses. Other treatments may require the 
HCP such as for receiving prescription when needed e.g.: antibiotics and 
corticosteroids. The concept is a co-care model while on chronic targeted therapy 
treatment, wherein the patient is leading the process and the HCP supports where 
appropriate. 
By following the six steps described, terming, assessing, reporting, grading, evaluating, 
and treating AEs by their subtype, the scope of the AEs may become more apparent. 
For both the patient and the HCP, choosing the most appropriate treatment is facilitated 
by taking these six steps which provides a roadmap that supports the implementation 
of appropriate treatment options for AEs associated with targeted anticancer 
therapies.(3) The instruments that may be used to chart targeted therapy-associated 
AEs are shown in Figure 2. The top of the figure shows the instruments that may be 
used by the patient while the body of this figure shows the instruments that may be 
used by the HCP. 
A growing number of patients with cancer will be treated with targeted agents, most 
frequently as outpatients and over a long time span. Targeted therapies are high cost 
medications.(48) The cost of targeted therapies is an important consideration, 
particularly when compared to some traditional chemotherapies. Additional treatment 
costs include the costs to get all stakeholders trained about effective AE management. 
Further costs are costs to treat AEs and costs for treatment modifications. This 
indicates a need for awareness and early recognition of AEs among the patients, 
oncologists, oncology nurses, dental professionals, dermatologists, pharmacologists, 
pharma representatives, and basic scientists but also among community HCPs, such 
as primary care doctors, primary care nurses, dental professionals, and allied health 
professionals. Scientific knowledge does not, by itself, result in widespread 
implementation and social impact. The research from the clinic must be translated into 
practical use. Valorisation is the impact that can be created through the transfer of 
scientific knowledge.(49) Examples include developing an assessment instrument or 
applying scientific knowledge to a system or process which can be disseminated 
through a training program. Some of our findings show high potential for valorisation. 
 





FIGURE 1. Proposed new patient-driven co-care model of approaching adverse events 
 
CRO = Clinician Rated Outcome; PRO = Patient Reported Outcome; CTCAE = Common Terminology Criteria for Adverse Events; HCP = healthcare 
provider 
  




FIGURE 2. Instruments that may be used to chart targeted therapy-associated adverse events 
 
AEs = Adverse Events; CRO = Clinician Rated Outcome; PRO = Patient Reported Outcome; HRQoL = Health Related Quality of Life; mIAS scale = mTOR 
Inhibitor Associates Stomatitis(10); Derett-H = Dermatological Reactions Targeted Therapy-Healthcare Professionals(42); OMAS = Oral Mucositis 
Assessment Scale(14); WHO OTS = World Health Organization (WHO) Oral Toxicity Scale (OTS)(20, 21); Modified VHNSS2.0 = modified Vanderbilt Head 
and Neck Symptom Survey version 2.0(3); EA = Experimental Assessment(4); Derett-P = Dermatological Reactions Targeted Therapy-Patients(41); FACT-
Egfri-18 = Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18(5); FAST-EGFRI = Functional Assessment of Side 
Effects to Therapy-Epidermal Growth Factor Receptor Inhibitor(7); VHNSS2.0 = Vanderbilt Head and Neck Symptom Survey version 2.0(18); Bristol Stool 
Chart(2); SF-36 = Short Form Questionnaire(36); FACT-G = Functional Assessment of Cancer Therapy - General(8); Skindex-16 = Skin Index(17); MESTT 
= MASCC EGFRI Skin Toxicity Tool(46); CTCAE = Common Terminology Criteria for Adverse Events(12); PRO-CTCAE = Patient-Reported Outcomes 
version of the CTCAE(13, 47). 





An assessment and grading instrument wherein the presence of AEs and their impact 
upon HRQoL are incorporated should be developed. As more and more patients will 
be treated with targeted therapies, alone or in combination with cytotoxic and 
immunomodulatory medications, it will become increasingly important to understand 
the multidimensional experiences of AEs. This is an important challenge for patients 
and HCPs in their effort to assess AEs. Therefore, in this thesis, in addition to 
assessing the symptoms and signs of the AEs, the influence of the AEs on the HRQoL 
are addressed and a conceptual co-care model of a patient-driven approach to AEs of 
targeted therapies is presented. 
A continuing concern is the use of the CTCAE instrument since it is still commonly 
utilized in oncological clinical trials to assess adverse events of cancer treatment.(12) 
However, most CTCAE items are not specifically developed to grade the severity of 
targeted therapy-associated AEs and therefore the CTCAE is not recommended for 
direct application for assessment of targeted therapy-associated AEs. Development of 
a comprehensive grading system similar to the MESTT(9, 46) seems appropriate for 
staging the severity of targeted therapy-associated AEs by CRO. DERETT-H has 
mucocutaneous AE grading items incorporated as well.(42) Grading of the severity and 
impact of the AEs by the patients themselves as outlined in the AE co-care model may 
improve diagnosis and management of these specific reactions. For the 
mucocutaneous AEs DERETT-P seems suitable. For other AEs, a grading tool needs 
to be developed. 
As outlined in chapter 7, the study participants felt the need to rate the experienced 
mucocutaneous AEs instead of the influence of the mucocutaneous AEs on their 
HRQoL. Therefore a combined assessment and grading instrument should be 
developed. When patients can separately rate the mucocutaneous AEs and their 
influence on their HRQoL, they may be able to better capture the effects upon HRQoL. 
AEs may be assessed in a three-part scale that may measure: 
1. if an AE developed (appearance symptoms & signs) 
2. the intensity/severity of the AE (grading) 
3. if the patient is distressed/suffers from it (impact AE on HRQoL) 
The proposed questionnaire is modeled in Table 3. 
To be able to develop evidence based guidelines for the prevention and treatment of 
targeted therapy-associated AEs, more research in this area is needed. As outlined in 
chapters 2, 3 and 4 there is currently scant AE evidence upon which to build evidence-
based guidelines. More evidence is needed since guidelines based on expert opinion 
are scientifically not ideal. However, until clinical trials establish evidence base clinical 
experience, expert opinion is the best available guidance. 
By empowering patients to be more involved in their treatment and in the approach of 
targeted therapy-associated AEs, the entire interdisciplinary team may help patients 
maintain their HRQoL, promote treatment adherence, and support completion of  




TABLE 3. 3-part adverse event assessment and grading instrument 
 





Complete only when marked ‘yes’, 
so when you EXPERIENCED the mentioned symptoms or signs 
On a scale from 0 – 10, what was the 
SEVERITY of these symptoms or 
signs at their worst, according to you? 
On a scale from 0 – 10, how much 
did these symptoms or signs 




Yes/No 0 = not at all; 10 = very severe 0 = not at all; 10 = very much 
symptom 1 Y N 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 
symptom 2 Y N 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 
symptom 3 Y N 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 
sign 1 Y N 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 
sign 2 Y N 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 
sign 3 etc. Y N 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 0 – 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 
Y = yes; N = no 
cancer treatment as planned. Well-designed trials with appropriate terminology, 
assessment and grading instruments wherein the AE treatment response is the 
primary outcome measure can bring the evidence desired by patients, HCPs, 
pharmaceutical companies and the society at large, to bring more HRQoL, enhanced 
treatment outcome and to conserve resources. 
For the generation of a patient-driven AE conceptual co-care model, the critical items 
are derived from questionnaires and case report forms used in clinical targeted therapy 
trials.(6, 32, 33, 50-55) For the identification of terms used in patient files the medical 
records of oncology patients on targeted agents in the Waterland Hospital in 
Purmerend, The Netherlands were searched systematically from March 2009 until 
March 2014. Terminology used to describe AEs and recorded missing information has 
been evaluated in detailed AE diagnoses. Terms were identified in prior grading 
instruments.(9, 12, 46) The identified components for a systematic, patient-driven 
targeted therapy-associated AE approach can be summarized in 6 steps:(1, 3) 
1. Terming – the establishment of the diagnosis of the AE by subtype 
2. Assessing – the identification of symptoms and signs of the AEs and the impact 
of such an event on a patients’ HRQoL 
3. Reporting – the collection and reporting of in-depth characteristics of the AEs 
4. Grading – the classification of the severity of the AEs 
5. Evaluating – the exploration of the taken measures and discussion about the 
treatments to be initiated 
6. Treating – the institution of the most appropriate and effective AE treatment. 





The AE management skill is an important competency since there can much be 
achieved by individuals. However, competencies in AE management alone will not 
make a sustainable difference for society at large. Competencies in several distinct 
core areas may improve cancer treatment outcomes. Recommendations include 
developing: 
1. explorative AE trials in a structured way in early phase drug development 
(phase I and II), 
2. long-term advisory boards, steering committees, summits, and roundtables, 
3. interdisciplinary teams with key disciplines involved, 
4. thorough training of pharma, pharmacists, HCPs and patients, 
5. patient centered drug launches, and 
6. easy, understandable patient information written in the same format as the HCP 
information. 
These seven measures may promote adherence to the cancer medication, resulting in 
improved patient outcome. 
The work in this thesis lead to recommendations to develop collaboration with patients. 
The conceptual co-care model of a patient-driven approach to AEs of targeted agents 
in oncology may be complemented with a 3-part adverse event assessment and 
grading instrument, evidence based AE treatment guidelines, and obligated 
educational programs on the AE core competencies, and applied. 
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Context 
Targeted anti-kankertherapieën blijken effectief te zijn in het behandelen van veel 
soorten van kanker bij zowel volwassenen als bij kinderen. Naast de toename van het 
aantal targeted anti-kankertherapieën is er ook sprake van een bredere indicatie, 
waardoor een groeiend aantal patiënten met kanker in aanmerking komt voor deze 
behandelingen. De duur van de behandelingen die overwegend poliklinisch of in de 
thuissituatie plaatsvinden kan variëren van enkele maanden tot jaren. Targeted 
therapieën worden toegepast als monotherapie, maar worden ook ingezet als een 
combinatiebehandeling met o.a. cytotoxische chemotherapie en/of 
bestralingstherapie. 
Onderzoek en praktijk laten echter ook zien dat bijwerkingen als gevolg van deze 
behandelingen ervoor kunnen zorgen dat, ondanks de effectieve werking tegen 
kanker, de therapie tijdelijk wordt onderbroken, een dosisreductie wordt toegepast of 
de behandeling vroegtijdig geheel wordt gestaakt. Het bijwerkingenprofiel bij targeted 
therapieën is multidimensionaal met een wisselende mate van invloed op kwaliteit van 
leven. Veel bijwerkingen zijn overwegend symptomatisch. Hierdoor kunnen deze 
bijwerkingen alleen door de patiënt zelf waargenomen en gemeten worden, terwijl het 
behandelteam verantwoordelijk is voor een adequate vastlegging ervan. De hieruit 
voortvloeiende interventies sluiten niet altijd naadloos aan bij de behoeften van de 
patiënt. Deze discongruentie laat zien dat er behoefte is aan een integrale 
patiëntgestuurde benadering van bijwerkingen. 
Vraagstelling 
De centrale vraag van dit proefschrift is of er methodieken en instrumenten 
beschikbaar zijn die als basis kunnen dienen voor de totstandkoming van een integrale 
patiëntgestuurde benadering van targeted therapie-geassocieerde bijwerkingen. 
Bevindingen 
Het onderzoek identificeerde drie concrete bevindingen: 
1. Huidige bijwerkingen-inventarisatielijsten zijn van beperkte waarde voor de 
diagnostisering, rapportage, gradering en evaluatie van targeted therapie-
geassocieerde huid- en slijmvliesreacties. In het algemeen wordt het 
patiëntenperspectief nauwelijks meegenomen. 
2. Er is momenteel beperkt wetenschappelijke bijwerkingenkennis beschikbaar 
om evidence-based behandelingsrichtlijnen op te stellen. 
3. De gegenereerde wetenschappelijke bijwerkingenkennis die beschikbaar 
gekomen is, is niet breed ingebed in de klinische en onderzoekspraktijk. 






Het signaleren en beoordelen van de bijwerkingen door middel van patiënt-
gerapporteerde uitkomsten en de behandeling van bijwerkingen zijn algemeen 
geaccepteerde pijlers in de zorg bij anti-kankerbehandelingen. 
De toepassing van goed gedefinieerde bijwerkingenterminologie, in combinatie met de 
ontwikkeling van geschikte bijwerkingeneducatie-, diagnostisering-, rapportage-, 
gradering- en evaluatie-instrumenten, is nodig om een gedetailleerd beeld van het 
bijwerkingenprofiel van de patiënt te krijgen. Daarnaast draagt deze aanpak bij aan 
een effectieve inzet van financiële middelen doordat intensieve, tijdrovende en 
langdurige behandelingen van bijwerkingen vermeden kunnen worden. 
Bij een systematische benadering van deze bijwerkingen is het van belang dat alle 
belanghebbenden bij de behandeling betrokken worden, zodat de targeted anti-
kankertherapie zo effectief mogelijk voortgezet kan worden. Belanghebbenden zijn 
o.a. de patiënt, diens naasten, medisch specialisten, verpleegkundigen, data 
managers, huidspecialisten, oncologisch voetzorgverleners, apothekers, laboranten, 
farmaceuten, verzekeraars, overheid en goedkeuringsinstanties. 
Implicaties voor onderzoek en dagelijkse praktijk 
Een integrale patiëntgestuurde benadering van targeted therapie-geassocieerde 
bijwerkingen dient systematisch plaats te vinden vanuit een geïntegreerd, 
interdisciplinair teammodel van zorg. Het in dit proefschrift voorgestelde co-care model 
biedt hiervoor een kader waarin de drie bevindingen in dit proefschrift ingebed kunnen 
worden: 
1. De ontwikkeling van een gecombineerd driedelig patiënt-gerapporteerd 
beoordelings- en graderingsinstrument dat zowel de symptomen en de 
kenmerken als het effect van een bijwerking op de kwaliteit van leven in kaart 
brengt. 
2. Het genereren van evidence-based behandelingsrichtlijnen gericht op 
bijwerkingen van targeted therapie. 
3. Het ontwikkelen van verplichte trainingsprogramma's voor zorgverleners is 
geïndiceerd. In het bijzonder voor de professionals die in de dagelijkse praktijk 
direct betrokken zijn bij klinisch onderzoek en zorg rondom de patiënt die 
behandeld wordt met een targeted therapie. 
De drie bevindingen binnen het conceptueel co-care model van een patiëntgestuurde 
benadering van targeted therapie-geassocieerde bijwerkingen biedt handvatten om de 
kwaliteit van leven en het effect van de targeted anti-kankertherapie te vergroten en 
de kosten van de bijwerkingenbehandeling te verlagen. 
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